var title_f2_49_2832="Urea cycle";
var content_f2_49_2832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Urea cycle (UC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The flow of nitrogen intermediates in the urea cycle (UC) is depicted above. The UC converts nitrogen, derived from dietary protein intake and the breakdown of endogenous protein (catabolism), into urea, which can be excreted from the body. The steps of this cycle, and the six enzymes involved, are indicated in red. The dashed red arrow depicts the overflow of excess carbamyl phosphate (CP) into pyrimidine synthesis and, hence, to orotic acid, which is excreted in the urine. The dashed green arrow depicts the generation of nitric oxide (NO) when arginine is converted into citrulline by nitric oxide synthase (NOS). The green cylinders denote the ornithine and citrulline transporter (ORNT1; SLC25A15), and the blue cylinders represent the cationic-amino-acid transporter found on intestinal- and kidney-epithelial cells (SLC7A7). The pink cylinder denotes citrin, a mitochondrial aspartate and glutamate transporter (SLC25A13).",
"    <div class=\"footnotes\">",
"     ARG1: arginase; ASL: argininosuccinate lyase; ASS: argininosuccinate synthetase; CPS-I: carbamyl-phosphate-synthetase-I; NAG: N-acetylglutamate; NAGS: N-acetyl-glutamate synthase; OTC: ornithine transcarbamylase.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Brendan Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2832=[""].join("\n");
var outline_f2_49_2832=null;
var title_f2_49_2833="Hospital phototherapy PI";
var content_f2_49_2833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baby getting light therapy in the hospital",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The eyes are protected with a blindfold, and the temperature is monitored with the small white cord taped to the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2833=[""].join("\n");
var outline_f2_49_2833=null;
var title_f2_49_2834="Color flow Doppler PDA";
var content_f2_49_2834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Color flow Doppler in a patent ductus arteriosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 187px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC7AiMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5YZ2z1P4VoNomrroK622n3g0hpfIW8MbeUX/u7umeDWYetfRE/jrwFL4Eu/AK6jeDTU0WOOG+aFvszXyEzGRU2eYpaRypJGML+NO4HzxuPqaNzD+I/nTaKQD97ep/Ol8xsYy3HvTKKAH+a+c7ju9c04zOcbjnHpxUVLjGDjigZKJ2GQpO3Hen+e2Bgtx0JP8AnNVqcDxg847UmhpkyTtu5P40xpWJ7g98GozweDSE5NFguOMjHuaXzX27dxx9aYetBpiH+a5XG4/nTd7f3j+dNpaBDt5/vH86XzZB1dvzplJQO4/zHxjc2PrSb3/vN+dNooEP3sP4j+dKZXxjcfzqOigdx+9/7zfnRvb+8fzplFAh+9v7x/Oje395vzplFAEiyup+8SO4zwaQux/ib86ZRQFx29v7zfnS+Y/95vzplKRj0oAcJZB0dvzpN7/3m/Om0UASebJnO9s/Wuv+Dzsfit4PBYkf2ta9/wDpotcZXY/B3/krHg//ALC1r/6NWh7DR6x+2ZcSRfE3S1jkdR/ZMbEBjjPnS84/rXj+ieGPFviSxmv9E0fVdTto3Mck9vE8oDAAlSRnnBBx7ivWP20yf+FoaZzwNIi/9HTUnwQ8feGvDngO1stY1Swtb+38S/2m0V3Z3Ex+z/Z1jZomiXCyn5gCxwOSR0oYk3ax4XJd3SytulmSRRsPzEED+79Paolup1KlJpAV6EMQRVvxHPaXXiHVLjTPP+wy3Ur2/wBoO6Tyy5K7z3bGM+9ZtA+Z9y4dQujHs+0Tlck7TIcZPXir+ieIZ9KklY2llfpIm3yr6LzkU8fMFyAG461iU4KxGQpx9KBqbR2r+Ps20aL4X8LpKrMWlFhy2cbRjOBtxxj1pIPHqIkwfwp4Wd3AEb/YMeWQwJIGeeMjmuJpwAwefwp3ZXtH2X3L/I7S38eqk4ebwp4VmQZyjWG0E4OMkNnqc/hTV8eyIrIvh3wwFPUDT8A8Y6bq45SMHIFNIwcUXYe0a2t9y/yPQtW+IlpNqMz6V4S8O21m2Ckc1n5jK21dxLZGcsCenGarn4hLsUp4T8LJcBmZphYnLZOQPv8AGOfrmuFBxS8f40g9o/6SO5HxBjMUol8IeFHlfbtlNi2VxnPG/nPHXpin23xFjRts/g/wpJBj5ols3jDHGATh+xwfwrgieMdqKBc7/pI7kfENgwYeFPCgIG0EWLDA9Pv9PaluPiBA1yZLbwf4Vt0D70VbRyU9Pm3g1wooPvTuLmf9I7m/8c2My2rQeEvD4n8oi6eWCR/Ml3H5l/eZA27Bg9wT3qt/wmVmbZg/hDw6bnzFZZfKlChASSpTfzk7ec8AEd646lHWkHN5L7kdhp/i6wjJF54Q0K5jCPsUCZCHIbaxPmHIBIJXuFA4613/AMJ/Ct54/nmnXw/4cstHtCIp7ySGfDybf9UgEvzSYOSf4eCT0B474R/D298da8Iv3ltpFuQb28AOEH9xTgjzG7A9Op4FfZ+k6dZaHpVppml2gtNOtV8qGFcnaM9WJ5LHqWPejfRCc7f8Mj5o+LPgK68C6bHqMGjaDqOiyS7ZLiGO5R7ZiflRwZs7SOjdz1wcZ8zu/Eulv9n+w+E9Kt2SILMTPcv5kgJJcfvRtBGBt5xjrzX3DrENnd6dPaalEbqyula3nhwdsiHlgSOnA4I5zjpXxl8V/AM/gvVxNblJdIunZ7YrJvaEZ4jk9GH5HqKtxurolVGnyv8AIzv+El0YaTGv/CKaa2pidi0rS3PlmLaMDb52d27cSc9CPSmWnibSVW4+2+ENKnZoisJjubqPZJkYdv3p3Dr8vGSevHNbxV4v1bxRa6Vb6vJbNFpkLQW4gto4QFZixyEAHp7cdMkk87UFXOptfEumJcxtc+EdGlg3gyRpPdozLkZUN5x25GecHGe9E/ibTjPK1v4S0WOEuSiNNdsVXPAJ84Z44zgZrlqWgLnUXfiXTHlBtPCekwpsUEPcXbncFAY584cFskDHGQOcZpW8TaYbCNE8Laat6JGLT/abooY8LtUJ5vBBDHdk53dOM1ytFA+ZnXaf4i0hvth1Dw/bF2gItjBPcALNvBBfMv3Nu4EDnpUOn6/pyXkZvfDttNbf8tIre6uInYAHkMXYDnB6Hp2rmKkDKx+fOc5yOn5U7iudP/wmd00rS/ZU85pPOL/bbvO/IIbPndQyhs9c49Ksf8JhFaau17pGlizckssn9oXXnLkfNmRZFzk5/A9+tcdu4wudvvQrFelK7HzM7geLYnXT1ttF/wBMt1Ybv7Qu2xlmYeUBJlOGORk5OTxmmrrFhHaNHc+HIkuW2yo7XdyqeWVP8JfJz8rAg4wO9WfAPhjxPDc6B4j0vT0lt7jUBaW3nHCyybCWUqPm2ldwyOc9Oa0/GM2s2Hjm0s73S9Ku5BFZDT7MQfaRLbqqC3iDffbcqqDjBJJ6Zpp6X/rsHkyhBfwTwpLF4YJRhkGOW8ZfwO/mivdr7xF4rtrkpceFdJu5WVZTLczzXEnzqG2l1RQdu7aABwFA5xkldEKE5RUl1OaWKhFtPofIlJS0fhXMbiUtKB3HNGBzk0AJS8fjVzR7RdQ1ixs3nito7ieOEzS52RhmA3NjnAzk45r6u0D4W+HNGn8OwXvh+31Vbe3uYNTnkUnMvyt5oBI3bsMka4G3duzmsK2IpUNakkvVpFxhKXwq58i/hSj5iK1PFGlT6L4gv9Ou7WW0lt5mTyJSGaMZyoJBIJ2kdCays9q1jJSSlF3RNrbi8Ae9IxOAM8dcUHk0h4qgA/Sikpc9aBCUp/SkpaAEpaB+FdZ4J8Eaj4pMlxCBDpkDqs105Hy5I4UdWPPYHH5UCbSV2J4B8Jv4ou7qOXzoYFgcQzjAQ3JAEUbM3GCxUHHIBzTPh/4Mv/Gvi2Hw/ZSRWty4dne53ARhAS2QASTxjGOte4aXZWOiaDJBaTx+QhhWRY2ZkUsykNkDPO1ScDIPXJGKh1vwdLrmvXms6Bef8I9qljZw3Fi0KNCzgr/GwwSzMzAt2G3IOahy6XIjUu9VoeYfFL4XXvw+stKurrU7S+h1BpETyY5EKlNuch1H94V53XUePNR8WzamdO8bXmrS3loxIg1CZ3MW4DlQxPBAU5HBGDXL1S2NAooopgFLSUUAFFFFABRRRQAUUUUAFFFLQAV2PwcAPxX8H/8AYWtv/Ri1x1dj8G/+SseD/wDsLW3/AKMWk9hrc9N/bQ/5Knp//YHi/wDR01eAV79+2gc/FTTwT/zCIv8A0dNXgVNiQlFL9aKACvdP2XPD+ka9qPiRdc0qz1FYLaJohdRCQIS5BI9yK8Lr6H/ZBI/tPxSvAP2SDvjP7w/4ipl/l+Y0ct+0zo+l6H430+20TTrTToG06OR4raPapYs4J+uAPyryGva/2sDn4i2AJz/xKoeTn+89eJ1rU307L8jOG2vn+YUtJRUFikEdaD6ZzikooAKKXtSUAFLSUUALW/4L8MXfirVvsdo8UUUa+ZPNKwVY0zjgfxMc4Cjkn2yRS8O6Rca5q1vYWiOzysAxRdxVc8nBIz9MjJ4r6hi1HS/DXga10Hw9ppgaDJc3cG2RrgAb3kOSyyHjGMqBwOBVwg5OxE5cqOk8O3vh3wp4ftNL0hJLa2VS5znzQwxuLDBLsT/EOOMDHFWv+E3sEMaxJOFbkRyjyhtyQH3YyVbnkenavmTxb4mvHimL3Nwt4ABHJJhiUyAVzz0HGP59a2JvCXi0fFi48ByeIbT+14lV45WJEMriESqgyvXa2ORjNaNQh7upK5panusfib+0XlNvJbIXl8s+c6S7+uNqLgsvbCgkjv1rA8YTnVtOv7LUJY7gzIttPHkSYUNlQQiBYgp5GcsMZJrwqWy1uw8Pab4j1a+jiTUbyeCG2ZSkshiHzSHav3Q5C49eMYrs/CmpTa4IdPSO7lzKTLBABGpXHDOqjOMjk1cHF6oiaaWp47r+nDStUntEmW4jRiElUEBh+NZ1e7+IYbOaO70UbJ42XdcTSDa0RXupYZXqCOAcDk84rx/xFoN5od0qXMUv2eUb7edo2VZk7FcgVnVp8uqLp1ObRmRSqSrBlJBByCO1JRWJqFLSUUAFLSUUAOPXpjjpSdaU47DFKe+OR60DNjw9rV9pt1Ytb3l1FFa3iXaLDIRskBA3jtuwMZr7DTRPDOvT3t2fD1jH9plWU7izS7kztO/dlCMnAQgc9+K+KLcfvkA5BYZ/OvsDwjqQSRk3c7uO3f0r5viStiIULUJWvvbf5Ppv0PbyrCwrQnKSu1b8b/5HXvoWly7WktixCqgPmv0AAA+96AUVoxyhkBzmivz9ZpmMdFXn/wCBS/zOt4Si3rBfcfnyxySfWilbG446e1IK/ZD5gSnYoGScCnIdvPf2oGkXtHYQaraE5+WeMnA9GB4r7qttVg1G8uhDJudTlvbNfBluCJUb+FXU4PI619P/AA11uV/E8kc5AjuYynU9RyK+X4kwzq0lUX2bv8j3MroqrTqPqrf1+B4x8d1/4u14lOQP9JH/AKAtcAQB3rvPjZIs3xY8TODkfayM/RQP6Vw207AzA4PQ17uB/wB2p/4V+R49Ve+yPnHtQacwxz0B6UnGOnNdZmNpwU7C3YED/P5Un0pdx2lc/KTkj/P1oENpQCegzSV1Hhfwje6vJa3FzFJbaTM5H2l8IJArqriMthWYbwcZoE3ZXZf+GPgafxdqha4Ekej27bbmWN0EhYqxREDEZLMAuRkLuBPYH6gg8PpfMqtDBpMEPmRPbW9uVjD5DllUkIq5KkhDn5fc4wPB2i2+t2LafY2+m+TozbbfTrqNluI2BOXGPmRJSoDHLc5PfA6yPX0NiU0+AzKjOk9mswBgdQp/dt2bJBwQMc1lKWpF+bVmuttp9kV+0pCtvAwKMIBOhzkE555O7nqc8+tYfiK6liuC+lTz2N5ayIypZBZZTHk7h5eepK5x6DHBxW3aGJI2vVSK4md1MnkAL5DDOFC9nyxJwc+mcVbgtmVFntbSKERAfcDb2Xb+pzuAB/HFZ3sVa5wvj3wQfiB4PW1lQRathbmz1CaEI7HL/u5Gb5xHhs45K54BAr5G8Q6LqHh3WbrStYtntr62fZJG/Y+oPcEcgjgg1+hUpUMGkzluASCT7ZPbtXlXxl8M6X42toLK6nhtNShVxYalKmPNkyALckZLhjn02ffGRkHRS5dxnyp4F0u31zxt4e0m9Li1v9Rt7WUxnDbHlVWwexwTXuV78HfCa+OPD2kMdSsGvdWu7CSylvY5pZreJXKXKFUBQMVHysD146ZPiWoafrngLxVa/aYzY6xYyx3cDHa+0gho3AOQRkA4I+oplj4t1uw8YN4ptb3y9ea4kujdeUh/eybt7bCu3nc3GMDPFajO51X4faZrfh7SNY8GRX1q95rp8PvY3s6znziu5ZEdUX5Mdcjg96k+PPw307wQdIvfDo1FtKuzPayG+XDi4hkKseg+Rxhl9QCaxLv4heLIrvTNVuNXEWpWW97CGG0gjjg8wEPJ5SoEDMCedu7vngVzt34u1698ONoN7qU1zpZuReeVOBIRKF27g7AsPl4wDj2pRkpao1q0ZUmoz3/rcwqSiimZBRRRQAUUUUAFFFLQAldl8G/+Ss+D/wDsLW3/AKMWuOrsfg3z8WfB/wD2Fbb/ANGLSew1uemftoc/FWw9tIi/9HTV4Ea98/bO/wCSrWIxydIh/wDRs1eBU2JBRRS0AL1wADmvoH9kIka94mzn/jwjPT0lFfPte8fskyiPxPrwYjDWS8Y9HFJjRmftVMD8S7dcDK6Zbg+3LH+teNda9c/ahlEvxQJXothbj/x015FWk9/u/IzhsFFFLUFiUUUUALSUtJQAUU+ON5W2xozt1wozSumwlW4YEgjHIoA6HQYbizvUkVJo4WQuJTGUDrjnDDt7civVtb1+11fS44L6RUlSyRbfdEWilZB91RtIViCSMkL24rzbw9q921paWltd34t7QtLLGIzKkS/3sA52ZOWAHqa076IuINS/tS3gLIZA9tOJAzjkZVtp9sdRXRTdloYzV9GcJfZa4kd2zk/Lk849x2r0zxv8S7TxN4yt/F2ieGbnS/Esd5BdNcnUTcRuIkChPL8tcZ2pk57EY5rze7vPtX7yWGL7SZXkkmBOZN2MArnGAQTwAfmOc8Y1rGyv5dOkMaNHv6eWOSD2IJ+79K5aklHU7sPQdZ2V3bsdH8R/Hg8deL7S+fT10HTrONkitIn80RMzPI75CrlmdiTx6dcVH4L1u/nv2tGvYo7JnZ5JZ3WAliuMl1UtzgDGD6d65O9nMkMVrcpDEbdcApAFlPYBjxn/AD1rT8DWqJrtjdahbiW28xSqyKpSUgg7TuIAB6H61vCo0kl6nNUp2u2erWlqlyRZz3duYNwkTy0ZQuB08yT5nIz3AHpntleIdOsdVsltVe6Fs24QSSs9y52nBkUZ454GOorpLO30K61dJBaw2UEca4t5pjPdykNzkBVTGTnAJHH1r0HSvC8t5q0eoyyxXNngsn+kFFUADgKFO/gc8qBzXTKaitUcfK2fJnirwtq3hieBNVtJYorlPNtpmUhZkzjI9/UHkd6wzX198TrGy13Rr2yv7z7daKoe2TzHXyZenmgZCZAO0LnGCc5NfK/ibQL3w7qJtL9QSVDxyJnZIp7gn8vrXLOm0ubodMZpvlMiiiiszQKUfzopVHIyDigBVGeO+cUDAPI+ooVth4weetKDkDgcUDFiwHBJI5GDX0ZpN80TgjAkz9f/AK1fOW0kkqDjrXXW/jS6iAzGMDoNxArixmG+sRSPZyrHwwimpre34X/zPpGDX8QqGfn8P6iivBIfHEzRqWt1J/36K8L/AFdi9bI9D+1sN/VzzuQ/OeKb6U9kPmMAOfQcmnKjodrK3rgjpX1LZ8slcRYzxjIyeDnFOCAtjOOM56UjMBngc96aSxADZ454palaIkB2ckEe57/5xXpmm+J4rO6hkRwGwvfGPwrzB+Dg598c4NSpZzMwUIc9vf2rKph1WVmdmFx08I3ydS34l1F9V8Qahfytva4meTPrnvWdvxx19uopHUo5UjBU4IHrTenStYwUUorock5ucnJ9RT/CeaQjBIz+VH0ptUQFLSVoaTY296l79ovktZIYDLCjRsxuJNygRggfKcEnJ4+X3oEVrO3a6uUhTqx6+g9a7Wzeawikt7Jv3IXyXWNtykPgMWDdC2BkY6gdKxobUW8JDQlRwNvVumQTjpVwMYYZGmM0vmOryJhYgSucDceB97IIB688GlczlqdpoPiq8shpllb34iWNnaOaEhniOcfvNgLlCQcx9hjmu90r4h3Gpa/p0rXRtjcuXmtobcCIzE/vC5BLNGFQANwSWB6DnxgzT6fcmC4vUyp3+Zhvv4wNrL0ZRz2685rd8HKwubuY3DefZ2MkuVkDJiRfLQZ6/el3deuOOK0ow9pOMe7RjP3IuR694E8bC6QnxDvidM/6ekYjLksojjZthDSBHIU/eAVuxr07Tb+1uWE0VkcSRl4sZlM0ZONw2DGSACQRuB4NfOK6lLYWOqQxaium2V7b+TKCryJu8xCpwp4I2/fwSBmvVNK+JE+oX1rPqaQwiENNdS23yQRwnbiVmJycnZkHGCT1yBW+aUIYWryrS+xeA9piYNxV7LXy9T0d5WmAX7MXIPyHDR4UEEMxPBAADFcdq4vxBrV7dxWSeFIBeCMkGSNAO43wq8n3SwDEOMgHHPBrQsI/7V0TyJJ1bSbpvMuQ8we5kUnJA8t+EJznPO0+uaz7bWrbwxY28+orbwXot/LJV1mFwMsyBShZlVB/ERjkZOa840bPMvib4Pe/tUttZSCzuTKrWmoufPubiVwd8T7VBMW7Zg/w5yN2WrwuaybQZpF1GNDqEbFFg3B1Qg43MRkH2Hfr06+8+M9Wn8QTyQXFlYtBZgXTNZ3ITyRjjczli7Bm2gDcMk8D+Hh/ELaZ4nn0iyvreCyUBIhqdupe5AVQrrJEWVCN2dvKngnJBpp+09PzOum1gdZazey/l8359l03euh5RNI80rSSsXkY5ZieSajqW4he3uJYJl2yxsUcZBwQcHkVHmtrW0MHJyfM3e4lFFFAgooooAWkopaAEopaSgArs/g1z8WfB/8A2Fbb/wBGCuMrs/g1/wAlZ8H/APYVtv8A0YKT2Gtz0n9s7/kq9j/2CYf/AEbNXgde+ftm4/4WvZZJ/wCQRD/6NlrwToTzTYkJS0lFAC16z+zpetZeI9WK5G6ywf8Avta8mrs/hdfNZaxeFWKl7Yg+43DiqirtIUnZNlz443jX3xCu5mcufJiXP/ABXn9dH8QLo3niq7lJJOEHP+6K5ynU+Jk0/hVxRRSUVBYo60UlKBxnjj3oAStXwxoN/wCJdattK0qNXupzgF2CIg7szHgKB1NU7Kyub6UxWUE1xKFLlYkLEKOrHHQDua958E2Q8MeE4zaJdtDe7JLi6AUAyhf9SwJK7QRwcjk8nsLhBzdkTKaitTE8X+AoPCEUFpplzM94CD9vSRAtw/XaVydo7AEjp0PbzDXYBHc/NBdw3T5eYSlSpJ/u4HTr611HinxRDeTTRW26zlaYmYKu1e/pnP459jXHXaAR7oZw8Y6fvAT+XBFXPlSsiYJ7sk0dLk3KXFoZYpomBSSL5cn0z0HFdJd6bdXU+nJqmoWqQuS8pAVfKJ+8NwBHOD04z2rkonKpskU7JWB3gnI9cc4NdVPp+n3fhVbi81yX7VaQr9mgUGZZFLYMYyR5bDO4j7uOhJ4qE9C7XKXiEaC9narpNnqFve+a6v8AaH8wOmcKQwABPrhRXRaZZXdnZpDerdxTqAf3ilTjHYEZx2rI8L6fqiXsRubV5IEyIopXO1WJ6qoYHt2rrZbKWOcGaMW6448zdHjPqpHIrzsVXTkoI+ryTBunF1pXu9ErPbuZF7pZmgmSUtI7D5WLAsD25rG8MP8A2fr1gNPvbUXMUrkTvbA7fl7Fsgn0446128aRRxtiWGTOcgwvgDHYgj9RXO+GY7Y+MWgskkWK4iJP2dDO4I5O0ISw9+RVYOfNKzFxBQhTgpwSvt1v/l956zpNvfpcQT31pZNNdEyqsxt55HGBtODwoHPOAGJHHHPfzNctYrZy3NkUQgsjOZmcnnbv3qg9SAOmABXl93dBLeKyN/qjQXB/eRpZpGHj/hEnzhnJbjk/njFekRWUT6ZBeRQasY9u875YiUfbgKkf8IHqMcc17ElZq+58attDP1ifTzp8jXKQCa0kywRCBkDgmRsjufugk9sAGvJPGGm215pF4XYSBdoQTBi0DHqwkPHJx8orp9TvZLW4ZJ44EeNiTLcyNKjjqeu0475J59SKzNf1GfVVti9wN8b/AOjx3A2ySgjB8qJRtVQQTlsHHrWvKkrGXNd3R4PPE8ErRyDDKcVFXSa9ZX9zfTLMzSrExLTSEhU9QM9sntXOupRirAgiuGceVnZF3Q2nHoOKbTl56YyKgoB7fkaUHIJ64Hen7WRmVhgjgqeKcApRmDIGBUKmOT159P8A9dAySOPAz1OMYzXdnwzbyRxloQCAMnAHauJs03SfN1z+AHfmvdLazaQAY6AZ9+K9fK8LDEKfN0t+p5WZ4x4blt1v+hwS+F4scR5H0/8ArUV6AbLnjI/DFFTLB2k0cazRtXPAH4diAD1B701pGCjHTpmmufnOQVBNBy2RgDHWvIPogdgc5JPHHNNXjvjHIPvSADnnFBOTmmJgTkcdT617H4b0eKe7jEiZwgbaRx0FeOxf6xQTgZHbNfSGi2HkXDNjkRgD5a97I6UZynKXS36niZ3inRpKMXZyv+h4d8QLNLDxnq9tGoVFmJAHTkA/1rna6/4sKV8f6rkYyyH/AMcWuRrycUrVprzf5no4OTlh6bfZfkBooArsPhpfeFdK1eS/8Xx3t1HFG6RWcFnFOku+N0JYyOApUsrKcNyPauduyOk53QtNfWNXtNPjnt7ZriQRia5fZGme7HsK6efwJ4i0ye4DabJNHbsUlltz5ikHlXG3OVOOCMjg9xXI3pt/ts5sBMtp5jGATMC4TPy7iAAWxjOAOa3vDHifVtKuS1hqV9HcyskYVZfkcZyA3PY02TLm6F+zgt7twk80qSFdomiKkk4IAIz06e/pWhJ4d1xdFkuZ9F1A6eq7muhbO0Y9DuAO0ZUjPtjNe2l/B/j3wTcabq+kR6J4i0htxtbUhJPNYZL7lBBRyQTu4BOc1Q8O65/YmiX1lF4wh0zXdGuvs8VqIP8Aj5QgF497DLsSGXpwy8ZBzWWpF/M8EaZFUb4yVwXdEHAUAY29x3/Gun8EW62mg31+7N5d1dQ2x2YZjGA0r7cdT/qxjHWtT4jeGIPCmsS2Ud613ZTFZLe5JQbw4B+bHIbOc8Vj6ul1aeHdP+wxzfZFjmvrtogSFEkwiR8dQCI164HJrpwleNGrGpLZGdaDqQcF1PQvE3ge/wBH0jztVtVuobklSjEwT2SLhmfazqkhKso7qCSCOK5eG1fV9OuprS/srQWMilWXUFMjoR91EXJc5UEk/Kccetc/q3jjWvEOlaVpXiO9a/tbFyYS6pu6FQWf73A4wf1OKw4Lye2vJJdIuNokUqyhd+VHfbjBA/nSxLq4r99N3lt6f1952YScMO/ZO/s3bmtu9/6/E9s8FqunRvdwahBLe3yy/aN2EkmuEG6NEXPVNuGOFXD43FgaqXfie6vtbmublpHt5TtaNCu5E4yI2K/JkDsKwNE1y7m02a+iuiJpEktnJHyOpxu2E8Y+mMGuk0q7a21+GLQYrINYAPM9wzSGZWXzEl8tQWZQhCkH5A3PavGqKpWl7O9mtz67CSwOUUp4ucPa+0SUVayj11bu10ta70PNNR1OS7NwES5MMEaC7YThlCKSEI4XscEdznHoMCXUmmlmaZ4Sgb5ky0ZkGeCRnnA7enWuw+Jdvt1Z7m81OTWAsh+0yJB5Ecc5PCF+jN1OR0XHc1500ZkaSRS8kfypJI2FyfY8gdOv+NeonpY+KvztyZoywWd9aTSPILa7VA1vDFASknONvUsOOdx47e4wHVkdldSrKcEEYINaH22X7a120jeczbgZTvyO2T37du1aJNlJod9mzimvZDEUvprlhIGBYuFjB2kEFc7um3rziquON1uc5RRRQWFFFFABS5PNJRQAtJRS0AJXZ/Bn/krPg/8A7Ctv/wCjBXG12fwZ/wCSteD/APsKW/8A6MFJ7DW56R+2dkfFay64OkQ/+jZq8Er3z9szA+K1l2P9kw8+n72avAyPQ5pi6AaSil+tACVd0u9ewuTKgBJUrg1Spe1CdgJ7+5e7u5Z5MbnOeKr12Xgi/wDBtpoHiKLxhpV/f6hOkQ0x7OXyjC437yWJwAcp1V+nSuOOMnHAovcLWDtSUtJQAtWLCzn1C9htLNDJcTOEjXIGSfc8D6ngVFGjSSKiDc7EKB717B4G8LW+mRZulgu7qYZbKh4yBg7FdQWVuvK9fpVRg5bEyko7j/BPhW10248oXIfVo8JeRKWjkhzyAAcB0PHI69MGtDxtBd2FlcWsVzESvMluHMUbIfbnj0JwfWu8/sm8aC0kgkMkbKVSK7RT5i9ShYAg4Gfm6jjg15N4/iaZbsW5dEhXYYpZiXjUH7gYjJA7BgPaupWS0Rg7uSueW3L4kKAbQpIAJOR7VBXu/wCzpb6XJ4W8dXmsz2VmYbjS0XULywjvPs/mTurfLJwA2QpPYHd/DXSDwhp/izxf4+8AzaNY6BfJqEOq6Yyoq7YAypLtYD7jRtvCDgEnjiuRnSfN+mQrPc7GWVjtLKI13HI55HcV0+tOv+g6RHaw2bTmOWZIGd1IcKyMFLEZwfu9s44Oav8Aim60bxH8RNZu7CePRdLSbyrBre3zGIoxsViF5BIXcTzyTV3w1Fb6V4jjmsNZWPULIA24kVxb3KnrhlYuMk54Uc0pXUG0XTV5pHoOn6HHJosG2O8l+TasUtviZvwIAH61ReyS1bY4uxKfvW80AyF/HIrvdNOrX3lS6dbXE07puLWbg5HGfklCt1rndcljbUXN3dNHeLgut0PIf8VYBh/nmviabxSk/aRfLr5/ja343P0DD4iEmocyv26/dv8AfqczqETuGFtbuy8lo7YPhM/3vlFea60DZ6xELOfyvNG0iIiPaM8jK4yD717Xr95A+kx/Z7iyaVeNkEoLY75+Y5PHpivLtcW2ji3XEtxdyHAG+BYwvPZmxgCvosmtVhzyfLb+v6/U8rPKk3SVOEG/PXT57fI9EtLK5GmQvJZXZ3OPKkYJEHIUFsFiAx68lsDoK3LbWIbrw15dwt4fJUjcEAMZBwFZWK5/DNedWeyXwtax7XEyuA8r3hIlB9wSoT2xXoa3Ef2RLOC3e/vTGywo0iTJCgGS0fACgDJ3Yzxkc19EndLS58POLTZxWvX8MctnJqEE0iI25Zdox0OMqQf5du9Uzq8s15H9kaGBLr/WSGbfKQOwUjjPOSBxmqWvadqllq0V3IkMMAyUy4/HLbiXP05rEmvo5xcqbSRZnIVpNql2X6Zwij6mnKbvsJQVifxVZNfX1zPb3G6ApueCAkkEcAE9Nv0ri7yyuI4xNcIYg/Cq3XH+FdnHqltbRvawlGtwA5NueWbHVmP8Xv0GOK5TVruW+KEK23J2ruLlsdST3rGqk9TSndaGRT0IAIPXsaGzgZAGB+dNrmNx4f5uSSOvNS4BwQRwB93v9ar1KhAzt4zx1/nQM0bIAycvn2J/Wvp6DSypJYHGB07cfl/+qvmLSWj+1xCRXZS6gqqksRuGQPUkcAV9Eat8VvCEc0q6bFrU4DkeTNAkLx47bixBx7gGvUy7FRocybte36nkZng5YhxcVe1/0NO4ijjmZETIHfiiuSf4laZI29NG1kqwBBBjIxj6UV1vEUm78yPJ/s6t/L+X+Z4FMSxJJUMTzzULgg4NSykoxOOenT2qEivn0fXMQ0vp/Wm0tMkfEQkiM3IDAkD0r7K8HtperXOmz21hqJh1e3mmtPtEccREcW0NK43fKhZgFPOfQAZr47066aw1C1u0ihle3lSZY5kDxsVIOGXuDjkelenzfHfxXJPpcqWujQpps8txbQxWpSNWZGRRgN0QO20DHJ+bdW1LE1aKapu19znr4SliHGVRX5djnfjNfWmo/EzX57GC5t4Vn8nyrhAro6AKwIBI4ZW781xNWL67nvr24u7uV57meRpZJH+87scsx9ySagGA3PIrJycndm8YqCUV0Eo5/OtDUNT+26fptr9isbf7FG0fnQRbZJ9zlt0rZ+ZhnaDxgACqBGADkEGkMSpY4m82MMwj3YIY9PrmoqcGIGMnpgYNAHS+DtXisPEFndXURkt7eQuU8woSCOR5gwRntnI55r7I0fxD4U1/w9bavf31lF5hBj8zbFNblQGEQIz8yHPPJ618Ku6lkManIGCXIOfw7V7v8FtftXsb22vrTSry2tlE7C9kMYlyPmQb8gshAIIA4JySDUNeREny6o998Vx+H7hYTr97aSRN5mE1CKN4bnKgnOV7BQdwwVx71zHi7wXY6v4Zv7Xw5GyXwtVilsdLCC1uATlYRvB2jPPByp9Caxdb+IVrfWHhO3/saKY6hI4ksb7EsMMIBVisgbG4DJAPY89jTNB+L/gqbWoQugatol1OCFlR41gcdSxXdt7dR1rPldx8yZ88Xnh+5t9Qura8tbmG6gcRzI8JZo5M7QrKM8k4A9aaPD19NJGY4Lq3JhM8H7hlNyARkxcYbrn5c177H410DwV8SvEOo6PbzS2moQ2rMIYQqq5dZJWXc2DuXLKRxub2rLtvjFFbXekahdWJurDS9K+x2sVuwEy3bJCjuX3HYmI3A2gHDcjk12zpz9n7i6J3/MmnOHN72vkeZeGLptM1e2l02b97NIGKyqMEj5kkGQQeh478Zr0f+1tT/seG6jvZ2LSC2uy+pC1t3R3O3ztuGzl22kZwFORgVweleHNR8c+KL6+0HTjFpM+pyTWkJXayK8pKr8vyqBkA9uK9H8E6LBe6zeaFMG1JbcRf2rA1skUUcyScKGZzuBJbkLjJ9q83EVKc8Tz0krpa2/z/AKue3T9zLpUq/V3jff7u3W+368d43sNMEsejWV9qGq6fpiFruaORltY3PzP5Q4UdQpdssxJNeYarEgmkHkNbHaClqpLBQTxucnOcY7V9map4UOrbH1mGC10m2LPFBbMqxNGAB+93rl3JGd3QdAD1rwr41eGYrW701rUagBMGnBmdTtXP3sKoCkt3Ysxx2AAreLPDtyvU8ZkgNnLi4h4ZcqGPzDnqQDkfQ1FDNJDG4TgOMH5QePr6e1Ty2wBklUiOBTtBPIYjsv8Ae6dajSGZQqsHEbfOAOjdgf1xn3rQ0GGPzCDHy7HCoOSx9hUNWQjsssoQ7OScEDHYdumT+NTahqN3qUFlFczzTrYwmCEMcrHEGLBVGOBlmPPrTBGfRRRQMKKKKACiiigArtPgx/yVrwf/ANhS3/8ARgrjK7P4L/8AJWvB/wD2FLf/ANDFJ7DW56T+2dj/AIWtZZz/AMgiH8f3s1eB175+2b/yVeywef7Ii/8ARs1eCEcCmJbCDFFHSigApKKKAClopKACnKNxwMknoAOtHGO+amsTEtyhuFdov4gh5+ooQFuzjvdOnSdYZEP3Q5U4B9K9V8CXkbRZkuXivQQXj3HjBByqgjj2HNReD9V0+fTGtNV8vVNMU8OwCS2/YMwPGB69D3xVrxJ4QPhm5SeOzu9RsHxJBNbANJD3BUrxtPsSD2NdMIJGM5X3Oxg15pJ0htNQlt1cASR3KiSEnPJ3j88kZ5x2ri/i3JamTdfxySag8W2K4ikIUoTwAw+8O/PTOK5TV/E0Vys1vfW8hXcAZNgjnz/tjoR7cZ9RXI6ncNLJFtmZlUEqTH5Z5PoCfzolUir2QRpvS7KUsZjbawII71HTyzcgnP15pXKFQEUgjqd2c1zmx0ngtdSSae40q1vLpvLaKaK2jfc0TAh/mQZAxwR3FNUhNYil0qN7S5jfaYZGBw+eQFbkYB755psV9LZW2mxpFYsIAz77ScpLIzNnMhVslgOBgcCumspRrCx6XNcyadJJJ5ixyXY3o+RwxdssTnjgH61NaShBp/ibYaMpzTj+H+Z1VrqeqRwtBfslzCW+WK5hTAHrlU7+1bFh4hhtIsSw3E7A5VMlox2JAJyDx2FMh8HXlhakjUre6YjOPJkeUfXavP1pbfQpLMbpIBu5wJmKhh0yCyr/AJ5r5SrPCVk7Wt5XVz9Aw0bU7Tbb87fmitqOpfbUkYQRr1LMYghXByOVI3H6iue1DQ9P1aJXuGnjjhUk5kOz646Cum3WkKNG8MNu6ggLHt3N9GDMM/hTtHbSrvU411+/urbTwd29YSdxxwN3Tr265xiuzBptqFPRGePnRjQlOUbpLbuV/APhyC4WJdQngt4oVG1Pmt/OTu5kZWO7HACjJ65FdzqmoRWUNzDoWh6bbwWqhkuLtWnHoZA0hCFgOihW564rfh1nSdJ32ejjX7iO4GXuZMxAZ77pFUE+h2muJ1WJG1CWG9luo3ySsc12WLLnjLFQBgck8V9TBXWup+bVXdtrQ5jxvAms2rzxajLcj7iJNAIo1PrgHP5AD0zXlur3jtdCPfHFaxKItu0qDjrlV6/QmvWfE6SmOLy5JLi2ji8kQxI7t5WW4DngLlicAnrXm2pWcVlrcVvhTGTvSFEZmXPOWUgfz4q5rsRB23KlvbJdO32eaF+dxiaPCcf7IwD24NQalJdSZSWWMnaAzjEYA/ugD+VXL2CztYpBdSBr6XBzCgcrnn1wp9hXN30Cxt8kzuWPKsMbfYn19qzlojSPvO5BdYWYhXVwvGVGB+lQd6e5+UDcSR27Cmg8HgHP6VgzYTPH9KcpxkkkHFNopAdt4G8SSafq+iLDodrfSWl0sqC2gIu5zz8odcknnI46gV0mt3l/4z8dXepSeHZxqFr9jSSzuSsSzbMLsnyq5llO0BVAzk4BA4434dIz+NdGij1L+yne4C/bPlBizkcbiFyeVG4gZIyRXpPxgMUthNfHXbvWriPUVSaF72BvsgWCPZ5sca4aU5ePcpKKY2AJzVRS7CZ02v8Ai7VYNTaG+8DPb3EUcUbRLrLkJiNQANvGMAcdulFOvfiDoOmyRW2r6540S9EELumkahC9qgeNXVUIjXorAHgfMD9aK7YVJqKSf5f5nJOnFyb5V+J80yHLEnGOwphp8ow5yMc0zv1rgO0XBxntQeBxjBH1pS3pTe1AC9KSlIoz3zQBd0rSr3VruG3sLd5ZJJFiBAwoY9Mt0HQnn0NS6/ot7od2bbUIZIpVOCHXbn3Hqp7HuK1PBHjjWvB1xIdLuC1nP/x8WUvzQzcY+ZfUZ4bqKt+ONXHia4S4tppboKm9FMW14F/ijfHHBxhhwQex4oIcnzeRxwOPX8K6rwF4Ql8aX+qxQ31ppsOm6dLqdzPcK5QRRlQ5ARWOcNnAHY49K5UggkMCCOoNdh8MvHEvgS+1u7trMXM+oaVPpsZLhRA0hQiXBVg+0p90jBz1oKOi/wCFM6hDc6t/aGu6TbafYWltf/bcTSJNDOSI2VVQv1GMFf8AGuK8c+GL7wZ4q1Dw/qjwSXdmyq7wMWRtyhlIJAPRh1Fdv4J+L3ibR7rxFeILjU9d1ZbcJdl+bcQvnGwKQUIO3aNoArmfiDqaeKPF+oa1a6DcaX9vbzZYGmaYLKTl3Viq8E5ODkDJ9sS5JaNmkaNSUeaMW16HJAbsBQS3869B+D19drr0tkLae8t7y2aJreOeGEvgZG0yqylvQcH3rjtO0qbUbow264O0sWkUqBxWxo41Tw5drNG81pNG29ZUmC4IHVR3P0zx2qfax5uS+pc8FX9h7dwfJe17aX9T0PQPAetwGfUrK2nub2GyuTJpptZIbiCR0aKMbWA8zIdmDJkfL9K4e2huPDWvQzPFc2F3aSBolu4DlZFPAKsPmHqBmvoLTviL4g1HwTbata6THeS2E0aXUkV/ETESpw+4N8ob5RtYDknNeUeK/GniLxa8Q8TTi8SwDjy/KRFTeRkgr97ovc4q6EPazcUzkqXhHmadmctrmoNczSajqZFzcTP553sxZW9iM8DOBngcCsaMSavfWtkbq3aS4dY/PlUoASe5xwB/SvQ7H4beK9cWA2Xh2c27jfCZgIg4PRgzEYX0J61zXiDQNa0HUk0qa1ls71ZAEUcYc8Aq/THbIOK6K+Ii3yx2X9f12Io0npdav+v67n2F4X08aJ4U0uDSLdEhtrZJFgSUBX3AAeZKwz13OWwOwHSvAfBOvX6+ONWvJbNIJZrllkTTSsEbsTgCRSGLRgDPyj1JOSK9r02zW80fQdE1LToYvIsYpLoNiW2R/KOQSCPmIy/JUZwcmvGPhdbXVj4njtLXSry5Rppkku4wnlvEMkgs2EXPdix4GADXnxoUqNNNRSnL3tOztb1vZO+763uaynUqTlZtxi+XW129Xf8APy+47y71qwurg2OtXeoiSN0n+z2Ctmc7sh3cjGwDb8q8c4zwTXKfEHRRqd1c3kFlPqmp3c4gg8zV1kDS4Py43DCRjJIUYz/FgHPpXig3F7qVtDZXj2CNJ5aIYsecyjLeWxBG3tkA9zxXnOs/2Rqd5fafp9rbLBaxf8TLU9Lt42VAefJjYkl2JyPQ85z0p3a1M5I8h1zwzJpWtQ2cjWkuF+U253KXXqu4AlgDnLcDPrWj4L8Iy69BfXes31rp+jWrEz3dxhQvbseSOyjJJwABnNaOo3ulz6SBcXN3PcTOYUtlPMcKL8olKgYCgjKoFGcj1NctJcm70f7Lf3McVrC5MAZiFJ4y3GfQDCjP05NbJX0JUmyl4ou7Rb8xaPGYdPhXECuNzsv/AD1k/wBts9D90ECufcM0byIjLHwHYnOW784/HFd14R8CXviCSW/uF+w6FC4ae7YZcluFjjTOWkYnCr7gnisrxJbtb6qllG0DWtqWEcKSCQRepYj5WYYyxztzxyOtb6lqSVomDbaXc3VzZ20Co9zdsqwx7wCSx2jJJwvPriq97bS2V5Pa3KhZ4JGikUMGAZTgjI4PI6ipL25aaeY7ywdyS5Ykv6Ek/wCAqrQaK/USlOO1JRQMKKKKACu0+C//ACVvwh/2FLf/ANDFcXXa/BUZ+LfhD/sKQf8AoYpPYa3PR/2zcn4r2X/YIh/9Gy14KQBwMH6V71+2WB/wtizzx/xKIu3/AE0lrwXjHXn6UxIMYBz1pKKUHBoGJxj3oIwaKSgQU5QWOFBJPQCm0+M7HVvQ5oA7Lwdo9vPbfaJmnNxyUWNCykYwRjrnr6/SpdX8HNBFJNaSZcsPLiI2P7jB9jWzpF49zZp9gzaXqxnzLe5Q4mGOGRs8++T+lLo2ppql1JYazZx5jGFKR7SxB+63PT0xXSoRtYycpXLnhHw1fyXY1PRp4WuolKzqQIGk9grjAPHfg44r1bRPFS21mNL1CKK5ZV3SWF7bmErk43RvyCB3ULx2rl/DVhZXs9s2nySWhyyLqNkz+dEM8oyEESA/Q/UGul8d+ENSttKa5llS8tkxtuUUERLnjzABuj+nIGeCKpRV+UhyaXMea/GrQLKVYtT0WQTkDbLF8jGIY/56qfm+jDIzWF8Jvh1D460rxBfT3Opr/ZTWiC306yF1NL57uhIUsvC7dx54G49qf41tr/TCurW08iNLhZA5V429FDjrwOjYPXGawfCPxA1zwjp2tWeiNBA2qzWs0lxtbzImgkMibCGAAJJBBBBHHFY1Vqa09tDr/DHwit9S+IviPw/c+JIoNK0eSO3bVYodyyTSyLHFHt3cMWYg8nBUjPevOZrQaF4nl0/xDaSzrp908FzbRTeUzFWIYB9rY5HXBrsbz4x+JSupNpFvpmhzalerf3U+mwujyyBNuDvdgFzlsAfeJOawvFuvz+NNavvEl+tpbancSIJrazt3CsAgHmfMSATtGRnqScVkaGRZadd3ZMln5vmoQARGwxx3YDAP1rtPCl9a29q/2vTrp7uLOxopjL5jD+6NrFTnjI6VxcUqSWMrxyTLeRkMhSFRhe5Lhgc+2DWr4fhuWa1ubOaWG+lkIN3BNIsg55zkbT+B781hXipxaf6r8uh34Ocqc17PR/J6eV1ueu6Vrd9KI5bW3AuCg3QIk1wwH+2CBSX7XSN50whti/MhhQIRz1MQJcn1xihoWk0+STVL3Wr+cJ+6N2EkRjxwduWAx3XNU2uF0xUOk2KefKDmOQwkf99PuYd+MDtXgQoxbcopf15/5o+yhVlyqy166a/d1XmiRCr2TtZC8kcklmLhVYf7jncM/hXB32pSHWPKisomlUho5bmMxlSPcPitXT4/E9zqN2I5UitmZn2zHMUJ6gAqwz+WPasi6torfVWbUlRb9sBWcx+VIOuSWc4P4/hXo4KnGNVxbT/M8jMq854f3Yta9T3L4aX+s6hpTW11PLJp6DPmxEWryknkAupdgPUZrs7+10ueGO0iKwE4U74dwU46M7ck/livI/A/jPU9JEy2tnDqQAGUstzBVxxucbVX0xu+maoal8ab2F7mK1mhEmcbHtxImfb5sce+c171r63Pjm9WjvPFemWGlQgz3CT30gLLNHCgjhyCMkljtYdiFyPTmvHdb1OC0trhLZGKOcPe+Y5eQ9wA4zx0z09Kx/FniqfWUc6hqtxq19NwocYihHoqjAH4DFc1qkrG0hhxJCscY3JJMzb2zyyjAAB44/U1XM0tCFTu9S7LqdsLCe33nbnci5yzk+rDpj361zjMSACcgdBTaK5pS5jdRsFHrRRUlD3ZWC7UC4AB5JyfWm/U0mKKAJY2AOcDPpipYm2MCB7fWq+MZxzxn0xT17Z5HbNNDNOE7YlGFHsaKSBV8pflJ9waKvQzMuT5ZDhskd6aTk06XO85xzTQfQVkaAfwBo9qD145oJ49/WmAUnYetJRQIU1ZsL640+5We0k8uVcgHAOQRggg9R7GqtFAPU6bU7zTNZt7SOzs5LbUDtVxkupbp8h+8RjHDZI6AnpWDdwG2nkiZkZkbG5T19x3/OoKsPcyXEqtdyySYGNzfM2PTmglK2iIg7LwGK8Y4449KmiuXwqGWSMZ+Z1JJ/LNaMWiyXdqs2mj7UxG5o4XDunPQrgMD7gEHPBqrKrxvFGkSJcKQAQCrhs8ZGce3b3pNX3KjUcfhdjY8PanNZSvJdSTzIQY2VmJ2PkYyScAdea2Z9bEuxLy1UWsh2sFKyk4PIx69OxrJ0O3YavBHrGbSJn2SykOQoPcpGQT+Fe56cPDltpapF4jt9Q0GY+RNYXS7LmMtgDY7qzgDtxyPpXNLC0pT9o46nqQ4izChh/qtOraOvbr5u7LHw78OP8A8K4vL2PVrqy0RY7i42R4R7mcssaCXgNs+XaB6k89q1PBPwTtLKexvtQ1Jr1VYT+RsAjPfgHPIPPIwfatZbOx8DWEVzAFurFgkDXUlwzeRbxDK7wisGKkE5VQwLAn1G/L4t8NzE3NlOZpAu9zHdHYF7SMpYZyeM4znrxTcVzOUVa6V/M872rdNU5ybs2187f1c6+SF5IwGkdXbGWVz1H1/wDrVx/izw1aTQrqtxY6d9vtZFdZEtQzTknaFZW4YksOpzxwRXQ3VwBbRT+dmKRFYO8yrEN2MAkZOTn0wfWvLPiv4k1XRAun6SkFxbXsJjeOOPEgzjG07gScDgkYxnmpqrni4rsOlNQnGT2udhr1vf29nqK61rVnaNfWotVkit3EQXbhg0eGA5IAZm9hWN4R0+O/8NabaRzYPnCe6XTGFpbSW7Y+Qx4xnqODkdc84rgrH4j6xrtlHo2k28stzJAIzb20WJFC8klshVXAxnpjNetfDu11G20GEa39mfUOVJhASNBk/Kq4XaB3IHJ9a56GIxVZcuIgoJWSsui+S/y7G9bB4fDRXs587bb3uvu6X+/TUlutI0jSrMR3NzJBZed9odXnb5o1O5o5O7QgY468AHNMXTrRfD9xcWOmaXoouNrwytbqrBfly+xV4O0NgAcZ6CtjWrVbuKMnzLiSM7okCnaGx13D+prnZtKnuII31OG5u79if37Wq+TH3wI/MwwA6ZDZ711Na6I5LnlHxS8I6dq+vf2j4NtpGS8tD9os7WPy0VyWAdzu2xllCnB92O01yN1oulWOuw/2/YzTWNjaxg28F4stxNI33UAT5EDYJwvAXkkk16zNY6Tam81FA0m24aSaWRFKl+Mnaf8AR0A4yfmGcF2XAFeJ+LPGWkpq17Hb6et6iTmWOOS6aeGSVvvySScNKTgDsMcDA67QTsc7bctDovGHiq4+zKGhh0TTlVkt7SHlrfcOZPaRuRkZcKTymc14rfTrPOzRJsj6KPb/AD2qXV9UvdYvXu9RnaaZuMkABR6KowFHsABVIda0fkaU6fKtdxKKKKRoFFFFABRS9aSgArtfgp/yVvwh/wBhOD/0MVxVdt8FBn4ueEP+wnB/6GKT2HHdHo37ZmP+Fr2eR/zCYf8A0bLXgpzjnmvd/wBsz/krNp/2Cof/AEZLXg5PrTEg7Uv8qSgY9M0AOyMj/ChuSSeO9NpwPrj0pFbjKcD29acybc5IJ9FOf5U3Iz0pok6HRZ2s5oVuruaO2bBVoj93p972/wAK7kanJYSpNA8V3BJx52zIY9gTjINcL4Tkhkna2u5pUhIzwu5R9fSuxspQCy2upW0kcWGDx5Eq9sDbgfh/+uumk9NDGa11PXfBl5aNHFcWSRQLIQJ43O/ORwUdTkf7p756V63pd0sAW3hNu8MwxskYhvQ/Pgh/oSPrXztY6pbwSLIl0ba7YY/dOsZkOB1BG38K9H8G+Kb+3t5DfaXbzWpUH7RjyiDnH7wgsgb0PAPtRON1dBFpaM574u+BTY3Fze6bGIre4OBCiApLleVbd8oI7Z2+2a+adTtRbzyRtbyQSRsQUbsfTnn9TX6B21zpmpWLW0sZkt51BktbqLKqD2I5UD3yeuc15f46+BmgayjXWl6jPpTlTsR3MlvjI4UnJRfzrOUubR7lJOO2x8ec4xmrVyt1pt1LbtLslXAfyZg6nj+8pIPX1r1bxn8Edf0ZfOsYnvFH/LRAskUgx1Vlz/48BXn0/g/X0spL0aXcyWqZ3yxIHVT3+7nAqeWS1RXNFjfDOmaxf3Rm0G2WWeFTlQUY4xz8rnk8dhXo1jb6xdWESatp2r2scfL3DT/dJxn5FKlAfYe1eZeG7t7PU1UWlhceZ8pS9iDIPxP3frXotvrUUY8mW1060MS5EUUrSKB7OrSbfyGOleZi5Vb8sev9d1+TR7+VKCXO3t0drfirarzTNyC60KPZbefqNxdjISFosgHoPnIBAPuTWbr63VlDLcQy/wBliMZ81IFYfQ5GT16gVHPqtpqcJeLT9RngJIadsyRKAMYWQbeP97Brh9d2nz4bq5tcI4VRHEGKf8DBJP03H9K5qeG5Z2b/AF/T9D06+Nl7G+vlb3f1enozci8fXem6e0MWqXt1eSPuaffuTbnldrAY46YOBXOXmvz6tq4ub+4DoPlUSoWIU9cDkA+9ZOk6bcavrVlpenATXd5cJbQAnaHd2CryemSR1q/beFNYufGZ8LW9sH1sXb2RhDjAlVirDdnGAQec44r0qWHp0pc8I6nzVfGVa0eST07XO41bUrC18Jpa6e9vaQsNr+XJLmX3KFuT+C815dM26VjknnvWj4m0HUPDGu3mja1b/Z9QtGCSx7g2CQCORwQQQfxrLrqlPmOJRsKrFWypIPqKsRLbywzvPJKkiRgx4TeJH3AbScjaMFjnnpjvkVaKlMoWkqxeWxtZEUywy740kzE4cDcoODjowzgjsQagpAFBJPU0UUAFL260lJQBKp2tng+1SjI5AAI4Ge5quOMHNW4Y8xbjyh4BP97rQBZjXcoOBRSRqGQHew9uKK01FczXHzHuM9aZU0nuck+1RdayRTQYweeKO3vRSUxBViwtmvL63tYyFeeRYwT0BJA5/OoBjIz0q9oTBdc05j0FzGTn/eFJ7DW5Z8XaJJ4b8Uaros8qzy2Fy9s0qKQHKnGQD2rIr2r42fDbWYvFHiLWyjNcX/iL7Ja2ESb5JlnV5Y5AVJ67SNvXPXFcf4u+Gms+FdH0qfU1YarfXk9mdNjQO8bRhCMMpIfdvHC+3POAuZD5WcKcYHBzSV6voXwY1TWNS8O2iXf2b+0LSS7v3uYfL/s0JO0JVwzAsxZQAOCSSMcE13WufBXRpL/SrK7v4NE1m80iBNP0xMs99eRwkz+YTxHlwFBzgnOOeqdRLYOU+copHhljlhdklQhldTgqR0II6GtyDxPdNsTU4otQhU5/egCXd/eEo+bd7kn3Fe2698ALO78Z6lZaVrMGml7qN7HSQPtM5smeJHuCS4IVS7nDckIee9Y3wc+Et9f61d6te2EOo6Haz3umhJYyTLKsEoWQIeNocKMk8MR6ZD50tCXBS3PN7DVrGW7WW7O8yn95FONsa4Py4K9/fA7jvXpvhKLQNXIltvC2i6vqpdkltrBZ8qg/iWJT9eR60y3+A0kPh6/vJtQOralHYTf6DpWJDa36mHbbyMu4M2JHyowfk4JFZNr8B/GiHU7f7Jt1uz+zSQ2cc0ZFxFKZAZBLvAXaYuh9fplc8SXS7Ht3gzwTcarpkn/CXahHfBZy0NmUS4jjQgAeYX+cPt4PIPHOa6+/8AaFqX2bz4JDJbLtheE+W0a9gCvIx264rzm18L+IvB/hmwk1rx9FoMljqDLd6nJI1y5hlhi8qHy2z0cP8rYCgMw4PO/renfE+41LTNPXU7N7HEh1C+vLOOOIOs7rGFVMOd6CM7QT97OQDgZWW7L5WtEa15pNpotyraTp17e3TorG4S1MhYYwmZ2bGRuySe1cjr3gC11SZHkt9EeR5XlubzULqT7ndlEUnPPYkAdBWF8TPix4j8AeMv7Lg03RZGTT7Qu0izOGYwru2gSAABgwGB09a5L/AIaT8WlGB03w5uY/e+yScfh5lNU3vsJ2PZNG+Humw3Si2uLH7PC67lj0yNRKu0YBkZnYn0OcgV6RZWgSCNIIgyooVSkecj+lfIGoftD+PrqEJFe2Fpxgtb2MYPXPVs1xWtfEHxXrisuq+ItXuY2+9G124T/vgEL+lXGCWoH2v4s8X+HfC8U39v63YWc0eCbYzBpz06Rrlu/pXhvjT4+aPtli8N6FLf3DAr9r1X5FA77YkPT6kH1r5zMrHdk/eOSe+ajz3qxWOi8V+NNe8Uzu+r38jwswYW0fyQoQMDCDj8etc5RRTuCSWwUUUUDFpKKKACiiigApVODkEgjkEUlFAC123wS/5K74Q/7CUP8A6EK4iu4+CRJ+L3hEkkk6lCST/vUnsOO6PQv2yyD8WLYEk40mEDHr5kteDntXu37ZX/JWrbP/AECof/RkteD0xIWikooAXtSUUtABSjOemTSDrz0pyq2C69BxmgB6uYnDwuwb3rcsdWkVgcIl0QB5nl53D0bAzj6Vn2lxGqiCVVQOfmZ8snfnA79OlWLWOSwuHki/fWhB3smGUr15GeD7GtFdbEvU7jSNWF8kqz2cAtx1IlDlTzypHPbpWnoGu3UVxMbG/shbwj5wpfkdty9T9f0rhU1KRJFuLNSWReXL5YqcDaSO3GADz7mtCeaC7UzpnTr9eVEjbSM+h64NaKehDiexw+K5LrSREkjJNj5WtZRKoI55Vgp79iKu+HPHF9pMzHVbS7lt8YZ0STleByCCMe4z+NeBSeIb2znLXEIWdh8zwS4Vh6kcjP6Vc0rxXNBcmb7dPb4HylQOM+6kfyocovRjSl0Z9hCbw/rGnLcPALfzlz50QKEH1DL1wRxx29q8w8Y6Jr1nqTXFja22q2zjPnwoJbgrzgsyMkg474NeTxePpoUlgm1G4l3YUTW8Sc+5xgk+561mnx1dNHcW0+oXXkMSYpAuQCT3XdkfUNU3UVoWoc3kaWq+F3vdRmu7OZdOuFbLAzlZFPGflfaenYFiam0C1W7vri2v9PbVnXCF44GBc4zmRTtbPfqc1S0f7VefaAmoSXXmpt2SCUq4PrhyAe1dNo9j4o0W3D3VhLb2TZO6MOMJjrwoB+h5ryMfXhKLUWlJ93b7urPo8swdak05/C+2qfr2sU9d0W2WxlS20myVkGWS4kksn+nk8bz16c15TrqFbwj+z/sG1QDFknnucmvdYdf8PXNs9vqUxumbh43RHd/bYDv/AAxXnfi+PR73XltdOt7SwEQUgylrZNvXG1u/vznNc+XVpufs5xfrrb+vkPNPZzpc0bL5Lp8r/K5zHgjVoNC8Z6Bq94sr22n6hb3cqxAF2WORWYKCQM4HGSK9Oj8e+BdI8ca94v0i18Q32p6it48VvewxQxwy3D8kPHKWACNKucZ5FcrrugaVNZhtMvLae8iUDybadWXHpnblj+ZOe9cnc6LewPia3a2/6+WEWfoGxXuODR80pJnVfFzxhpPje80XVLCxubHUo7FbS/jcho2aM4RkfcWY7cAlgPujr1rgauXtl9kVc3NrKWwcQyb8fXHFU6lqxQVKfK8kcv5vcYGKjpVBLADqT60J2As2tjcXUFxNb2txPHbR+ZO8aErEpYKGY4OBlgOcckVVIKkgggjsa3/7CaHTFuotX0+SaRQTZ2zvJOB1+bC7R0/vVgnrzTt7ql3DrYSilfO45GDnpSY+pxUgFJS4+lFAAKmiPzDqRnoKi+lSw9Qe3tTQGrC6iNQI0YepWilt7plhUKIiPVoQx/PFFVoQYzY5GaaRj60rYyTk+1N7VmaMBQOTSnoOMUhGKYhKu6Odur2RAzieM4A6/MKp0qMVYMCQRyCDgihjR9FfEn40+IfD+teM/DltKWvYtVkXT75lQtZQlm3qvy5LHdgMclQTjHFcwfj14mXwLaadHfzt4ihuGB1SSGJmS18tVWNDtyGJBLORuPHJ7eQ3tzPe3c1zeTy3FxK5eSaVy7ux6kk8kn1NQUrIR6z8RPjFq3jDwLo+jT3U32xmlk1hxBHGlywl3QBdvO1RyRx8xJ561594g8Rap4hOnNq90bg6faR2Nt8iqUhTJVeAMnLHk5J7mspNmT5gbocbT37fhTKLID0PTPiRql38X9L8ZatdfZZ1uYFuHtIztS3ULG6qhJ4MYbjuSfWun1T45akvxaTX7QzT+G9PmkjstJilNtC8OGClgAfmJIckgnPHQDHi1JRyoDufhp8QtQ8EXGrS2816wu7KaKKOK4KIlyy7UnZeQxTJPr711enfF2S5+FPinQdfb7RrVzCkFpesrNLcI9wZJFlfP8O+Qr/vYrxykosgOku/GGq3nhJ/D15Ik9pJqP8AajzS7nnabyvKALk8rt7Y/Gu5074sax/YXg7Q9N1TVLae1kaHUJ3n/wBchuVeJVfO5Qqjb24JHTivIqWk4q1hp2dz179qaQt8Yb8LLvSO3t1Ta+4KPLHA547nHvXkRNJ9aSmlYQUUUUwFNJRRQAUtJRQAUUUUAFFLSUAFFFFABRRRQAV3HwQ/5K74R/7CUP8A6FXD13PwO/5K94R/7CMX86T2Kjuj0D9shGb4sQsAMLpcGef+mkleDV7x+2McfFyEjGRpkJwe/wA8leEnbgYznvTJE7UlLSUAFFFLQAlOVipyDg9KT60UAPBZkxjIHf0qxaEK6HzhEc5DKSCh7H/9VVkALc5x3x1/CrUbwFSjQ+YSchwxVx/T9KpAa1rKFlMRSC63AkOUILZ7E8Ent/jT2mtbmFlmju7YR5y0Slgh9fpWNcoscxVTKkTdPNXnpU0TyWs+PtW0Y4dCSCD2PfHsRVcxNhv2e1BbN0suejBWH507Tbi2s7lWvrSO/tU3bofNMe/IwMMPmGCQfwxWy1kmqxBI5tKlnBBZrfdHIR9G2qf51XvdGhsbiG2vGuLG7bdu+0QtEiDI2tnJJyM5wOwxnrQ1YL9CjDFJcQZitvNRSWKx5LD3PJI+tRBYpJYwwmXc21gV3lfoOM/Q1rRWD28YmUpLFzm4gjZ8fiQvr2NFraRNc+dP9suwWzvWMnj33c5qXFtGkZJPU6vwre6TpUKpqkt5Ao5jlFnKu4c4BGSDznt3rt4NXsNWsVkg1uGOIME8iWIKJSTjAG5Dmk+HE2o2tp5On+ML6wt35FvdR+bFz6go2B7ZrV8T+GtZuGNzbWmnX6uPn/s3SVbJx95gFXk+ozya4K+VKrLnc2n8n+h6uHzypSSpqCt81+Jyt3eR2DXC3etT2pU7VhOjblYdcbt7HHuQR71yt74k8uVVtpLcwF8p5ZJCHHqAgB9BtOKsa/8AbYFjgPhee1kjVtpAmtnweuVMhz+WKx/Cvi2fwxqd41rBbXv2+A280V3E7OisfmEbZyrkcbsGt6WGjRSslfvbf8DCtjpVr3bs+l/+Dd/MzLzU7ie6ElubuOdSS7Fy4I7YyASPrUWsajdairNeXkt1EgAyYFjIPuAKpXRW31J/MhuWgLN5S3SneUz8uRkc/pmrmqi58yK2bS5bMyDcoFs0byj1xnkV1cztuec7X0RhSEFjtGAKb2qeW2mDyDyJV8sAuChGz6+lRmKQIjmNwr52Ng4bHXHrWYxYYJZyRDE8hBA+RSf5U1W2NnaCR2Io2ujYIKt0x0rpv+EI1s+EF8Spaq+knf8AvEcMwVHCM5UdFDMoz70dRnPi5mYeWjyKjdUQ9fbH9Kv639vvJ3vtQWQO+CzTbULYGBheOwHQdqzopprdt8MjxMOMq2DVuxu1Wzu7ea0huPPZCZmUmaLaSfkbOBuzzkHOB0rVNNWIs73RnUH9a3dJ8P6rrdy1tpmn3MwXDEqnEYPQs3AH410k3hrTdIzE9wt/fjhwrp5Ufrljx+XIpRpylsKU0tDlvCWiN4h8Q6dpYm+zreTrB55QsELHrjIz9Ky5CoLLGDjOAT3Fd94EnEvxQ8Ooi26LHfIMQtuT8+/1rgJMZ45Oeo6VzKT9vKF9El+Ll/kjX7Cfr+ggx+NSKemcYB7c4qPJzz3pyD3x/WtkSaEMmI1Hy/iaKWNMoMBD+VFaakmbgHr+dNPHA/Gg/XmkrEsBzRmil2kgkdAMmmITOTRRmgnNACUuaSigBaSiloASilpKAFpKKKACiiigBaKSigBaSilPGRQAlFLSUAFFFLnjFACUUUUAFLSUtABRS8nk9+9JQAlLSUtABXc/A7/kr3hH/sIxfzrhq7n4Gf8AJYPCP/YQi/nSexUd0d7+2Tz8WoecY0yHj1+eSvCcZOBzXu37Y+D8W4s540yHoP8AbkrwimSFLRRQAlKOlFB/L2oAP5UuOM5H0rf0bXrWwS0E2k2twbdidzAZfcQSTnOSAoA7DJ65q0fFdvJDL5uj2huHDbJgBuj+UrHtyP4fl/75rJzmnpH8SW30Ry3bFGecnn3rqk8WW6tbEaLagQ5UruOHRuWB47sAc9ucdaI/E2nq0sraFaSSmNRGsnzLGy7QvuV2jkZ5Pel7Sf8AL+KFzS7HO/aZRCIzJ5kY6JIN236Z6fhUG4+g/wAK6VvEln9kS0GkQvCrRhnkYF3RQRg8cHkcjsMc1a/4S6xa+nlm0S2kt3k8xYWCkBsnc33epG0fhQ6lT+X8UHNL+U5ax3tdRRxypAZGCGR2wq5PVvb1q288sck9uZxNGhKZD70JBxuXPQe49a3bbWIH0R0TQXl0+0Ox7gHOwuwZA524+Yx4OeoBxTJfFGnmX93oNksIhwse0YEpHzN06ZA79qftJ/y/ig5pdirZ3LJZqsGoRh8jdb75lL56gdV9s8V0unW2mWuq2skC3TzSEMsF47wq3fA2Et+eKzZ/FGmXsc9sdFBR2YxBNu8ncTEpwOi5x3OCRWrpF1M+oWSaJ4Qu/wC0TN+5EVoWaYcF8YGQdqnGOmT0FYupVUluvmv6/A6IVm4Neyv5/wBant/hJ/DurQoslvc6ZfYwY5m+1wn1wxIYdezHv3rd1GPSrGGSOMWLTqB5c0MTxlDxjlmJ/wA4rzLS7572CE3A8uNn4We3CBABwFxk9ePrxXUpf6wkUe2fVHtkI2PHMDtHHCg/e4B4JHXjGBnsVSpLVxf3r/M4ua2ljm/iB4nE1gYLmG5utm4eel9GT6HIUAj8vSvIvBV1HafFfwvd38gtbaLVrSWSS5baI4xMpLMzY4AHJPHFes+I9Yu71Ik1NdRmnD5VLuISF8dSoU9Tz0z75NedX13ollNBb3uiCMwsHk8238qRwPuZ3euOexqZ1KjXwP70OM2nsezeNfGem32q+H9Q8Pa9o2of2b4lvppk17UFZo2y3l+Uw6WxA+QqCFJjyeDh+l+I/Ddv8VPAmo3HiQW0gmv5ryzudeXUbSy3W7qrLck4UucDbn04B6+Dwaz4aaScXekRpEyBVVEyx5G7ByMHjg9unFJDq/h2TT1Fxp1uLlVyMRAAsN2A23HHK57nFRzz/l/Ff5lc7/lPTdC+Kmj654t0bRdTmvP7AutJn0PUNU1eVGuJhKSyySNnACPtAJPALEmvP/jHqtmdZ0vw/oN7FdaN4esY7GG5t2BjuJT880ykH+J2PQ4+UVn/ANveHFu5ZW0RGXCqiIq7D824sc8g9RjpjApp8Q6CqRmLQkSb5tz7VIXLDoOh4z19an2k/wCX8h88v5TmYrqRAyoxVnPzMeSa9Dt18Q3HwOvLkaih8PWWoJY/YQFAdnJlMh+YMWVtoAKnhzjgHGG+ueHJJXd9FkVWtzBsXadpBOxgTznBwT7Ct2zWfUEkTTvDkVppc5Uvc3KrF5aFvmUMeCMZA78k1SqVHooslza+yebiFt67yEB7vzXQWOoFVUSXCIinJ8uJF/DpxkV30lr4X0wkG60nzFYsTbfvEPTAaUgYxgnCBs9K5q61jwxDLMgsIblG48wJkg4Odpbk8njPQAYxW0KtSCuotfNf5kSm5/Zv9xW1XVWmhuf7PupYbB5WlFqWMjKhPCvKQocDp0P0FY15qitZmFFhUsfnKpuOO2Cen4Vqf8JJpCxRyx6NaCWKRtkPlDDLggFmzyPVcck5zxTU8Q6CbqZ5/D8JjYqiKihcJkbj/vfe6eoHapnXqPXl/Eauvs/kL8K2X/hYvh7YuMXSnP0Brj8EjODj1rsYPE2l20UE9npslnqkMiSrc2xEZ3Yw2D/D7Y7jNB8Q+H2nM7+HYwWWRTED8ueSpz65ODxwAMVyrnVWVTl3SXTpf/M2dSXLbl7/AKHHDnipYsYHQH1NdVDr2gx22P7BSWdlJZ2AADFwxUDsoBZQeuMfhaXxLosM+bTw5b/ZzH5ciSMCHIChWxg4I/ed+SwJ6Vt7Sf8AL+RPNL+U5qKMmNcFcfU/0orsW1/Q3d5B4egk8xjIWcKDljk8DjvRWiqT/l/Ff5k80ux5yeefWjjPXFK/DHHrR/hQb2EpKUdKXHBoEJRT8DP/AALFMoAKKcQNgPf/APXTKACiiigApzNkKNoG0YyO/Pf/AD2pKSgAooooAUDPTOevFJTm60ijLD60AJRRRQAUtJRQAtJRRQAUUUvagBKWjtSUAKQQSCMEdjRR3oYYY/WgBe1JR2NA60AFJRTmGGYDpmgBD0Fd38Cgf+Fv+Ejg4/tCOuErvPgV/wAlg8I/9f8AH/Wk9io7o7v9sUH/AIW0hHAGmQZ46/PJXhHpXvH7YQB+LaZ/6BsH/oUleEUyUhD1PGKKVwBjFC8kZ9cUDDHvSdqXtSkcN7GgQ2ij2pRQMKO4xkH607+D2zTVHDfSkFrCUU5/vEdhwKHABOPU0wG0UUvcUBYkt5Vibc0KS+m4sMfTBFerfs8w6zq/jmM2GqzRvpds90kMhMiShmSIxhTJGBnzQfvDp3ryfaMt7A1Ytby5tI7hLW4lhW4QQzCNyokTcG2tjqNyqceoFS0nqVdpWPY9NvNP0u/u7WHVtPv7iGV4ppJl86G4IOC642tyecnrnqetdFMNAvIAh1i20q6C7iEmuLdVcrwSHYptyQcd/UV8+XV3calfS3moTy3N3OxklmlYs7sTyST1NR+fMisqTSqrAFgHOD9a1U9LWIimpc19T1vXJ4LG3kgg183ySZGZWR1bAPKtllxnoa8ynZYeT+/ydyoH3rj/AGsHINQx63qcalUvrgKeo3kim3OoXV5GoupfM56kDP59ajmk/Q6JypSTk78z8lv9/wChTlIZmcALk52gcD2ppORUsoxGpHU0xQD19qDBotadey2E7OkFtMzDbtuIFlA+gYHFVwVDDzVYjPIBA/pxTnUBQwGD/wDXpBy3PPOP50lFJ36j6WL9hdWcU5dopIuPlk3liPwxz+lWbrXnKkW5mmcjb51y2849FU52/gTmsUj5D7AUKB5wHYnFWptKyI5V1JLi7nuP9dM7/U9Pwqv0qeJQZIxjg/41JEoYsrDI2k8+1SU1YqmkqUIpIyO2aRlAUYHbNOwWIxkinAc88/jUiIpXOKbtG5RjrQIO+c8mnrnKnJx9KdEoIYEZApyj5lHbOKYi1GxCABiP+A5oqaBR5K9fzorVRbRLaP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The systolic image of the main pulmonary artery (MPA) shows shunt flow across a patent ductus arteriosus (PDA) (panel A). The ductal retrograde flow is seen as a bright mosaic jet superimposed on the normal blue flow in the MPA. Note that color away from the transducer is coded blue and flow towards is red. There is also a very small color jet of pulmonary regurgitation (PR) that is in the center of the pulmonary valve. Color flow image in the four chamber apical view show early diastolic inflow to the left side of the heart due to the large left-to-right shunt (panel B).",
"    <div class=\"footnotes\">",
"     RV: right ventricle; RA: right atrium; LV: left ventricle; LA: left atrium; RSPV: right superior pulmonary vein.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2834=[""].join("\n");
var outline_f2_49_2834=null;
var title_f2_49_2835="Invasive urothelial carcino";
var content_f2_49_2835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Invasive urothelial carcinoma (UC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Photograph of a surgically resected urinary bladder opened anteriorly to show urothelial carcinoma involving the mucosa that surrounds the orifices of the ureters. B: Cross-section of urinary bladder wall demonstrating transmural diffuse growth of urothelial carcinoma. The tumor invades the perivesical adipose tissue. C: Microscopic appearance of invasive urothelial carcinoma (20x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2835=[""].join("\n");
var outline_f2_49_2835=null;
var title_f2_49_2836="Duane syndrome type 2";
var content_f2_49_2836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Duane syndrome of the left eye (type 2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Limited adduction and apparently normal abduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2836=[""].join("\n");
var outline_f2_49_2836=null;
var title_f2_49_2837="Lisch nodules";
var content_f2_49_2837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lisch nodules in a patient with neurofibromatosis 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The iris of a patient with NF1, showing multiple Lisch nodules (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Friedman, JM, Gutmann, H, MacCollin, M, Riccardi, VM (Eds). Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 3rd ed, Johns Hopkins University Press, Baltimore 1999. Photograph courtesy of RA Lewis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2837=[""].join("\n");
var outline_f2_49_2837=null;
var title_f2_49_2838="Intracranial pressure monitors";
var content_f2_49_2838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Intracranial pressure monitors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventriculostomy allows both ICP monitoring and therapeutic drainage of cerebrospinal fluid (CSF). Subdural and intraparenchymal monitors cannot be used to drain CSF.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2838=[""].join("\n");
var outline_f2_49_2838=null;
var title_f2_49_2839="Thoracoabdominal aortic aneurysm on axial CT";
var content_f2_49_2839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Thoracoabdominal aortic aneurysm on axial CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 480px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHgAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+K8UuKAPtP/hqvwP8A9ArxJ/4Dwf8Ax6j/AIar8D/9ArxJ/wCA8H/x6vizFJigD7U/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6vivFFAH2p/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1en658QNK0b4aR+OLq3vn0mS1t7sRRohn2TFAgwWC5HmDPzeuM1+bdfavxL/AOTNrP8A7Auk/wDodvQAf8NV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1eEfAn4d+HvG2jeMdT8T3GrQwaFbxXIXTnjVnUrMzj51IJxEMcjrz7dx4Q+Evw08TavpunRnx3YTanYnUbNruWyKzQg4zmNXKn2YCgDv8A/hqvwP8A9ArxJ/4Dwf8Ax6j/AIar8D/9ArxJ/wCA8H/x6vkXxvpUGg+NNf0izeV7bT9QuLSJpSC5SORlBYgAZwBnAFYlAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxZtq3baZd3IDRQv5ZON7DC5+tAH2R/w1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8h/wBjLGF866TeQcogJx+NOXQJpdvkCVgRuJKdqAPrr/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6vkh/Dl0kYdkkA/3ahbRiFz5uOM/MKAPr3/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq+On0uYE+Wyvj0qvNaTQ48yNlB74oA+zf+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq+LNvNJgZoA+1P+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4rpdtAH2n/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFjLijHHBoA+0/+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+LApPQEn2FOMTjqjflQB9o/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxYUYdVIH0pMUAfan/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxXikoA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA/VSiiigDwD9tb/klmlf9hqL/wBET1x/wE0HWfFH7N/ifQ/DtxaWt3f6w8Ek1yzKqwmG38zG1SSSuRj3PNdh+2t/ySzSv+w1F/6Inr4rFAH394E+GWoeB/iFLqWlaot34fu9Mis7qK62JOJYQFiZVijVCoQBeeeSTmvgIUlLQAUUUUAFFFJQA6kpQpYgKMk9AK0oNIuGj8ycpbxY6yHBP0FAGZg0Z5roLbSrUyBR511IfuhBtB/rXT6f4Qv5SrRabFCGH8YJ/PNAHnGRnij8a9THgjUyrM0NrwcFQo4rMvfCdzE7LNYqzAZ+QY4/CgDz89P8aXFdHcaNGjFWtpEYeh/xqA6MjYw8iZGRuGaAMP8ACkrVl0aYNiOWJ8njJ2mqk2n3cJxJbyA+wzQBVoqQ283H7mTn/ZNOW0uGGVglI6Z2GgCGira6ZescC2k/KnjSb4kj7OwI68igCjRmtD+x7rOD5YPpup66HdNn5oQeuC9AGZmitRdDuW6SQZ9C9Ry6NfxqWNuWUd0Ib+VAGfRTnR0fa6srejDBpuD+maACijBooAKKKKACiiigBDSUppKAFr7U+Jf/ACZtZ/8AYF0n/wBDt6+K6+1PiX/yZtZ/9gXSf/Q7egDz/wDZE06XWPC3xP0y2aNZ7yygto2kJChnS5UEkAnGT6GvU/hv8KdY8O+IPCt9PFoWlR6NZS2142lSu8mrOy7Q02YowAp+YZ3nPfuPheigDq/ix/yVPxl/2Gr3/wBHvXKUUUAFFFFABRS0AZOKAADJq7YabPebnjAWFPvyNwq//X9qsaRpguAJ7rKWo4HYyH0H+NdBbW82pvDBZQhQp2pEn8P+P40AZ1lBawbDbxfaZc48yToT/siuo07w7fanJ5t1MYVcfOT1K+mK6nQfCVvaRpcXhBmb7yEdf930r0Lw34Ys2UalcBmtkO1IGPOO+aAOZ8OeC7OKHbaWxunLY3vyo49a78+AruwtIHufskMUg+UKQ232JFad9qMS20MUSQ2dnGuEjiAHXux71mzatbpAyrOzoMkIhyM+uKAOe1rTo7BSly0bjOG2Lkfge9YF74Z0+8UhVVeOGxiuguruS9kSVAEjXIUsP6Vi6hq5tzuubyPbuON2OfagDk9Q8DbR51sVZRz7n2rEl8K6jBv/AHDbPvAg5xXXN42so1VNjSkcYHQ1Ql8c+aSI7cJzxuPagDjbnQGcSNcWygkfIcYJrKOgQELtMwbuVxivSr3xZp93bmJ4ByRtZRyvrXPzNalnEMrPE/ABHP4UAcb/AGLAH/1kxXrxirA0iyV/9RcuFHOW6/lXQtDaxOjz70iJ4A6n8K2NHj0uVTuEZctgb3wRQBxkOkW7P8lockZwxJxWja+HLyVN0Fig3fdOzrXqUMdhDE4iSJ2YDKhgcY71dju44MJ5bM2Mg44oA82t/CepBW3IMMARgAVaXwRqjANG4Utzgkce1d3qOqIkWbQhiqj5SMH3qPw1qEl3qUUTqY9w3Zk4GfSgDzi58M6zbsTtWUc/I4HP4Vh3djFGxXU9N8k7eWi+Qj6AcE19tSfDzSNa0q0uLrMV80a7poD8p/CvOPGvw1n0eF55THqGmb/ndly0YPqBQB8sTaB5q7rCYOevkyfK34HoaxJ4JIJTHMjJIOqsMV7J4l8FPAHn0YsygbngY5IHse9cZJIl0Ta6vHvWPhXxiSP8e49qAOKwaK1tW0iW0DTRHz7TOBKo6ezDtWTigBKKKKACiiigD9VKKKKAPAP21v8Aklmlf9hqL/0RPXxWK+1P21v+SWaV/wBhqL/0RPXxWKAFooooAKKKB64oAOlXdN0+a9dimEiX70r8Ko/qfaptK0w3e6aVjHbp3/ic+iiuls7SS/kjt7aLbCv+rgXp7n3NAFO0tUt5Ui09DJN0WVhhm/3fSun0zwhPL89+jmMnOM85967Hw14bt9OgV5l+0XTfMh7qfSvQ/CdrbjUEn1FQ8cQ3iAj/AFh9CaAOe8F+DJWs2kisoLSEKSzyD5vwrs9J03S0jkW8hlnygCSFtgH4d6dq+tR26SXVy4/eyfu1TAA+g7Cuen126dyoCJu6seSPpQBZ1u1treBvkC4PBBx+lc6s8cYInkGD0IFO1DU02M9/ciTaONxAYVy2o+KoVXCuq9hvXdn3oA6VoNMu2IkgQjb1Kjk1lXfh3RnyzBIhngg4xivO9Q1q/nnYRXbbT02LtFUWkvpSN7zN35JoA9Bi8M6XMHME6CMHGHGce9YWoaVLZTt5DJLEpzvQ9RWNH9q2DyXmx3UAmrUVtq2Pkt7sg9cqaAI5reXcPLlLqo7H1p1tpV3PtVSwQn5Ru/WrcWmasgC/YZMc5b1BpE07WbV828N2uPVev0oAtWngye4icvPgBuTuJrVg8E2+SktxnbghscH2rOi1jxJaxmJrdmiXkI8Z6VZsvE8zSGPUdPn8sf8APIEZJ780AbEXguwjG8nGGydo61EPDelIVWMLknlick1oQutxbRvbTzBCed/FV/7EQ7phcSLIPvNnhR24oAuQfD6y1G1kmtIS4UfOq9RiuW1TwOLeQy208ls4HyCQFcn+dezfDnxXD4emEGrWkK2rYAmiGSP9pq9g1Cy8P+INKeW5js7q1kX/AFoxkehB6g0AfB+qWd7Zkw6tbJMW53suRj1J61iSaTaXin7DMYJ848qbkN9G/pX1F4v8Dto8jNZSR6los3fIaRPZ/UehFeQ+JvBkLrJd6QwiYD/U9Vx7Z70AeP31lcWE5iu4Wicdm6H3FVsV3M6SxRtBfwmeM8GN+3up6isLUNF2QiawdpU6vFj5k/xoAw6KKKACiiigBDSUppKAFr7U+Jf/ACZtZ/8AYF0n/wBDt6+K6+1PiX/yZtZ/9gXSf/Q7egD4qooooAKKKKAClApKVe9ACqpJwBWtpGmrMFubwFbXOFA6yH0FO0DTFvJmmuMi0hwXAOGkP90V2ulaNdavdFlVYbdcArjCxL2xQBlWlrNqM8YRQWxtQKPlA/u//Xr0fw5o62E0KJGG1Jx8sa9IuOrU17WLSYI7TRIRcXrthePvN2xXoen+Cp/DNhavq0kf9rXQ82Vd2SoPUZ/pQBnWejvI4+0tvucghv4QPStnWNZs9JtYmupx5cKhQqr9+ovEeq2OnRxmNthYjbGTy7elcFex3Wr3LXl51ZvkgA4QD09aANhtXS+nlnZWKtnbG3QDtiql3ra20BWK2mkKdGC4wfSrVlB5MWFiHl5yPY/WrTqJCA67pDyV+lAHB6l4g1KWXKhQFOfLHFYl3Ff6j++8hAGxkKhyDmvWdO0CCWYTTxAbsZb0P+NdRBYW0CxjyY9yjggdaAPAIPC+oXDjZBJvU/3cDBrWsPAWryOPKiCMATiT0r3WSBFAwi7em4dRmlKBm8tsng47GgDxyL4Xak0hZ7m3hOM/Jzn61ZT4VzBcPqa4zwVTofQV62vzJyP4e1NXBUtnJH3QPWgDyqP4YTBZNuoKzn++uTiqcvwqu8gw38LZOeVx+VewkZQfKAfX1qNgm5lxgjkelAHi8/w21u1Y/Z7tGG07cSEc0lrZ+J9KYC8IltwATvBJH417aV3Ak4yOmOtR3Eatt4PTGW70AeYwalY/K8lzGjsMkFcbT6VdgntLhQ8bxSnkAjqK6TWPD+n6gD5ttFuH3X28g/hXJv4VitrwyRvIDjLBeBQB33gj4g3Ogzw2l5uuNKOAy4+aL6Hv9K9SvvFtpLHD9jRbqCXKyqy4BU/56V8/JbLHCo+Zgcnnmr/hvWvsl0lve3QTc37skcAemfWgDU8R6SLPUZ57CNo7F2LJAPnaP33entXnnivw7b6kpmtYRHOgySO/1r2/T0S+/dfKocDC5+/msXxL4PuY7eS/sYjIqH96qDlB9O9AHzXLFcWkpDgKFG1wRlcfTvWBq2jo+Z9OQju8AOSo9R7V61eafZ6pf3SviKROzcZrmtd0C601/NBIjUbgyDr7GgDylhzTa6fVNMF1mW2QJcgbnQdG+lc0wIPIx7UANooooA/VSiiigDwD9tb/AJJZpX/Yai/9ET18VivtT9tb/klmlf8AYai/9ET18VigBaKKKACtfQ9MF1uubklbVDg46yH0Ht6mqmlWT392sK5VPvO/9xR1NeneGvDo1KRGZDBp0ICj1Yf4nvQBm6Tol3rE6AIqxRjapUYRF9K6+zjTSLqKw0KL7Xq8pAUKm4r/AHsVY8R+ItG8O2iWhdY32/LDENzfVsdKr/CP4p6F4U8QT3t9avJ56eWXI+eP3UnpQB6XpWiyWsRS4QpKcPI0g+Yt3z6VV1rXItLikjt8fa26KOdvvWPqnjxtauHOiyqiuWcztIC/J6ce1ZltDGI3WW4aeVgRnHOT70AQQi8urh5r+aQyPy2D/TtWpFbwuMMzlccEtToLZgUUxk8dTUssLxRq4TIJwD1CmgDMv9Igkiba4zt+VmOfwrJh8MG6O2WTAz93byK6SL9+AkiEYOAx7e9altC2xdwbzOVJHf3oA5qDwPaReU8jM3A5/wAa04fC1hDsPkE8Z+c1vMPkUNgg/KVPenKrFmLJkA7NuewoAqWunWkaK8UEQQclcVcRSmfund1GO/b9KXaTyVO7PY9KXhi4yAfvEn3oAZ5O1cBAXBqYRDABKkjt6UgAIUNg8n+KmwjCB2TJ3bceooAa8CuqMRnPWqdxp1pNmSSFWXsDgGtFWO0lgQc4AI6CmgE8kZPXp3oA5y78O2JV/LEsLt2WUjHqaxX0e9tHDWV2+1Wz8wLb67iZRIQO3YY4OfWqVyScrnZgEEjt9KAOdht71pJI7l13cklfT3rY0rWZ9IZYC7NaPj+LCj3qKUbcMAVbG44rOnK3DSRspIC4IPv3oA9Ntrsy26jgAkkgcjFVb/w0b9ZZLUCPy8H5iATnngd64TRtXu9NkSCKUTwL8pjc8r9DXqngnWoNRTzbWN7rblHR13GM/TqfrQB434m0KGS+dJj5cj8DIxmuO1zw1c2CpdQMZFGclegHt619SeKfA+m+ILRkLCx1OMcSKwdW9m7ivIrzS9S8PXf2TUYlmikG6MocqQOOaAPCNU02O6DSQKEuF5K4wJP8DXMupRyrAhhwQe1e56/4X82L7TZqRKw3bRXmfiHTXmDThCtwnEid296AOXooooAQ0lKaSgBa+1PiX/yZtZ/9gXSf/Q7eviuvtT4l/wDJm1n/ANgXSf8A0O3oA+KqKKKACiiigAqzp9tJd3cdvAAZJDtGe3vUC9Dx1711/hPT28rzVVWuromKJScFU/ib8elAHS+HdAF9dR2lvlbG24Mo6ue7H2Pau61bUNM8PaY32g+TbR/dwMNKcdAO9Qzz2fg/wuXdlBjXDL/FI56KPevDfEWt3mu3ZuLxyUHEcY+7EPQUAdFceP71dcj1G0t0iaJ90ILcqPevSNL+M994ohWz1e2330a4jlQ/w+p+lfP1eo/CDQZZbiTUpUxERsj3D73r+FAHfWMEV9dNPbwteTt85eXOE+grrLbQZ2jU3BAbopTque1aei2MNpaq0UW0E/MB2rTjK/MoJPzZQZwTQBjro6LFgMSGOGz2NVBozLdFjJ8+cD6d66JdwQsMFQSGB4K0zcD8o5P8Ge//ANegCO2hWOMqVJXHQfzqVcCL5TuK8BSOR71IeSq/MVK5Zcco3fmoidykrhiB8208t70ASM0YWRnO5VUbhSPgcPIwJwSQO3bmo1IkdlU5Ug7T7HqBRIjBVwN4PIUnHSgCSIttIHIORjjIpFGRncPLIK4HUGlV082Pzhxn72OR+FDxoHkRBk9c0AI8YQHLZJ+6o5xSbcyGMAhSQwY9h3pw+UptOFYAN9aiKhN2xwQM+4z6UATSOoAUAtGG5weSahIGzBJIJ5bsPcUE52tzkH5R6n0PtTmTbIQMMSeQDwvsKAIZEUZKsC27AX29aoXsK5Kxqx65x16VpsArngkY7jGKgkQSsm0kYOcHoaAOQvkMcmY84B4GelZN3GXcl1U8ZA7j6V0WpYVtgG1gxwf71Yd3GVxwDg5x6UAX9E1mTTlBjleaNDkqT8y/SvdfB2qQ3mkNf3FxCLNV3GcyhdvqHBr5fuDLBLK8TlWXlewrn767ursOHuHXJBYhiAT24oA9y+Jd14Q8QTvd2EkUOpRHC3MBH736r6VxCzuY2tNREc+3+Mc8YryC/wBU/soo0W92c5J966jwv4q02+tXW7uvsl6pztkOFcex7n2oAs+J/DElqTeWGPLPJb+6e34V5x4hsASbuHnJxLgcZ9R7V9DeGraXU9NupHT5Ilzz/Ep9K858W6CNPuGnWNjZz8BSOg70AeQGkq3qdqbO8khzlQcq3qD0qpQB+qlFFFAHgH7a3/JLNK/7DUX/AKInr4rFfan7a3/JLNK/7DUX/oievisUALThjbzSeg7+tbPhmyWe8+0SqGhhIIUjh27LQB0vhPRXLQ2m0rNcASTE8bF7A/4V1vjDxPF4X02Gw09F+1lcIpOQo/vGnwovh/Rbi8uULzyIZWV+uBzivHdY1CfU9QlvLpsyynJ9AOwoAr3Mz3EzyzSM8jnLMe9RD060E0UAdx8LbGXUNUuI0ZliVM7h2PavaNGsvLiUuQZBwSRx9a5P4XaatroaTQD55vmdu5rv4WXqTg/dPqaAJlG4Ywcg56UDkbCqZYYPtzTwFVw4z8wyR7elDDAZlJHck9qAIXhjJLDCuRjb2NTgDbgZyOq+n0po2sBgfNn7vbFOORLu6jpx2oAc3CjgY57cjNIgycfM24AcjGMd6SMZjO5wGbv/AI0gJ25YsQAQMdM+1AD3Bbdzt2jBwetKpOFGRwMnI6im8NH8pLAggt3NMdFcAglVToPb6UAS5Kqu4Dbk7T6D3pVYZAHB6qSenvUStvPmZAyehbqaVSGJ2jDj7wI4NAExOSCuM46+tJyGBY44yQKiD4wPvlOAp6/h60r5ExD4Bx0649qAGySqAwyBkdxVOUKMMRtH3hn1q2ASC5AYDgnHQVWmkWNX/iZeVJX7o7Y9TQBQvGSPEeMo33uetZ9ygwURcAn15qxcEmUscvxu5GM1M6I2CRyMkkd6AOfvlZdyW4IAxk471nDXNSsbsvp15NDMoK+ZC/lnHofWtnUIj5ICsFOODmuP1O1FvA+JwzSkbnPb6UAVpLy7F2Lw6xdRzs2TMrnOfeptH8bOb+S01bVWxGNsc0pLBj6Fuwrl9RmjihLmQ4UkAetcm7bnZvU5oA+pfh2IfEBvIXHzpCZIZUbKufSuS8c+H3t5Hv4Y/LcH5owM5FVP2addaz1ya2eVWKgMkb9CvQivb/GmnxahHPdRxgkA+YEAxtPegD4112zW2vCyDbFMPMTn8xWWe1ej+PtDNs9xCFGIh50J/wBnuBXnLdemDQA00lKaSgBa+1PiX/yZtZ/9gXSf/Q7eviuvtT4l/wDJm1n/ANgXSf8A0O3oA+KqKKKACiinAZBNAFvSrQ317FACAGOWY9lHJP5V7F4Ss1Eh1FowERRHbKfQdK4bwrpLtBDHEgN1ekYI/gj9/rX0po/gu0g+Hl5rupSfZ7a0t3eEDoQo5Y+xNAHzX8T9dk1LWGsxjyrVjkj+Jz1NcVk5qxeTtc3Es8n35WLmrOh6Tcaxfx2tohZmYbiOij1oA9F8D/DBNYsbS+vpmMVwoZETj869s0fRYLK2gt4I1SOJfL2kc4HFHgrS103Q7e1VhsiUKPY10BCyKSwOV7gUAPgTyYf3eAp45zUTnHQgHPXsnvinKwUnLA+nJ5pgzlSi4lGf4eD9TQAOcKi+XgscK3XPtTTtZtuCrK+CDxtqVlLQIAQqnlUJ5J+tRtFyp2/f4I3chh2/+vQAjZAIwecjnpn1pcHc6qfv8gdz7CpAHlXYWUOx43HIGO9RvLhOMhguDxzigBsnDjnD7eB6U84RFb77eq/w1GxURr5nzkDjPUURlTkYEffzD/LFAC5wCiHDNym0Z/OiRgm4spZ+mM47VJLGYkBDbs9f8B71AHDElQ23OS23mgBeisrZ+YEgcke3NOA8sNtGT1+XGBSMOFSIsHH4BhQfuMM5fHylO5z0oAB1c5BYD5QT1b3P0pseEUeUSIj8zZ69eaQO275jGDnBL9AR6/h3pqRKzFVBynzLk+/f/CgCaUc84GSduB2qtLhFwMkEYOfWpWBxvcEsTkccVXvJGWGQNjLLwegFAHN3BL3hzyVY8n6VV1JfKBYNvdhjCgYq4rrczyJGcsvzNkdPpVa5JnugqxttX+Jejf8A16AOT1m3uJw0cSO2TgkjoK5jWoDCVjBChBz7mu81CG82su913n5MDkV5x4x+0Wdu88m4fNtGe5oA5DxBcCSWOIHJj6kdKyBQ7FmJJyT1pKAPq/8AZW8QJJYJa3HlzMS0LM4z5Z6rnPYitT4k6DFJNcqAoilYkYPAJ9P8K8r/AGYrjT/7bu7S8mZZ2HmJEDguAOdvvX0ZpOmWmq382n35KrIpMZPJ3Y7+4oA+L/FthJHveVfntn8t+MHB6GuVbjtzXuPxX8PyaZrt1bXEZBkDQSEdyOVb8eK8QlUoSjDDKcGgD9UKKKKAPAP21v8Aklmlf9hqL/0RPXxWK+1P21v+SWaV/wBhqL/0RPXxYKAJIYmmkSNFJZyFAHc9hXrnw68MPqWo21nar5oiIH+9Ke/4VwfhWwchr1kY8+TCR/z0Pf8AAV9Z/s/+HfsNtPeyR757ZQApx80rDgg+woA5z9pHQtM8I/DO28uTOp3Uot8n/lpxl8ewFfJhzj2zXrv7THjZPFnj57azk8zT9JU2kbA/K7g/Ow/HjPtXkGc0AL9avaLZG/1KGAdCQTmqIzniu5+FdklxqN1M6b2jQbfrmgD2HwzZizsEhCjC4IAHFdBHGpC7CMZyQRwDWbpKsMhwQFxitRcIm4tgZyQR1oAVN2wkluDkr3WkwNxTOQOfwPOaHzId2GAJP44p7qNwJwufvH0oAGDE88KQOQec004RACMjJBPcn2qrqV6tnApWGSeeSVIY0iALPI7YVeSAMk4ySBViC7huwkisd/zLtdSrI4OCrKeQwPBB5BFAEbyBNxDZK9cDn6VMjiQbgxI6YHYVBeKzSrs5BXPydRRbE+SSm04btwT+FAEu8glxng8hego2swOCGRc89MfWlXIQAcOWwWY9fbFGGkDtlhtGSqr3PqKAGMuGDYVkHX296EZS2GLOp5Jz19qfIsefkwQQDnBABpuAAwGNi8496AFUsEQYwpOWPtSRsZAoBycklvX29qYkgG1pSRnCsR/D68dzUWRbXpjgnW4hb543HAkHc/h6UAW2AUKAQMA7sc5qncRlmy5wMZBI+6BVmJRjIKBzz0wB7VW1G8gsomUJl35A7se4oAy5WXzjyqjG45POKpreNqE/2ewC+UCQZW6Ad/xrPm0m91OQu0ux3bIwMDb/AHa3bPT5LePaFZJCRhcYxgdfegCG4sowipESSBnee+PSuH8W2rwxySyMQeASR2+navRWjuAoIPT+Fv6Vynj9ZZ/DV7HHEfPYc8c4+tAHiGoXRuJmxnyweKqU90eNikqsrD1GKbtPce9AHU/DLVo9F8a6bdzy+Vb79krHoFP/ANevsSwukjvLW7kgVrOXBck5VkPf3r4SB555+te9/Aj4p21rBB4Q8ZNu0iVttlety1m5/hJ/uH9KAOr/AGgPCcWl36Xtsu+zlPmRKOm09R9B2r5j1O3+y300WCArcA+navtj4wCwvNB07SLWYXBjjk+bdkkY45r5D8WWhWKCb/nkTbvxzwcgn+X4UAcuaSnMMU2gBa+1PiX/AMmbWf8A2BdJ/wDQ7eviuvtT4l/8mbWf/YF0n/0O3oA+KqKKKACtHRLL7ffxwk7U5eQ5x8o5NUAM123hPTHW3hQK3m3rDOR0jHY+mT/KgD074PeHP7a16FzEEaV/LRVX7iDqfcYr0n9q/wAVReG/h9a+GNOkWKbUyIyiEDbbp1yPRjxVv4MQ2mlarIJ3S3t9Psmk3McKo/iP4CvmT41eNT478f32qxMfsEZFvZqTwsS9Djtk5P40AcPGjySJGi5diFAHcnpX0X8K/BUej6b5t0GW7lA3kjj6V5x8FPDv9ra81/coGtbXpuHDOelfSlvGI0EYwBwXXr+JoAkgg+zQoiqrgcAjvj+tOck4ZG2Z5AboBSqMDKHCgHGRwfy5qN1ARt6jYfulD9729qAHxuY2DKY2x8xz0xTZfnJ3LsJbd14P0pvyncSZBg42g5zSqmVkUnLDGF6kj1+tADMssaq4Zl5DKPfvRsGwmJjgHCsBz+NMDfw7hyME56fUdqaQDE4YhOgBY8EeooAsCXG4cLIp44wCO+KSVxNxHIGVjkkcMPpWZqt8mmwLLNHNN5kiwwR26l3ldjhVVRyST2qzZzx39ossMoljlXKbB97nn6Edx1FAErhcLjLuBtPy9R6VKUIEe8IY2+U8ZIH93/69QmTLMgIMhH3l5Ye2akjcsux2UkLjC8AexPrQARrtXCuZUI+Xjn8D7UwbZdu/PHGScZ9zQkgZeN4TOfl659D6D3pZGyXEjFxn+FhwPegBrlk4J3nO0qP4afDF5a7gNyqclQccf0p3klkDIyhQch2/jFTrEZoJPsk8UsgGCM4J78+g7c0AZ4vY55zbwwuJ2B81Y1BIHp6Yp9pODGw5UgbCOox65rzjxlrN8L8xRWUlvJDuWTD4JHoCOo9qx9F8ay2TCK6Dn5v3avkGgD2eIQlVU7zsGNvXiue8Y3q2FncMgBEa+ZtB7D1rj5/iKjxmCyUec/GQOh9M9673wl4bXXNKuBrrNNDdxkOvT5ccigDxiz8Z2ccjmXWIYGmfLeXGW2fT2r1HQNJumsopLF7e7tZ8NHcRPu3n/GszXvgN4fsIVvYZLw2IBKqZuWPtxXbfDWex0jT7JreyMVnagjyMYfPrz796AM6bT7mNSZbdwRkNx0rm/EHh6x1u0NreWj7eQGT+f1r165+IGi6lqMmlC1ZD5e6R2j4GfQjg1y6JvuHjtj5kSk4x2FAHzZ4k+F95ZCSXTJfPjTnyn4cCvPLi3ltpTFcRvHIOqsMGvt2SyhmjKyIoydpJGSfxrkvFfgPTNdsttzZAFRhJUGGH40AfK+kX9zpWo29/YSvDd27iSN1ONpFfbHww8UWXxL0GDVdLEdp4isnRL+0VsAn++P8AZPP8q+WvFvw01XRRNPYj7bZLliyjDKB6isv4b+M9Q8CeKrTWdNbhDsmj/hmjP3lI/wA80AfT/wC0xpgkkFzEoDmBXJH94Hr+WK+SvE1usOomSLHlXCiVcds9R+ea+n/EXi0+OGkuQpSJ7cKkbHgKRnNfPPiy0UabkHMlvOwIHo3/ANcUAfpJRRRQB4B+2t/ySzSv+w1F/wCiJ6+MIIWmkSNM73YKo+tfZ/7a3/JLNK/7DUX/AKInr5I8Iw5vnumGRboWX3Y8CgD0TwNpCG+hjKZtrRTk9AW7k/j/ACr0PXPivH4N8AappemEnXb52SB88xIRgufcDOPesDQYYrHRY1mXBI3s2eua8Q8S6k+p65eXLfddyqj0UdBQBmSNuJJJJPJJOaaBSucmkoAmtbeS5uEhhGXc4Fe4/Drw6ulWpJ5lf7zDv7VwXws0xbzUp53wfL+UZ7e9e52FusalRsx7/wA6ALUUa8MD8udpqfjb8oIXPQmmbW4YxlEDdjwaCd4PyHnoc4oAcxCptwDzkY7ZpSyB1bBKIe3PPvTd2GB4ORjFJuLPJkkMBw+ePpigBt1BHcQvFcqskDjBU4ZSMcjHfrVWA3Ed5GZD510xWOOaRsC8GNqxSseBOBgJKThxhHO7a1XJH2smcF36ds+9JLtkhdJVWaJhtkjkAKOuOhFAE9mttKBNb/NGzMrrICpUg4IYdVIIIIPIIINNZQhLKqbWPGe30rPSW4hvQhYy3b7UjklbC3vGFilY8CcDASUnDjCPztapYblbxBIBhQSHypVlYHBVlPIIIIIPQigCZsCUmIYK87z/AEpks8UUYMxYnliUODx3PpWP4s1CfTdPjkt/LVt2AXPy7q5nVo7jUI1+0XPyrzsTofUjH9aAOsu9bVYpJpZVSKN8hyeWOPT3rFGr317IwsbS4dcnPHXHPWpvCf8AY0FrLPMkktwvDNJ8x69s8UjeLbiO5eCxsmjG1iN44yDwKAJW1CS12R6kCmRnk/d74rEvtVuftKzWs6PGM43D5Wz0PHQ+1LqM/wDbMitcttfoQFPNS2vhiFhv8yZEX+4QOKAID4o1i52/ZrIR7wB5uNy8cbsdq7rwb4Zl1WVXvSZHT5ypJJBPU+30qp4a8PDetvYxhWLZyzFsj0r3Hwh4eGi6WqzfPcvy79z+FAGOnhqGG1Xy7YoBweAR9frWbc6bDbq4WMr7Ec/X/wCtXoFxPID5YQbM9egz2Nctrc4iuBHegfOC6EHlj05PagDgryC3t5gJ9sYJ/djOQT71LcaRFqULKLd41UZY4x+tdGdHW8KvCOoLY2524rp/C+lR2UTRXYEvnjIkyQPpQB4Hq3gvTJ5GjmsYJTjG5xkiuF8R/DGw8t20uWWCcAkRsNyH2z1FfVPiTwu8V29zBFHLbDBZcZZa5O+0BZ4JHRXX2xyD2oA+Jrq2mtbiSG4QxyxnDK3UVHu4x/Wvorxx4GtdSgkjni23gyUuEHIPofWvAtb0q50fU5bK8UCZD26MOxFAHrfwy1u41LTyZ5WYwKInLHJwBwR+FYHi2zG/VLZlO9h50YXqxHT8MVS+EFyV1i6tQcNLHuT046/pXWeMocalazIvzSoVznoemP1oA8VPam1PeRGC4lhPPluyZ9cGoKAFr7U+Jf8AyZtZ/wDYF0n/ANDt6+K6+1PiX/yZtZ/9gXSf/Q7egD4qoopaALukWbahqEFsi5LsM4/ujkn8q9n8D6ejzzX6qBGmEiT+8o4FeWeEYgHuLkqSVXy4yD91m7/kDXt2hWyW+l2whYIjJmQn09vQ0AcZ8VPFF3ZpJpFrcOn2uPNyQcHZnhPoe9eTpl2VUX5m+XH1rV8Xaj/aniK+uudjSFUz2UcCl8G6edT8TafbAHaZQzY7AHJoA+mvhdoCaJ4XsrZUXzmAefK9Sea7DaGb5jwR0U42gVHbj9wgUEERjIxjIqR5FJ5wOnCnnHvQAxiu3AZlx0xkZ+ooZ1b5AyncdvIxz706UrvAKkgjgDgH6e9QsUA8wgqgOScZ6eooATacMUyhQ7Rz8pp2dqHeXRDgKPQ98GmiSQr1Bzk4Ix+NKjIWbfyvJIQ8sKAEG/JIQykf3D29Ce9MGWkcLgkMQVBBAFSTbV/1Y/djBVVOOahA3FliUnJ79T70AQ3dnbXEJguYw0Uow6sTz34+mM5HSstWvrLUAG8ya4nbPb/T/p2W6AHsJgOzj5t2FSqfIQAONwAPNVbxLe6tWhuVTyJBtkQjkn1B7EYyCKAH2sttfWsFxbMrREZV145z+YPbBqXarSANugJ4wOSx9W9vesEG4tdQbYxurm5I5xg3+O/oLoAfSYejj5teLUrWSya985DbFN7SHgDHc5/EY7Hg0AcB4n8Q6rp/iZtM04rIwGRxzIvqfb2rf0zxFex2tpDJ4eRry5l8mLy3+Xef73euXtLe88Q67c615z2tnnEQK5Z0zwSOwro7y3v2SNrO6COjBht+9uB4Oe49qAKfxL0LxTpUiRajdW3lyIXUQEqoI6j61h/DK5u9D8Rw3N5NMyEbyhJZW5+6a6rxTe6vrzRzarcLO0SgqI12qPXP1riby5No0lu8UkYDBgWHUn+lAHpGvJpfijWZbmCSPT7lwCgnAUHHXCnjJrgPEmjPp6Sre+VdQnjerBtx9BUlr4ruLeR7e9toriObhSYySD2XPatS01CS+8y2l0eK2Vv7hJPPqT3oA4TQtPE2tQRlWUH7quMAHt9K+tPAluYdIXZtfbH8jgZGccgn1ryrRtCsrElbeFTMFGTgseeozXtfhSwltNFgilI3nJclfyAoA4HxZqV7biXTXQhW/eLu6t6gf1rh1mvUBMU2w7somAdox2r3fxf4dt9XsUWRikyElJl4wewryybwprFrc4liaRC3BUfqPSgDH0W0S41DdN9/uHHyAdfzrtNIsGu1WTy9jKcMo43j1pkGlrYWDRszGaUgknBC8961dJ0+d45JkuSwBwd3zY9AtAF5bfT5NNZXJ+0IMhQvQ/WsU26yAB2kLMTtA6fQVev4JXDLbqwkRwWwDkilSydiRsG8jI28496AOW1TTkkidJd6uRtPGc+2OmK+dvil8P5NMmk1PSoGNuSTNEB90/3gOwr6pvojtW3w0LMc7uoOKxPFGmLLZpcMNyOu1wPT0oA8G+FuoPceG9sm6RopPJHsvUZ/OsHxlb/Z73V4WREWSJmyOeg3D+Vafgq3Oi+KvEWjuSVRwyD2yTn8iKj+JqhGLouUeBuR67TQB98UUUUAeAftrf8AJLNK/wCw1F/6Inr5e8H24FnECPmuJuf90f8A1819Q/trf8ks0r/sNRf+iJ6+bPBpONPm4ZEXaV9DuJzQB2/i65isvDV5MB+8SDywM9M8A14SevNfTvxA8BSL8FNX8S6lM63OY5beBOAIzIqjd78k18xOSWOetACUCipLaF7iZIYVLSOcKBQB6h8GAqx3RcYBbrXsgIG1AVMeMDjPTpXnXgDRW0fTsPIGd8Fg3Ra7GGWWNy8LBh/dPC/hQBqIvQAFeec1IeFUAndzwajif91nC8jcSOcGmvKGAblz/tHn8KAJXKcq4Ue54NV42852wSFT071KVZkJcEkelVGZonDOVwPugjBz70ATtGNpILKM/e6sP/rVoadFtEZkTex9Ky5nVVKK4Lk8fQ9RiujtIgqxL5YGUA3L0SgCve20N/D5EsCSwSgrsIwG9sdxTPAnhVPG2oXBuLkS2Vu/2e8uFkBe6jAx5My7g4kACgTfxIcNkqrVtyxx2sckUWNyjOeuDXDeILgS3dvJZKbe+EmRewSNFLCvcCRSGGfTOKAOT8T6VrV94iuNC1FSINHc208rHiZhjEgH+0hVv+BV0en6fb2kC20MaiMHgsuS31qRXvrnUrjVtX1SW8WRI4wrRoskjJkAkqB0BAJIyQq81ZtLe51UAhhDCATu24Gc9z3oApmzgijdYlUBjk9h71nalpMrxALJIzqw4x8h44/AV2Nt4elChbuRSXyVKrkAe9NPhsGQTecYkiH3Q3+sHdT6EUAeeaQbiOSYXEJd06nOQB6iujtUKsFByyfNjqCPf3pvjHTza6ZLd6dtk2csw6hfpWXouowzCGPzDJvA4zhTx1z2NAHtfwq0pZVnvJgpUH93gYzXpTycESHOeFKdq87+Fq3At53mLCAnEYLY/L2r0OK3LwMEZG3ZwVGAKAIpLdrhI45eAeuw/KcetV7vQorwtHcRReUFwuV5B+taEwaDHkgHauCCaleRVVSqM4OOBQByo8Npp9wlxazyqoPMQYkY7nnitVJXdSIyzYPyMMAf/WrZZA5AJypzn3qmkYVlVdoc5OCKAJZIGkhJzsd1w+1c7vxrm7zT2t7lBDjBQ/KON3qa6sSnZwGLCoZYd0gZYyG243dxmgDhNZ8Ow6nabYwDKB1HGD718v8Ax40GTT0SSaHbcQSYaTH3lPTB9K+2IbUKisg2sDgbu/1rwL9p/TVudCuJldcxQ7iAvUigD5w+EWk32teNrey0pQ908UjKpOMgLkg13vjm3misYUuU8qW2kKOoH3WHUfnVH9k6UQ/F6CQj7tjcnjvhK9A/aIsI4/E1zLEzE30Ed15eOE4wc+5xQB81+IY1j1acJ91sOPfIzWbW34lUGW3kAwDFtP1BrEoAWvtT4l/8mbWf/YF0n/0O3r4rr7U+Jf8AyZtZ/wDYF0n/ANDt6APiqlIpKd1NAHZeE4SbG2SMYllnLc9wBx/WvXLxLn+yJ006NpJYLRp5FVchFAzk+lebaVbLEbSPzRuhRVKBchgec59ea+o/CelQaH8HtY1S5hWS91DTZ5pSSSfKVDtUmgD4ZclmZj1Y5NesfBXwxcTSzaxJCxjx5UGOp9SK8vsLSS/v7e1t1zLM4RQPevrjwppiaPoVnYxICsKBVPQ57mgAt768scxtC11CCeB95K17a/iliwB8vU7x8wPpQy7hkALxjBHU0bPKBVwpBGeFxQBLHIil87ixG4beVP8AhSE4LEsQc52gdvU0gEBV/NLMjKNvH3TmpJZLaSBdqFZ4+rLzkfjQBHvwdxbC4OGA6VFLKcENHubjaw4x6mmhxGgMhZgemBtpjuvTYUzznOc0AIZY+VLEg8qzAdemacriYhSyBwdr5JXp3B71A/8Aq+QUI5BQBufp2pI5QFChAUYfeHXPbIoAku5AqARFV2A7ghwCPYVTjjJXejyOpGQCM/hShRcR/vli6neVzx6n8qt29svkHacWpUAHvjsfb3oAzLmNbi3ktbg/K6ZKuvA5yOnP4jpUXgfwxdfEmSYXb3UWlRXRS9vI3xFqaDgnIwROCArMOGHJww+ZdUeOzjhbzpAGby1eM/MV9s1kwqdI23ultc6fct8v2y3YxuxHdtvDj/ZYEe1AFyN5tND6dfSIl7ZTNaS8BQXTjd7Kwww9mFFtDe37FIoZJWJydiEjPaui+H/h6+8Wa/e+IPE08V2hSOPEcIjaWVBt3uB8rHbtB2heFHHWvYIbWCG3VIYo0i4wIxtHHbH/ANegDx5vC/iD7MZhYqdykleGx/tEHv7VWsfC9xcFrfVrEbocMJOM7SM59h7V7gN5f94pMa4+bdgc9BWF4s0uW6gt7zTrjy7u3beFVciQf3T60AeIeM7G1iuIgCkZ4+6QW+me1W9JuReQiN7ISLbJhCvTHv3P41y3xTvzqGr2lzGiWcaTbZYh1Qk85H1rd8GDzrm8hWORoiRFE4PHOOaAPWPBenyx28V4Yo8yj5VxgMPp2r0eFdi/P3569PaszSokRIoRtaO1RYgxx8xxzWtgEnA+bqMUARXRZ4JgCUO3KsK4y3uL+SIAStuc4y4JyM120ikwvgEkg5zWTpdrm3iLgA4PHPrQBmjSbeK2In/e3D/Mwc4DfSpoljiU4UIoXIVV7/zrRv7OQ274l3becY5AphgURJJHKGbjr/WgCO3ZJAkc6luPm3D5vyq5Hp0Qj2wxokbdS33qsWtuUTL7Sx7irIG0gDGKAOU1fSmTbhAvP+tUdqzb3TIpNKnjVtjBC3JzjFd66BwVcAqeorLu7dd/lmMeSVIbAzx70AeAeFPAFv4n8e+IrqSVkRLSNMqMbpCTjn8K8p+KULRWMiSII5ohJG6g5HBI719QfDZPsup+I47dY/MEseCpyCpJ7V4J8eYSut+KUjgRYUlZlbHqgJx+NAH2RRRRQB4B+2t/ySzSv+w1F/6Inr5v8CQxrBaXFznylPzAfxDdzmvpD9tX/klmlf8AYai/9ET14B4Ht9/hmFkC7iWzuPJ57UAe/wD7UOv2un/CCC1tnhk/tgwQxoW5SNRvLKO/QD8a+LW5PFdL481e71HVVgup5JY7JPKjVmyEHtXMnvQAV3vw10J7if8AtGTaY1OFXGSTXD20ZmnjiB++wWvoXwvpcdjpsEEChlVQckd6ANeygxGDtCjod1aCKCRtXPYbaakY284DDnpUy4Vdxxk+1ADXOOMqT6DrTvmBAABLfwgjJoJbrGCM9x3pG2oWILbmI6jpQA8AsNxbGQOR3oZFkfI5ycEt1/Km5Oc4IOMq2cc0qnIG45B/iz1oARcJEUTCtnA4ztH1q3FqJs4yZHLwxDJ7AfjVHKoAoBZjzheox61z2tauryDT4Nssz9VU/cHqRQBt3+ryXYItnYQE4BI4waxIQ32iGB3DXV04TABPU9frirLSRWlpI/yqMcljjIHXArC0vUmk8XaVNzFaw3Immkx91O1AHa/ZY7vxJNaowaC3YRnacbtvGfoetdhtjjiKQKkcI4QA8D14rhdEnSz1x7i4bcHZg2D6ngD+ddpmGWMGJX5yxI5JHTC0AWElMrZI6L1zgVDLKzyBXKlugAHyn6e9SHa2FZuFO7I4I4xzUHkIGwEjVOoBb5SO5HqTQByHjW2mgsHkt5D5QDM8aD7/ALfh1rzrwVD5GpX9n5iJIu14htzlCcn6V6/4nRbixkRRsCDAI5JUdfevJ4bCaLxfpxt4nZnhBds8MAcDNAH0z8MbgromAjH5tqleQfwr0REIjBb7wrlPCMSx6NbwkRK4xgocZbHJx3rqI2zCCgJ7H2oAcWUEvgFu9Kvyk5O7PzcUked77l+U4/GpMqoGBQA0NuQnawA7GmugcrLtO7HT0qY880UANjAxwMetOfOOKM4FNPzY29KAAemOPevNPjrpS3/hSR+vlqwZcfeGOlemdPU/jXAfF29T+xDZq5V5T8/PQUAfDPw88Qz+DPHel6sqMxtLjbJEDjepOGX8a9/8e6ofFeo6hfNCY1liCQx5yVUDivnPxLamy8W3cJOR9o3AnuCc179G6fZdwHJjx068UAeF+J4v+JZAVH+pmZWJGDz/APqrlq7DxhhY5xyC8qnB7YzXH0AFfavxL/5M2s/+wLpP/odvXxVX2r8S/wDkzaz/AOwLpP8A6Hb0AfFVaWh263GpwLJxGnzufYc/zrNrofDAEaXk4AZwqxAE9mPP8qAOt0SFJ5GuXVkdjuAHQeh+le4/Ef4j2Vl+z/HYQTqus3sYsBEoyQM/OfYbcj6mvLfDFqJbcZACkjPORwK4L4kXMh1xbQvlLWMAKP4WPLf0oA6j4F+HWvdUm1SVVZLf93GCP4sZyPpX0HHGVUNwSOgx1rivhHpZ0nwVYA/JJcIZm55yeTXbExHZksEbkHOTmgAdQqqCyqckkD0+tM/eMqlXcIDwQcEfWmfuwWCr5i55JbkfhQQC+Vw3YDOcDtxQA88MSXZlxuKnmo/MDI/luMEfeYdKcu47guCoOW3DjH1pk2E5BDsDkgEYI/woAa2w4kkzvHc8r17dqYxDZ2fKo5LZxv8AYYzTn3KQHVTnoAPlH49vpUirKAd6RqvoWw34GgCNEk+VgNy9CAOn1NPhjYSeVH8hJ+YpjJ9qUhiVYOQMYII4P4+tODNBlkmeFxgMJMZ2nr0oAzz8sqLMqKjHAdWACn6dzQ3lxKZQ0hG4h3Y7VUAZyaj1qSOO1lmLl2XkA+ted2t5d+JdZmR55jYwYaSNCcNjtxQBvXN2+o6gdTkfdp8AxDgbdxHUgH0olvEuPD+mtI8i3EiySSDPysS2FK/gKoeL5zaae0CIqpICmw/fRe+33qXSFN14ehS3t7jyLNRBI7rnOTlCT/CPagD6D8CWyW/hTSiVEZaPexKH5m/pW/uikx85YdwE+XOf51xvwp1yO/0CLTZWaG8tThkJ7e1dn8pUsEGU+XA4KjvzQAhO0AJGzc8OvI6+lNKbpcmTMhGd2NoIHbHanA73HkSksvA8rnHsRUZBG4L5YYHO3PAP8zQB83/G+1jGq6xiFl2hXQ7fm3dRgiqfwR1JtU1KKCQIu2VANxxuI5yc967T45xBLjzmK7pLRhIS2MAZwTXnHwAgmeZFgR5PMl4kXBKH1ye1AH1/psaLB8mBkkkdefarJUk5HA6c9araduMOZSd/HzHucVPKGMZUzCM/3lHagB5GIyA3P0NVUyG/dgHJyMg4zVvOGUYzgdfShlbcpjwG/i9xQBHAJHL+aG3eh6fhTZYQFYLGu09c1YK56MVakKHy8E8/3qAII5mhQBo2IHHy84qRLqFnCb/3mCQGGKqskqz7Xd8Hoc8VYSJlZS/ltgYzigByygykYBXbkkGuf8T6jJpup6fNG37qXcr5GQeOBiuj2KOQAPpWP4qmt7fSZZ7gRt5Slhv4/KgDyK91658N+Mp7zTBEwkUxOhyA3cfka878fPLf+HdeuLh2M8kUsshI+XdtJwK6G+vItUnN1BgRuT3zzWB4wUJ4V1jBJBs5uj5/gPUUAfX1FFFAHgH7a3/JLNK/7DUX/oievEvhpAzeH7ISKMEs0ZPIPOCK9t/bW/5JZpX/AGGov/RE9eKfD2dm8G2MMSB7kz+XGMdSzYAz9aAPJtfJOuX+45ImYc/WqGa9D+NXgXUvBPivy9TRNl8n2iKRT8v+0v1B/nXnh9qANnwhai88QWkRAIDbjn2r6N0uHZCoVcADO7+EV4J8M1DeJ4i33QpzXv8AbsNnykkHAAxxQBZG1Wzk7m565/8A1U4hmwBvyf4d2RTDgZZ1VV7gDkkUIXAyUZD1GPSgCQk5yUK5HADbsH6UpZVXcSUOR0AbP+FRpvJYquHYZ3GlKbWG0KS33uMc0AIfvZXcWH5LTwNqgEkOW9sYprEgFmG5j0I4/SmMmScsSW56YyaAIrqXyreSYs28Kw3Dt9a4zw/uklkupI/3sjEqzEE/n6VveLbpbTSJnaQEkbQOnPvXJeG9QkeRY1KgDk7V5B/woA1NUu4oom+0D93y8jHknHb8a5SJjd3Lb2eK4l/eCIAMqgcqSfStLxNcfaLsyGQfZoWHmdwx+lez/Df4Z6Jp+iR3Wt6d/amuXcYk+zRy7Y7ZG6JuHcjk5zQBzrwprGgwa7pX7yNVWO+jT5jbSj+Ij+4x5Bq7oGoKG8qaQfPllwflr0W7+HWh2tm8/h+MaPfSELcRxXJaN1/uOp4YfhXN6x8M79Jd+nSbyzbxGn8PuDQBIJg6fKyoRglQOGHpUUoOW3orBuWJ4wO31rm7i/1bRpjbanA6qCcl1xnFRS+IY2tZftE7JlcxIAGzz60AaOr3KR2syQfNI6BGOcY9OfpXF6LGJfiFHGrcW8QXGfXk4Aqjaa5Jf6zMXiYRQqfv9PqKrfCO/RviWks7bYLmfarMRlx06/SgD6p0HUIJL4JDtjiVBGeMjdjtXUW0vnxMFY5HBJGK5eGwEc5+yJiNWySRgZ/z+ddFpiukJRiBjHI4oAvrwOSOByaPvAFTwe9BxtIbkdPrUYKQjLMEXGBz0oAkI29cmjcMf0pvmAAbcM3oDTx0BI5oAYw3AYyKkA2j2qC4uoLZGeeZI0A5LHFc5q3jzRdPt2c3KyychY1PLUAb9/cQ28JeeVIxgn5jj9a8C+JPjnTLrUPssE6MoO1mDZrm/HHj3W9euZo9MT7QrkghRwo9B615Dfi+fUBFdJ5U8j8xkYwaAMr4gIH8bFVO5naMDb3zjGK91vtI1bR2ji1SB4UaIMmB1GOv1ry7wfYxT/HTw1Z3sQmQ3cIkQ8hsDOK+i/jLqc6+HtDn1KMRXTyXDMnQqo+6P5UAfKPjzPm3BLEkSgc+mDXF11vidjPa3UxYf65Rj65rkqAFr7U+Jf8AyZtZ/wDYF0n/ANDt6+Kq+1fiX/yZtZ/9gXSf/Q7egD4rroPDnFpdnAPzx/zNc9W94aYMl5FnB2iUZ77T/wDXoA9f8HWatDC0sa+VMxORxg4ryPxrl/GOqZBybgjB/CvZfA6f2pDpOmeavmXFysYCehPr9K539pbwGngnxxbz2jGSy1OPzo9x+YOuA4P5g/jQB7D4e+TRbX5VjZY1Ge54HatMtHnaVBY8B8YI9qx/DqhtKtWJPzRLkbs4OBxWqsnDKyDB6HoaAJHLIDtKxgjuNzUTRllDuwXdyNo5YelRxBvMUcsF546/nSzu07kyNwBtUu1AEeQcgODt+9jOV9jSPGiphyoCEMFY4qRpG3LHtWQcg5PI/wAaichXyUPsNuOfrQBIkO1gECscEkseF9/pQTGXCYy49csF/wAPxpyPlFdgcH7xKYyfw7U59wRfMJC5LbyNuT7d6AI0cuQQ6pGflZWHB+lO2oq7chVXICld28Uzzs4ZNgUEAsx38+g96egdpAzKm4dtvzKP5UAZniGUxaPcFx5bGMlAMHPHf0rgfBEM0WgPIVw0srmTBAYj1rf8d6gltCkZKiNo2EpLc88Ake1cRpWpvYeB3LKwadnRWB7Z6+oAoAh8S3Ju9VSSKP7TACYkgQnLEdcdyffpXb+F9Qu/DJibW9Mvj4b1CHyJkWJtzdwy9wV/Wu6/Zi8J2q6C3ibULNBfzuY7ff8AMYkXqRnuxyc+le6StGAol2hW4AI4NAHzBpd//YGvrf6bc+fbIcxuG3CRT1DA859q908O6/Z+ILJbuzkKvty8R4YN24PUe9O1Dwd4Z1J5FNjAkhPzGJtu0nvjpmuP1D4YXunTvc+GdSlMg+XDOVcD03dDQB3dw4SEedIiIowS42sPoB/OuT8Q+L7O0uNkKmeZFCYBx1GfyrzLVvEWp6fLLZazJKssY2/voypK+hPeuH8UeJ7m+lW302CKKAJhpeRuPbnrigDoPiVr9xeaTfXd2qRh4/LgPUqD0GO9WvhTpMfh6zsZWdpJZ13mTGDk9BiuD8TzXTWejWLTpLc3O2TkY+UHjJPevSbKZLKbT7OUq0wQFzkfePTDdhQB9F6OpGmwoWDBRg56/j71cIwRlfmH3TXMeCtQee08mXJCjhev1Oa6aOZGKjepJ+6OuaAHqh4zn3GelDD587ztxjFSHjoBn0NRKMMSjkL1KkUAPXjoKUkmkYcj09ajNyqHn9Bn9aAGSwxzkkqQy9DnFTRqqjkkn3OaaZUfYpIBflQepqnqWp2enQSy3UsabckLnBP0oAmvbuCwhM11KqIPfn8PWvmP44/EqXWZZNK015IoEyC0bDB+taHxQ8dS6jZXAsbtZLh38qKOHllH+NeETwyRAed5okJO4yetAHcfDeae6s5LSDM03mqqIoyxJrf+IOlalpOia1baxaeTJ9hlePDcEbG5qT9mu0aTxVdXroXFtbSTRccPIvH9a7D9oe983wzb/b4FS+m0q5d1X+H5eKAPoaiiigDwD9tb/klmlf8AYai/9ET1418BZoDdWEdwAyQXCTYzjndjJ9hXsv7av/JLNK/7DMX/AKInr55+FjFZY4y7KssbcjjHNAHvv7Y2k/avh9Z6o0SvLZ34VZB1WJ1PH4sBXxs2Nxx0r6F+KnxBv/EXwuk8PXsX+lWE6ebN2lVThfxwRXzyepoA7n4Vy20WpTCUqJ2xsyM8V7hZEsg2gFRxkHivmjw7OLbWbWRjgB8E19DaHdrcQRBidyjkdzQBtbRk5OW/Pinn514Xd6etNRuSIyc+x7e1NYMc4LbPXpigBwJEZBKEN1Ze1BK7Mnbgdz0P4UocnJXb/vDoKBjrgt6sBQAiqgBzyw/j7VE/z4y/PtwKlkfKHBIycBQKp6hKY4CzMqKATg9aAOC+I9+hkhteF+gJ/OucbVl8P6WJwm69lwI0zwPc1X124Oo6y8uX8vdhRnHTqa56Zm1rxFBDFkpuEaEDsKAPSvhr4fn8TayLu6BaHPmsvQM46DNfRSytpccaIpjlPLIDyBWz8NPAkPhfwhb27rE16Yt0hAyBkZxWf4gtXEwZXAyOBjkYoAoS6pKZhIzksOQODn2qxbavPbbRHM6kfMRnp9awXRkPzKwY5O/HpTNrbmCsX2nkjoD9e/0oA9Ds9VsdXtmttYtYXJQ4ZlHQ9fxr5w+JvhZNC1FpNKmlOnux2gdRnnBr1exWQz7lfcDgNg8Zqh4zsmvdOuRMjFowWBUZAPXt1oA8TuJ/7H0u5BlRr28XCEc/L3J/u1yVnPLbXtrNCvlCN96kkHB9j/WtHxzJjUkiDsUjhChcYB+vqayJG3wJFOdxXnI4+g+lAHsuh/E6e8iS3nnvFlJwX5xgemOp9q7jTviha25jjElxJckY2S8ceo/wr500LU59Lv4riEncpxg9B7A16n4aka6tFupkiRmbKiNf60Aepn4hao7FoiUiI4V1wc/SoIviTLpbJdamsktrnEo/wrlC2XZX3MexXmoNSsUvrR7eYEQyDb8p5JoA9CPxo0i2tUuV024Nu5OJS38+OKik+NkN5Gg0XT1kJ4Mkr4XPtXntzYxz2i2qssUCpsYEcsRUWm6Ra6aH+ywrkjkkjr64NAHR614l1PX3K39yqxt0hXhawJtOtpcebE5wOMv0/CrZ3bdoTOOSpwMfSmnqNrKRjPJoArRWyW6KsSYX+HjpXnXjYpF4ogYoNwVc7e3Nenox24LE+gIry7X4ze+NJlmL+XbjdJuPCqBmgChY3r6f8adP1G3wzWjpOeOBhec12vxb8Yy+MNXS5c+TbxRGKNMnb6k1wXhG0fVLjVNXKFEuJfJhOPujuQfpxV7xYy28sNhaqXIADN1wx6ZoA4fxLMi2lrEg5kJmZvUdB/WucrV8SzrLqsoj/wBXFiNR2GOuPxzWVQAV9q/Ev/kzaz/7Auk/+h29fFdfanxL/wCTNrP/ALAuk/8AodvQB8VVs+Fn26xEmQFlVkbPpj/EVjVe0htmqWbDB/eqMH60Ae4/Au7t4fFOlNdqrJDdK2QehOVGfpmvSv2zLDzPh/pt3IEaWDUsK5HzBGQ/KD9QK8Z8Cq1vrepW0Zw5LNGAOAQc11fxi8aTeL/hNbWV1gXun3CvMQD8+Plz+tAG98P7l7nwlpcrgljbqc+tdKjyFtqjZ7k7jXDfCqeOfwnpaYRtsITJJ6jtXfowIYx7Tt+/xgr9PWgBJGZAA85J7DGM0wyDdknJ4IXZke1A3lRhFUN1B4x70HO5S0pQjkY53e1ADg252xux/dwMZ/rUcgVIQxLAA8nBJ/AGp41LFoyN5I43ccZ556Co2RFxjMhBwM/MooAIyyjc+/noM4H41ZuLhWihhwCV6E5+b6n0qq8JiPmONmB1dicn09qVrhgSIsMG4ywyPx9qAHx5lYdFKjAGM5Pt7e9MliDyhBJl1b5VUjGe+WpoM7qyshZV5Hbj0HtUVy6wxN5jo6ovCbduPqaAPJPHN62peKrvT1lgAb90ykfMAB1zV6z0YavqVvpxiSOyslQkKSWbHY1zUdwbvxTc3BJcSuzt8of5B0BI5HNe4/DrwzND4dOsTRELdOSqk45HGcdcUAdhoesDRNOis7f7ioFjIHCAdsVoR+InuY90jjaGIG49Pwrj7t2iYplY8feG3uegBqETmLCCdy33vkB4J4xQB3kOqBjnz0KqcONoGfqa1rPVfLYBpSR0I2/L+Hrx3rzUXoj8tZkEq8hQ3b1zjrU8F9I4wxdyvOcfJ6DHv7UAd14/8K6Z4z8Pus7FJlUm3uU+8px09xXyxFoq6Ld3h1Au32VeoGQ5B5JHevo3S9YMNq8ZIMZGPnPK/T0968b+IlnbxXWolMhpIjsZW6nHIJoA8xvNRbXdfWdfKJI3QxgEYA7e1Om126iv2mYsHjbAVec+x9hWLbyGNVVm+dBjduwcU0JyV2qrEHd85OSff1oA+k/DF5NHb2F9ohW7nuIt+zeT5Zxzx0Irq4fH8M0r2l3IIrtVBIDCMhu4ANfMPhrxDqGhSyfYpzGXh8raemPUZ6Vuadcw69dw/bm+0X7KFMh4H+8MUAfSmn+LZLUxyT3G6DGSrck1ux+NtHMxSa/FvJjpKMgflXknh/w3YLbBX88FGD/ePPtmty6RnZzILeU+ksQyPxFAHaat4m8pfMt9RtGVgSBuz+lZVn45s7KKX7XfwXVwckx7gNo+grkrODTTBqOn6vpK28d0MrPECVP054NeXL4D1KfXZ002QxaYknyXNwCHIPbHegDu/Enxe0xrt1thf3U7nCiEn939KZanUvF9huu0fT7LdljcEtLIPb0FXvDfgyw0Bd4iS4ugSTIeW+orpxhlP3+ucjHNAGVp+h6bpsIWwtIgvUOUBbPfk15l8XtMUIl5AgjOcMEGB+XrXsdxIFwpfdjovc15j8aZEXR7SONXMk0hCgfK2aAGfCTWG8L2mn6nEomWRWSWPPJU/wBeK5742+Lp/Et/qN0N0Futq1vHF1+XaTVhbOez8NWlig2XAUZzycn3rjvHMQtNPmt2LtKIGLkjqSO9AH3zRRRQB4B+2t/ySzSv+w1F/wCiJ6+c/CDC0bRJGb5ZIySB6bjX0Z+2t/ySzSv+w1F/6Inr5e8PTGbws+xC89jcB8+iP/8AXBoA7nXIbY67c6dJuZL9NrHsrEcHNeRarplxpmoS2d0u2WM4543DsRXudlHa69oluWXbJj5pVPMbDoa3fhxofhvxZ4lm0TxhbC5uGhKwliUJb1VhyDigD5jUlDwSD6+lejeDPGO1I4L6QLIuAHP8QpPjR8Mb34ea8FRmudFunb7Fd464PMb+jj9etedMNp5GKAPpPTtat7lCVlRmPVlPWtIXcRIxIDjoM18zabqt3p0ga1mZQP4T0rttD8eR7lTUUZefvjkUAe0xPvjJJUk859vpTxIrDOWPoOgrkbLxDZ3kKtbzBiewI6VojUYWQfv0VR15oA2pZ40+8QHAJIHGK4Lxnru6Nra2YlgMsRzina7qn3kS6QLjBw+fyrjLzVrCwV5GYTzkfJHnJB9SaAMnW5fsVkEZj9rnHOP4Vqf4YXkVh4stbi5iR4FdPMZhwi7gWP1wK5q+u59RvXnnJMrnsP0r0rTfC8tloFpaiMf2hdf6TLuONgHQH6dcUAfeGm3dtqFhDc2UiS2sygxupyrL2rPv9Dt7mdJApXb2BwPxFfMfwy8Zax4JkMAnW7sHO57aVsKo9V7g/pXrL/G3TXQfZtMuGk29XlXap98UAdLqHhGSSE7WQtvzsHAx6E1lx+DbuOIggJgHhT171x1z8YNcuZWNtb20EZyFQDcfzNa3h34yBWEHiCyfA4M9vyR7kf4UAbWm6HM0uzyW2OcKMYH1Nbuq+GYIdEvS8pcJCzDPGSBms3VPi34Zs9Pe4t5ZrmQfdRYmXJ9CTwK8Z8cfGPW9XtbyxtoI4bSbK5Xl1XrQB5R4uKnU4XkVkYA/IV4YZ9awhGjMCu31JA6enWt7xRdG+sbO9iK+bEDFJnpnPGB/WsGXbsRlYPG3Q+h96AHIjNxuVxnJ46V6H8OdSMiS20kgbbwo9K87+VU4GT0ypwDWx4au2tdXgfJGCqt757UAe0DBcqCD2GO9OBG9RIucjqD+lRR55ZeMcnnpkUEEgoQVbGCR2NAEjs68SFVJyQFb1+tMbDH94CcYx3BokcNGIvKRgBktjnP0pnmIRgdTjjHtQA+QKzjJy46sP5UjcBSRnnoFpQ+5QCArdzio3YqOWyoB5zmgCnq19Hp2mzXNxwiKdrFud3YV5jfG+1Izabp0ck+p6jh7h1Ut9mhJ6sR0rsNYiu9f12w0LRoRcardviGH+CMDrM57Kvp3r2DV9J0f4ZfDKbSdJVZdX1P5JLp+Jbh/45WPZRzgdBQB4q8EWjWMNla/8eNrGCT0Lt/e/E1wmq6iF+1X7hSQT5fzfec8YP0rX8U3iz3KWMDbhnDPu+964Hp3rgfEF/HcTR29sQba3G1WAx5jd3P9PagDIcljkkk+pplObHam0ALX2p8S/wDkzaz/AOwLpP8A6Hb18V19qfEv/kzaz/7Auk/+h29AHxX3qexO29t2PaRT+tQU9TsYN3BBAoA9Y8LylPF1wFwnmHIY9RW1d2Md3PqukXDq8k6s8R3YAbHAP41y4lis/EljcxPlZoo5A56Lkc8V22p6Us1wmoWjxtexnfJHnhx7UAZfwsnW1037DM6jUbOdkkhBIZVJ6ntj3r2CBomVS7EqeF5qn8LvB3hrxnaanqhJttXhHlCaM7Sue7L3GalWC90e/n0fUUAvbc/K/QSJ2dc0AXi67wyL5jZxz1PpTcMPnaMKBwdvH4e9ERbAOGZmHBY8H2zSlVKqWYnvkE7R7D3oAj27hsWTYGOSig7asW8rQOsiYBHAY9M/SoSWYgmTAHRaY77QCoVfUk8fUUAOnWWR98oZ2zuw5zgn19qIW2gl8ZYfw8Z+vtQpy48uM7zjOT/nFOVYyxQMm48Nz/WgBZGWSFVmjMuPvbWOXH1rB8Zap/Zvhm7uD5fl+WY1jyRk9q3ZRzgJtQHH3sgfj/SvKfifqz6pfxaPYbpFX5pnP8OKAOM8P3ZtrZrx1+WWQRKEGCwHYjuM19nfDO50/VvAenJaPC/lxKrY5CyHk/rXyfZaWjaW80sLtAAUgGMKxx972JNbPgzWdY8I3Ns6KQhG5UL43HPQjsPegD3rXdAniuiyBy3ORjcp/Csx9CuXVVSGdR1DKmOfeuo0v4k6FPpkN1fLLa3ZALwiPeVJ9D0IrA1z4sWwndNH05pi3/LSY4Vvw7UAY66ZcW0ivLEQC2SdvOenWnrFJC+JVJKjOSQBt9x/k1JpvxXWS4jj12wia2YEK0Xy4/PrXUNqXha8slngvYMyfdV+GQ0AYFrbSTSAJhl6KmOTXBfEovp9ysEkWWaA5Ujpk9fbFdTrHxEsNLvHi0qOG4kI8vztvyxj/GvMdR8XDV9SujdECOdCilxkg/3foetAHl52NI4kVt+SMjgHHpipkjhnDclJwBkZ24P9TTDbGKW5+ZImjYjyixDMOxH0oSZSoZlyF+bK5P6mgCYQDB3LIzDksx4NdH4KeO212Pc6MQckY6j29/aufaf5WaM5T7yjfz+NWtGlc6vamJAzF1C4Oc880AfTFkYmiUhiG2AgDvVnAfBdCZB1PrUGnxlLa32gKCvJPUVaIdQ+1geOVzmgBjoqorEMyqNpC9B/Wmwn7qrlgDt5OfxAqW4b5iSgBwMMOlRs8TLywyPTgj8qAFQFnwCEboMHkfSpY2KEbthbOPmFRIUJ+bBK/dK8Zp8rlYwRkjPAPagBpRZSYxnzQcgA4x64rzXxY8eteLAmRJaaWNgJ5DyHnP4V3HiDULi3ghs9OjM2o3beXBDjnceM/SrupeDtK8I/Dm7m1OU3WpsMtKTjMrdFA/SgDy2/vIo5VAACoBIZPQD0ry/xTO+pHUJZZZN3lvITjAxg4X88fnXR+KNTNtbPAkcaySckdSo7CvP/ABTeNa2q2Qf9/MoaYEcovVUz+poA/SeiiigDwD9tb/klmlf9hqL/ANET18m+CNSisdWMN22LO8Q28uegz0Y/Q19Zftrf8ks0r/sNRf8Aoievi0YA9j1oA9O028uvDOpS2k6syZyuDxIvZh7V2thLb6pcW+oWlybe+g+eJkOGQjnOa8p8N+JIvsw0zXlabT8YjmX/AFlv7j1HtW0RcaJNDcW0wnspeYrqM5WgD6UvfEOhfEbwHfaB4r2Wd5MmUuCnyiRR8sg9Gz1FfHPiPRLrQ71re6w6hiqSr91wO4/wr2XS/EMGrp5d0ypcAc5HDVfubSz1C3a2vbZGjfgLKvT3BFAHzrg0d69Y1j4Z2zkvpN5JbueBFIN4Y+xrM1D4M+PLCz+1t4fuZ7bbv3wEN8vrjr+lAHnqO8ZJR2X6Gnm5nxjz5MH/AGjS3VvNbzPDcQyRSpwySIVZfqKLe0uLhgsEMshPZFJoAY0kjAAuxA6ZJph64PWuu0fwLqd42b1ksYj18xvmP4V7X8Jfgxpup3LXOoQyz2sAB8zhi59AOlAHjPgbwze3syaj9mZooWDQhkJEj54/AV6Df3lyLrYLa4kuUOZC6FVY9wDX0vd3HhrwRZrbRw21pJ1igQCSaQ/X+GvJfEOrtrGqy39zEiIq4SNcbU9cepoA8subu8nvgZIGjYctsGMoewNereCPh0ut7rvTo7mK1uIyvmsRtJHYn61xE1vdvZyuAYpSC4A5IPYH2r0L4LfElfDekR6N4ptJLe3e4JgvU+ZRvP8AGvVRnvQBgatpN5ol09rq8L2soyA8n8YHQr6/hWpY+CdZ1KzW7g06f7Io3KdmGf3Uda+hNSh027e0/tC2t7kht8HmxiTafVSf50a94g0vw9Zi51i9itIj90OeW9gB1oA+R7/Q7mwS4jnu5GCsS9tIe5PTHtXOX16xTy7ZGCQjczJwGPcE13fxA8XWfiLxZd3OlW0ognCxB3Xac9CxrAt7HytQXS/LyJBvBI7dzmgA0iytLy1aNrcrHIv71j/DnvXKeJ/C1zpT/abUNJaDncRlox6Y/rX0f8GDpG270i+SBpwSY/OXiQHqAT6Vv+JvhrbSLJJokgiYgs1pcfdf6N2oA+MlcsoUnG0cHFXdPkJvrUAlw0q52n9a9Z8Y/CS9UNOtnNZSMxyY0Lxt+VeV6pot/pl4Y5osyRcrtXhvw96APa0ZlXB5+QHOfyoyuCGzyODn9a5/wv4mtNRtI4J5Fgv1UBkf5d/uK6IEhdwXfnhuc596AEwVCEMducdM0rZDkcew244prKgiO8qqnkZOMfjVe3vlubxYdNjmu7gcMIULL+JoAuMVERdvkjXqSelZF1qW9WeNAF6AngnHfFWbmG5hd1vlCv1O/hB+HrXL69fuJvsmnN5s2MAL2zQB3ngbxPoPgeHUNUuYTf8AiW/AhgjQfOyDoCf4Rnk1x3xE8WX+oXIvdRmDajKhTyl4SNeyoP5+tZVtJDo9g893LHJcseWK/OPauW1LVWEcms3Q3Mp8u1hYcM3v7L1oAxPEN4dPiNpu/wCJhMv+ksefLU/wA+vrXKSY3fL0pbiV55nlmcvI5LMx7mmUAIaSlNJQAtfanxL/AOTNrP8A7Auk/wDodvXxXX2p8S/+TNrP/sC6T/6Hb0AfFVP/ABplLQB30DpfeELC9iCCawY2s/OSVJyp+vOPwrtfC/iCCa0jiu8KQuEZx972PvXknh7WZtGnd0VJreUBZoH+7Iv9D6GuyjtYr2zOo+Hp/MTO6S3fl7b6+v1oA9N8GanfeD/FK6vZIW06QFLq0JwPLPU59uo969g8fR2fiTwhZ+I/Dsi3T2ByjdW8s9Ub0xXzR4c8TlUNreJ5kGNuW4Oc12dleSWdsws7mQWsg+YK5CkemBxQB2Gk6pZ6hCPJeNJl+V0dvmQ+1aAcso/1jr16YAPue5rzqbTYri4W8Nw8E6YAdCNpPv61dufEM+iyxmSG5uIn4+1Im4IfdR0FAHdAsyHcyIo7ueRRCUjO9H3ydMsvGfYVz9vr8LwpJlJAwyGbBBHualtfENhcBvLuID64IJ/H2oA2nKDChyzeoIBz7ijzNuP9WhA+6EGPqTWVPqZgjLRQQIcg+ZI2B+VcP4i8SR3Re1k1Q5J+eCyGWb8e1AGr4y8W7ZW03w+ReX7fK7Lysan07ZrjrbTYAJbcTNPPjfdz7icn+7nua6fwt4U1TW/3WlWs1tAwwyou6Ug/3m/hHvXoNv8ACl9I0yeS5ns7F1XOxP3jyH3NAHmdzqCSaXawjYoddnlN97jocdqzPEGvQybYzBJE3l7fM/iJHp7V0F7oNs2rLPKZJJ8csqjPHYe1Zl/pcc97Msir+6QlMe/agDU8N+C7m70q01OS9YGR8mFXJGP9sHpWjc6e0FyyzqiMBlWHK49P/r12X7Pms6Ze3NxpLkfa4IwwhmHJI6kZ616n4r8I6dr+myWxQWkrfNHPAoV1b1PqPagD51uLYTRp8gSNjgFRjB9s1YsfCWu3L+bo8dsyRk+aJG+/x29K9q8JfDyw0eDOpyNql9Jw8rrtRR/sr2Fbuo2mn6Tp0lzBDFBGq7Djgeg/WgD5H1SLfdXo1VTDJCfnh5BBxWdoVpbzSSbVjRIxkurZJU9/qDWl48E2peIru+YiVIZQpWI5Bz3PrTbGzhluIr2189MELMEXqvSgDL8TeGpY4hfWZ+0oOW4xnHf6+tcirld5dyUb7wHBB+lfSdv4R1aXT0n0+D7VAUyypjofSvNfE3gtbmV3td9rfKSGiK43H3oA88jIjDKElKSDnkAj0xXTfC/TjfeKrJB86R/vCBwMe5rnL2wu9KIgvoHjZWyG5wTXp3wHjiXUtU4Im8sEfKMgd8UAewIqpgCMlCcbUc/1qxCMRuu0gdlYYwaRFRQCjuqtwcjoaHnXZGv3tmVz3YetADAcuylyue680hPmDbKrLt+UOjc//qpqBSeHIB6AdaniQyE5A3jo3QUARRJ5Y2yJI/oemarX9/baejybFYkErbyE5LeufSqeteIFsYZIrdVlnJwdx+Rff61wmvau0H7+7uWLgH945/pQB6f8MrW1zf8AivW7iKOCNSkU0xwIvUjPTHQVwnxP8cQ67P8Au2ddHtAXthjBlf8A56t9ew7Vxk91d69DbySTyf2ZuLC03cH3Irm/Ek8upavDZQOWUALuU/IuOuR7CgDEvb7yvP1K8UPEjYjVj/rZTyAP9kdTXC3lxJdTyTTsXlkbczepNavivU0vr5Ybb/jxtR5UIH8Xq34msM9KAP1TooooA8A/bW/5JZpX/Yai/wDRE9fFea+1P21v+SWaV/2Gov8A0RPXxVQA6tjQteudKDwgLPZSn95bSco3uPQ+9YtFAHoFgtlqMgbSLgRzY3NbXD7WPsGPBrTh1W/sCsM6OoByEnyQB7GvLh1GM5z2rotJ8U3tpELe6IvbTP8Aq5vvAf7LdRQB6tpXiK3umWG4keEN03n5fwNe7+EPiPGunw2uvmUtGuI7u3OdwHQEf1r5HfXdIbD7JUB/gXqv+NbekayCQNL1ZGdukc3yfhzxQB9B/FS88K+K9NWSzshLqy423ZiCkj0b1FeY2uj/AGRCN6xKOSIlrIfxReW2xdQtgqH7pAKkj69KvQ+LLCdNshZM8AsOPzFAEV7pUqXAezZmlkOCZRlQPaui0a8vrCAxWt9cRqOGETlFzVWG8srorsuhJnjaGzjirYALEqcqD3PHpQAozM/n3LedN0G/nLfWnqFVgRggnlWGNp+tVlmSCaXzSqEKuwDg1b8obd4xsxuIIxQBBJFcJdyt8jwnHQVYERlhdSFJKkHcOMUiPiPao4I/L3pRam4BiVt5I+SFert2J9KAPa/B8lxf+G/CTqX2xFkk3HJZFBAJP4V5B4l1W48TeL9T1G5yyQzNaWadVRFOC49zXvmhaf8A2R4QtLExlblbYgqoLYkZST+tfPFlYXFmkn2phFc8iUMeAQew9aAK8kMVm7ybCSeSxwWPtSWsDsomlX94SVj3dUBPrVlGifh1DkjcWFI4DknLlyNv+5QBHdPJFCWtyQ4I24PIP19a6LSvFuuaTCBbX808HX7PdjzAx9GJ5H4VgpAA6h/nB6emfWnybUDM+9nzj5DxQB19t8W7+0j33+jxTlzjFpIY8fgciuX8R+JU1+4Zv7EeAvnLMBkfiKovtlLAbcrjOOtP584Keowy+vFAHK3dhaXDlVMauGOBIvf61GLe+ilihtXLSOdmFckE/nXXSxrIuZ41LckkjpWZfS2sUQW0k2T5yWjOSB7D1oA9S8DfCMR2q33jOcShgGS0WU7EBH8bd/pXReIvHfhbwRZ/ZNFgtHugNqx2wART/tMOteA6t4p1BYkgl1S4Chdg82UuzD6DgVxd9rAW4zbRSebnmWb5mP0HQUAdj4k8QX2s3N3fajOIw7Eu7LtyOwRf61ys2vW9pH5WlxsrsfmndcyPx+lUJ0mkButXnMMJB/eSt84+grHvPE1rY5j0SEtJjBuJufxA7UAbMwSFBea3c+TBknGd0khx0C/16Vxmvas+sXgfYIbeJdkMIPCKP5k1Qu7me9lMtxK8kh7sen0quaAA8GiiigBDSUppKAFr7U+Jf/Jm1n/2BdJ/9Dt6+K+1fanxL/5M2s/+wLpP/odvQB8VUtJRQAtXtK1G60u5W5sZnimU8FTwfYjuKoiloA7uPULLxA++NBaahtzJEGCpIe5X0PtWpo+t3emNJE4MiggMj9APevMVYqcjgjkH0rcsvENxCoW5QXCjuxw2KAPXtM8QW8jKzLsZeRFIQR9RXXaLqtvDfW1zdRBoTIDKjDKsvcYrwq01HSrj7kxtnfqrjIz9e1b9nf6ppyrIpEtueFCnzFx9aAPsLUPCPhXxRokrQWMaWd1FgT2WEcZ6jA4GK+aPGfwGk8KXz7dblayly1tKkeCOejjPX3FavhT4hPpyE219cWTbQHReUX8P61t6h4hu9bVDqF5Jfx/eUkg4H4UAeZ2Pg1JIljv9T1C7SM4AWQhHHpW/p8dlokyxWejrCu0jzT0x6Z7n3rpomjI3oUJHAQLmobqMOojY4eXgqBwPp70Aek+EPHWiWWhrB9nvY34DiEAKT9etYXjbxhea0otbGP7BaKw5HzO31PpXJRRi3CxR7QkfB461KzAspypJ4XsaAIlLC4UzFmLNlXB6kdelQ3PlwkxyKUjmySGbk5q5J8mWJwRyrY6Z9KAqPHHujG4HO7HNAGVb6JZ21wbm0aWK5DApOkhDxnHbFfQfw08Szan4VkfU5jNe2B8uZ1HzSLj5Wx6nv9K8PU+VJtRiFzy7DDCvS/g1bSzx6/tCrG6JEHHTdyT/ADoA7fXvFVpoXhd9beKRjMwWGHu7nIC+w714P4z1fxJ4mmQ3eqFYuotYRtiUHv7ke/1rqvjLObTV/D+mwswi06Ez7QfvO/ygn2GDXIupVQsSCRl5I3YAJ60Ac2dHhtdPlXzJJvtHy4BOVf39a07KyW30mDTw+zYmJMcfr3q1FZiK6lnbaXGCseeR9KfIysi4GXY8EjBH1oA6vwN45m8PbrL7I9/ZKQGaMhZI+Ooz96vSP7Q8J+K7UNPJZTM3Gy5PkyqfQnvXhFnAIjLJtcFz8+W7+opbmFZicqjN0yTk0AeqeJfhbo2o2rJbm5iDA4Mi+amexGOcV5BqXgO+8CavbXVhqPmTKCWZEIVh6EVLaSXttI/kalfqh42LOwA/CrV79qu4olfUJ3I42ytu49zQBpad47iOBqEBS47mN8o3vtPSri+LtMK5LSrgkfMvHFcTNpvmBkurdWYElHjPSmaRYaXHqsK6yP3bEFlyfu+tAHommahqfiKSSHwrpb3i8ZuZ2CxRN6k9/oK60eAbme1+0+KtZjhijG5orb5I1+rHrTbr4l+FfDekQW+jRb44l+SNF8pM++eSa8p8X/EXUfFAPnyxW1gpJWMtsT8urH3oAj8RatY2V3L5B8+3jJWNuhkx6CuQuFF4ZLnU3NvEeUjJ5I96zdQ16KCQNBGZZc7RcSEEAewrOu0urhftuuXH2a2+9vl4Lf7q9zQBo6p4gzbraWEO042bl6/UYrmdUuTomly5l26neLs8lTkwp3Y+hNUtU8URRoYNCtzApGGuJPmkb6elcpLI8jl5GZnbksTkn8aAGt1ptLSUAfqpRRRQB4B+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPXxVQAUUUUAOoBwc0UUAGaKKKANTTte1LT12290/lnrE/zKfwNbNv4ltJ8f2hZGGT/nranav4r0rksnOc0UAeh2lut5CbjTXW5Gf4DskH4Ust3ewr5U1zcRx9Apz1rgLe5ntpRLbyvHIP4lODW/aeM9ZhRUkliuEU5xPGG/WgDft7y6JV/tT5zjL88Vs2/iHU7dJAs4l/Dr7Vyn/CbeZj7Xo9hL6lcof0qX/hLNHlX97orxn/plMf60AdivjDUCq7oUGPu4XkGoZvEerXmVjiPJG5ydpJ9Pwrl08SaCMf6HqUZ6g+aDj6VYTxX4eSTe9jqU56HMwAoA9cT4veMo9Nt7U31knkgRlwnznA4ye5riW8RXC391e3K3P2qZi0jbtysT1OKwB4z8M4C/2DdYHrKpqKXxH4WkbelnqUR7qsgoA7KPxhCDiW1lYEYOFxmiTxzbjBSzcdvnBFcG/iPQGYCO21NeepkU0HXdFztSS/jBOSWRTigDvV8b2hQvMkiqOCI6nj8ZabIoI82JRwBIP8K8+OpaTMNi6qRk5xJbED8xT5rrTiP3mtW+3HASEnFAHoA8VacmSsqsx/2WJqrP4ojcjypZQTn7kWD+tcOt7oIH73W7ksOgjtj/ADqGXWvDiuQYtUusHj51UGgDpNR1xmUfvXdmP8cmePcCq0V/eXJWK0jYh1IJVdox9a51vF1rb7hp+h2iY6POzOw/pWRqviTVdRGJ7kpGRt2QgIuPoKAOlv7iytGA1C9DOOGt7f53/wC+ulY8/icwo0ej2cdovQysfMkPvk9PwrmQTSkkjk0ATXV1PdytLczPLKx5LHNQZOMdqKKACiiigAooooAQ0lLSUAL2r7U+Jf8AyZtZ/wDYF0n/ANDt6+K8cZr7U+Jf/Jm1n/2BtJ/9Dt6APiqiiigBRS0gpaAEJNFFBoAKu6bql7p8m6yuZYvUKeD+FUaWgDsbLxdFI2dWsEdugmt/kYfVehrorK5ivPn0fVFncjLQyHypR7Ad/wAK8tBOaVWZXDKSrA5BBwRQB7NHr+p2RaOdtzE/cmXH5GtKDxgkUZ+1pNEGPOw+YD9PSvLNJ8V3UQFvqTfarVuCXG5k9wa6i3ttOvwsmnaxbh+0UpwR+FAHdx+KdNmyUm5A4Urtpk3iPTyiSQTq8yn5lzg1wz6Ldxg5jhnx1dXX9BmqjW8sQBmtiBnOAR+dAHq1lq9rdRKktwmM/KDx+tXXJO58gvjAbdu4z2rx9bqCBVj8s/Pk7d3ApYtQuUBEF4CnO0F8bTQB66k8UZ+d45s8kM2AuO5r3D4ZXlhN4Oil0qWBT5pa4Mh24b3/AA6e1fGzy3Tb9t1AiEgE+ZluetXtPvrayE6DUpWDD5wrnDfhQB7p8ZNU0mDxpBdG8E0stsIisOCFwem78a5qS6Dsxt2gRXwVVSG3DuPY15c+oMYyba+Vlznypm3flmnx+I7+2X93LEvGAEAFAHqCszA7wAy9ARnFCxrhugyQSW/p6V503jDVFjADW4z1KkZqF/F2pCRZJPLfsFDAce9AHpnnKJAYwGVeCxPA+lQXjudjKysgYEoB8xHtXnp8a35JCRQbSeRx/Kp/+EtuGPzq4YDjDKBQB3silcoqq6Z3D2pGmitwWM0as3UFq8/fxM8vzNbpz1zOeKpSa6mZCGhjOOxyf1oA9EutWto0ba+9h1A7mufvtXigdpWmj8z0T5pQP6VxyTX15I32MPIjZ3AuADUd4bLT8tqWopFIVybe2/eOx9CR0oA0b/WyJWaNcyv915DvJ/DtVMW91Oj3V/IltaHOZ7tgo/4Cp/kK5+XxVHaHGj2EULdfPnHmOfz4Fc/qOp3upTma/uJbiTplznH4UAdZd+ItP01CmkRfbLkDH2qcYQf7qd/xrkdR1C71Ccy31xJNJ6u2cfT0qrmkoAXJoJJ60lFABRRRQB+qlFFFAHH/ABQ+H+lfEfQLfSNcuL6C2hulu1azdFcuqOoBLKwxhz29K8w/4ZU8D/8AQV8Sf+BEH/xmj9tb/klmlf8AYai/9ET18weCvhd4x8baVLqXhjR/t1lFMbd5PtMMWJAqsRh3B6MpzjHNAH0//wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zXgH/DPvxO/6Fj/yftf/AI7XlVAH2p/wyr4I/wCgr4k/8CIP/jNH/DKvgj/oK+JP/AiD/wCM18V4ooA+1P8AhlXwR/0FfEn/AIEQf/GaP+GVfBH/AEFfEn/gRB/8Zr4rooA+1P8AhlXwR/0FfEn/AIEQf/GaP+GVfBH/AEFfEn/gRB/8Zr4rooA+1P8AhlXwR/0FfEn/AIEQf/GaP+GVfBH/AEFfEn/gRB/8Zr4spKAPtX/hlXwR/wBBXxJ/4EQf/GaQ/sq+CP8AoK+JP/AiD/4zXxZTkjeT7iM3+6CaAPtH/hlXwR/0FfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/Ga+OYtKvZQClpMQeny4qxH4f1FjhoAn++wFAH19/wyr4I/6CviX/wIg/8AjNH/AAyr4I/6CviT/wACIP8A4zXyO3hq9U/O9ovsZRSN4cuwOZbT/v6KAPrr/hlXwR/0FfEv/gRB/wDGaT/hlXwR/wBBXxL/AOBEH/xmvkU+HbkLnzrbPp5lJ/wj10GAaW2AyASJM4oA+u/+GVfBH/QV8Sf+BEH/AMZo/wCGVfBH/QV8Sf8AgRB/8Zr5KPhi5JPlXFpJ6DzMGoH8Pako+W3Ev+4wNAH17/wyr4I/6CviX/wIg/8AjNJ/wyr4Ixj+1fEuP+viD/4zXxxPpt5bHFxaTJ/wGqpXBww2kevBoA+0v+GVfBA/5iviX/wIg/8AjNJ/wyr4I/6CviT/AMCIP/jNfFlJQB9qf8Mq+CP+gr4k/wDAiD/4zR/wyr4I/wCgr4k/8CIP/jNfFdFAH2p/wyr4I/6CviT/AMCIP/jNH/DKvgj/AKCviT/wIg/+M18V0UAfan/DKvgj/oK+JP8AwIg/+M0f8Mq+CP8AoK+JP/AiD/4zXxXiigD7U/4ZV8Ef9BXxJ/4EQf8Axmj/AIZV8Ef9BXxJ/wCBEH/xmviujFAH2p/wyr4I/wCgr4k/8CIP/jNH/DKngf8A6CviT/wIg/8AjNfFdFAH2p/wyr4I/wCgr4k/8CIP/jNen658P9K1n4aR+B7q4vk0mO1t7QSxugn2QlChyVK5Plrn5fXGK/Nw1+lPwn/5JZ4N/wCwLZf+iEoA8q/4ZU8Ef9BXxJ/4EQf/ABmj/hlTwP8A9BXxJ/4EQf8Axmvf6KAPAP8AhlXwR/0FfEn/AIEQf/GaP+GVfBH/AEFfEn/gRB/8Zr3+igDwD/hlXwR/0FfEn/gRB/8AGaP+GVfBH/QV8Sf+BEH/AMZr3+igDwD/AIZV8Ef9BXxJ/wCBEH/xmj/hlXwR/wBBXxJ/4EQf/Ga9/ooA8A/4ZV8Ef9BXxJ/4EQf/ABml/wCGVfBH/QV8Sf8AgRB/8Zr36igDwE/sq+CD/wAxXxJ/4EQf/GaT/hlXwRn/AJCviT/wIg/+M17/AEUAeAj9lfwSOmreJv8AwJg/+M0f8Mr+Cv8AoLeJv/AmD/4zXv1FAHgP/DK3gj/oK+Jf/AmD/wCM0n/DKvgj/oK+Jf8AwIg/+M17/RQB4B/wyr4I/wCgr4l/8CYP/jNL/wAMreCP+gr4l/8AAiD/AOM179RQB4B/wyr4I/6CviX/AMCIP/jNH/DKvgj/AKCviX/wJg/+M17/AEUAeAf8Mq+CP+gr4l/8CIP/AIzS/wDDKvgj/oLeJf8AwJg/+M179RQB4B/wyr4I/wCgr4l/8CYP/jNL/wAMreCP+gt4l/8AAmD/AOM179RQB4B/wyr4I/6CviX/AMCIP/jNH/DKvgj/AKCviX/wIg/+M17/AEUAeAj9lbwSOmreJR/28wf/ABmj/hlbwSP+Yr4k/wDAiD/4zXv1FAHgP/DK3gnH/IV8S/8AgRB/8Zo/4ZV8Ef8AQV8Sf+BEH/xmvfqKAPAP+GVfBH/QV8Sf+BEH/wAZo/4ZV8Ef9BXxJ/4EQf8Axmvf6KAPAP8AhlXwR/0FfEn/AIEQf/GaP+GVfBH/AEFfEn/gRB/8Zr3+igDwD/hlXwR/0FfEn/gRB/8AGaP+GVfBH/QV8Sf+BEH/AMZr3+igAooooA8A/bW/5JZpX/Yai/8ARE9cL8HY9Wl/ZS8dR+HlmbUW1CUKsOd5TyrbzAuOc7N/Su6/bW/5JZpX/Yai/wDRE9fPfwv+NXiP4caBcaRodlpE9tNdNds15FIzhyiKQCsijGEHb1oA+u/hafALvav4N/s/+1Dp6C6+xDD7Rtz9pCceZu/56fP9/H8VfnpXv/8Aw1V44/6Bfhv/AMB5/wD49XgNABRRRQAUUUYoAKAMmr9npdxdjcqiOLrvbpW5a2VpaqphXzXIyZWHT6CgDFstHvLvlI/LT+/Ido/WtRNAtYB/pVy8r9lhHH5mtJY2mdN7MzA8A85rSs9GvLnGyE7T3PSgDGgtbWGM+TaJuAHLgsasq8q8oEgK90GAa3V0KY7fMlVF6OC2MVuWPhiw+Vnk3t3ANAHBOJHjxLcFsnI5o8pWBDtklfl/OvUI9D0ZZI0WHzVfHP8Adqy3h7R8AfZm2ngN6UAeTNEFPByyjIHbPpT2iVSu7BOCxGO9egX2gaYHCmKUZbnHr60v/CJWDJk3O1um40AcBAqQuzSqCvIHue1Cwg53AFj1rptQ8Mxxp/o97E7gn5euBVNdKdYCwmj39NpOMUAYZj2jAKk+neoduAShCEc9a6iz8MT3g3ieEe2a0R4Jk2HzJkDdQTQBxi3dyiKIpZV45+bg0sskskX+kwwyhhzvjHA+o5rqrrwlLAqOtzGMDv61kSaTPlvKlRnzlscfjQBz0unaZKAxt7iInvC4K/rVObQ7dnxbXmM54lT+orpJdPuEXdJHnb1I/iqnLA6gCVSozy3pQBy9xpV1AhcxeZGvVkOQKoHjpXY+UQjMsmzHvUVxb290F+0QYYj/AFicE0AclS1r3uiSwQie3dZojyVH3l+orJI4PrQAlFFFABRRRQAUUUUAIa/Sn4T/APJLPBv/AGBbL/0Qlfmsa/Sn4T/8ks8G/wDYFsv/AEQlAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8AJLNK/wCw1F/6Inr4rr7U/bW/5JZpX/Yai/8ARE9fFdAC0UUUAFFH0qzZWU15N5cC59W7D8aAII0aRgiKWZjgAdTXSWGjraBZLkCS44KxdlPvV/SNJ+zDZbR+bcuOZcdPpXZaJ4XzB5uoOIkHOWPJNAHJJbSTSAEH0VVHFWYrFlLGVChHBP8A9avQEWCFWh063Qv03uOM+1XrLQg0iyXIV37jHFAGF4c022UGR4i9wvO0jiulTzWwscHlqBwAOa17TTo4lARAFXkE1dCBdjcFs9TxQBxV94evdReMoVRSehGMitLTPCqWo3vK4btz0rpjg72Uj5efpUZkAH3uAOfegCja6ZDETjIPrVhbWLlWXIPU+v0qWOdSCGYY281LGABlR8wGdv8AUUAQpZwg7gq8jGT2pGsbZkw8QIHH1qc4bAwSS2MDv71FPcoq7RksOPpQBUXRLBJlkS3UOCcH8P1rE8R2+gWSTT3Vv5kv3gi/fbjoBW6JJ7hwgDBefmHUVIunW0gJMStLyA7cmgDyafxXuOdG0v7JCFY/6QPmGKk0bxfrdxGYtQsYWmh5OTsZ1PTA/rXoupaNbNbMqwIjv1IH6Vz9xpCl5vLjMkceCC4wQw7+wFAFSw1/TNZ2RzRy2cpBbbN3I6/hUy6fbXNrHcRTRmKbJRs4JGcc1aisog5Msccj7drMRk/hVaPw3aqqhBLGit/qwxwB3xQBRfTzayiVw7luCp6D0p1ubPDRXkCBSxxnnI+tdDqOnhNOdXZwAM574ri7+WxtJ0GmXLXNsRho5RyT65oAZf2Wl3eDahoZs4xng1j32lyQMRtWRQeD2/CtO2u7OdfLn/cEcCQdFrXt9HlEJexnW5iK5yOSKAOBMBY71LhhxuaqF5p8d2GZlEM2cBh0b612eo2mxis6eWcfL/tGsqaxmVcsCyDjIGcGgDgrq2ltn2TIyn1xwfoah9u9drPCWRku4zLHjgH+npXOalpj2ymaP57c9+6H0NAGbRS4/wDr0lABRRRQAhr9KfhP/wAks8G/9gWy/wDRCV+axr9KfhP/AMks8G/9gWy/9EJQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/JLNK/7DUX/AKInr4rr7U/bW/5JZpX/AGGov/RE9fFdAC0UVPZWst5cxwQDLucD0HufagCxpOnSX8rKp2xR/NI/oP8AGvRNB8PtPDsWMw2393H3vfNSeFNCjmMdtDk2yEF2HV39fpXobWYjijiUhFU56fpQBlWGn21oUigXfIO47VbuVJkCk5dugA6VelKWikRKvnsflx3qWyg/eb5MNK4xz/CaAG6faAFWkRWcjgDt7mtSOIRgNInI7Dv71KkIiOPQdR3qTawGQct1IPUUACop6Z/oaWVUkQhhtx056UigNwrbhnK44qNhJKMoPlJwwPWgBxJVugBx09agm+aMZ4DDselTBGyN2R7kU1FRjgMAOnTigCqiFlIGPlGGzx+NU5zqDXiSQAfZowOe7N/hTvFC39toV5c6XEZ7qOMssfU5BrxW88U+MYA81wt3bmQ5D+UQo/SgD1G81DVheG2nCxxsCdyN0/Gt6xjExjjZmLcc56/j615l4ZvNY8VaJfXd4zrJpzK5uSu0SAnG0+tdZ4P1mKSJLdp0+0QNnJPD80AeknSysYEILNkA4q/BoDtEFBYMDnJFLoet2u5ld9sq9m6Gtw+JNNVELzjd3AHT3oA5i90qeNVbyS2OGHpWPe2pifb/AA/dyBx759a9Ugitr6w86CZJVB+aQc8Htis3UfC8htlkYAiIZdx6Ht70AearZW5jB8kYTkE96kFsszKQvyg4Ldga9TPg2KTTo5c4KgNsPGRmrGo6Tp6m2s4YU3ybVUAcqc8k0AeW6rp8kOlyTzIfIwyq578V8/vGxmmUMcbm6DoPavor47+KIdOt30m3VU8lQhZepz7V88XV3cWOmzTwQGSSQgD/AGc0AReVuhCrgMvvzU+m6ldadJ5kEpXjlM/e+tQ6hqDaXo9rc3kJmupv4ugSobOSLUYPOt5Mt/GHGMGgDtLPxLp+rIserW8cMxG1ZE+7VyXT2tQHtH8y1lI56gmvPPNjIxHJC5HXB6VteH9fls5dkhMtu3ylWPQe1AHQ3WgW91G4hUwzH/vljXG6pp8ti7pPFtRhhkYdR6161ZyQXVsGTBhbkHulVtU09LiHybhVkU/cmb7wPvQB8/arprWirPESbdzgHup9DWZXpviDRZNOklE2J4H4bjr7getef6nYtaTccwvzG3qKAKVFBooAQ1+lPwn/AOSWeDf+wLZf+iEr81jX6U/Cf/klng3/ALAtl/6ISgDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v+SWaV/wBhqL/0RPXxXX2p+2t/ySzSv+w1F/6Inr4sFABXX+HrMWumpOQr3N42xFzyqD/E1y9jbm6u4YB1kcL9PevSvC9mLnV12oDHCAuMcADigD1r4deGMeEdRvjDmSAom0dQW5NY95eKkjmRmGDgKfWvUfhoEg+G/iS5jG4yzMu3rjC4FeQBReatskx5cbZPuaANGz3iLz7jLSk/Ip6V0FmgMeZI8SHkis6yiM1yQ/CR8D0rWDsUAL8jIBWgBQAVyCcDoO9Jg7gxLqvr3pIndFDOGbPBxTiwDcPgdsmgAcOCSQqn1Xp9RUdw4WFmO7Pcr6etTMHVRtf5eoPX86qX0Mxj+RgrHkFeAfrQBSn1SY/Jbn7vTf3p2l3t5eXJieEEKpLFhgA9sVnvEybkkG4da3/DUTzWMk8YDp0Ljpx2IoA0rWExZdmKtjj2J6g1Ze3a82wsqmMAlgwBQj19qjdikZkdWCKPn3DHNc3r/iBksf7PsGKPNwXP8Psf8KAIfEkU0mlGw0G3EdvK5SQjhevLD1rm5PCcFpAxtmfITBG3nPY57Gus03zYtHtbd8BgCxyakcbTuwrDIZlz2oA87ivvENncJbQhpVbhDINze/Na15qWpW0Ci7tbhNp+eWMBiPwrobiGP7Ss8DuCh4RRxg9c1Mzhsn2z8w7d6AOe0P4iXmkXhRvNSIdGK8t9RXq/hz4w2l8TDqbQSAABmA2t+INeL+MtNhXypkITcdqqR0Y96r2PgDWL/TprxY4o2T7p3cuPb8KAPp24+IGieXHiV/LwQycZA9a5DxT8VtOS58rRzGLo8K3Uj3r5raC4gW4d5ZWSM7XBc8GtTTLNpoEJvUUHk54OPrQBreJ7WbVrubVb3UhOFch8j7hPaubgO0yInKIeh5yOxrpNQhddIe20qzkntQfMkdjjzDWVNp3nxpeWP+rcASAHlG9MelADbiyg1vT7eC4UDHYdQaoar4VfRvDV6NPEks+N8jZ5CDritlhJYsxMb4HX+6fxrS0HVDPfyCcKiiMnkdB/hQB4VuxyvBHcGuqskljtoHlQAyJvGT29a65fAltqPiAX+kTQTafKzOsYORu9B7E9qxNEOr6/q15Y3ixpFaq3mMqACEr0A/EUAaHh7XLjTZx85eNvvD2r0+zuYr+xR0+eIjknsa8UkjkikAkBLg8+hNdT4Q1iS1nEcrkxE4254oA7W/skmhe1nAbfykh6CvL/ABFpDxPJaTL8jHKt2HuK9iQxzw8uNvXGOlYWvaYt9aSwuoJXlWHXFAHz7dQPbzvG/VDg1Ea6zxBpLmKR41/eW/UY+8nrXJnr0oAQ1+lPwn/5JZ4N/wCwLZf+iEr81jX6U/Cf/klng3/sC2X/AKISgDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v8Aklmlf9hqL/0RPXxYvUV9p/trf8ks0r/sNRf+iJ6+LBQBv+FoSslzesrYhTahx/G3GPyya9R8JWxtNGlud+Se7cVwOj2pTT7KIEK85M7Yb7y5wufyr1CW28vTLC1iMZklYZA596AO78ONPpHhOSJZHBmjaR1zw2e9cppKBLGS4bZl2LB67VAF06VSGRTCRg8jpXGrH/oFrbxgZkf86ANnSS6WiuQp3NkmrwHmKCqcDrjtTIY1RBGAAAMD2oC4JwVBoAX5tgMRJ7YPehVUSDeAVK859aRSzDGSPrTLktsGCHBP5UASAgAggjgAkc1JgMQFIwRgDGc1XgQRxk7WJPcmn5yQu5l/2sHigCKe3iuEKspUnjeO1UdJ1ZPDF09rdXIjgny0ZYcFsdD+NaQJKk/KG3bs4xj6VwnxBilv/EGl2drE7eWDI7joOfWgDqb/AMRS6gqQWwMoHf8Ah47+9U7iBpJLZiymIOGcsMD05PrVqxt47VdsYC4Xk4puorPGqx2drcXck8gTZAoZiSCc7e/TGBkkkYFAG1qFuYQoK4V+S38hVFzkAgqrdVz7dqgg1GO7t/IW5CywYVo5cq8Z/uup+ZfoQKpSasUnNtBiQsDudRuCN2A9c0Aaats3BwEkfn/epsoglYKdhbIA5xiu/j0jRvD+mWiXll/aGszxCSRWfiDPQmsa8sbeWdt9vbBSfmWPopxxj6/zoAx7zQhf2DLOElA9eCAO4rP0TWH8M2n2K4id7RFbEqHcwz0yO3pUmsW+paZp6XdnLKLUS+TJHjcYz/dP881nWkNzeI86zh4WUgccA+/vQBxTXtza3t9exwgwOd5ikAOVJ64/Gux8O6FbzWsd7crEWlXeBtwoHarcOl6Vd6deQanv3mM7Jhxz6VS8BXofTGsZHG+1ZkyTyV7UAdQsKmIKqrsBxwcfpXnFx4X1C/8AEd4NODQwlvvNwCa9EgRppEgtGZSwHJGcV0uj2H2KwnllK+WRjJXkk0AeO3egaho6lnd25AdX+6w9CKxriM2V04QsI5o2SJmHqMY9+TXrfiS6intIY5U+dAQzk4DKO5+leYa+8EcKHJcrnYSfegDY8N6FJo3hWDT42ImdSXmQ4ILdQDS6Lo9l4X0W5BSWSN382WVz85Hfd60/wQ08tksM5lmVGLeZOeXzyB9BXQXcIfcjh2iIw6/0oA8g8RWn2fV3YyB4JyZ4gOynpWQshjcgAKQd3XrXVePY9t5CjAIFXgeo9K5IxO5528dDQB6r4U1D7XpiPjLLw1a2oqTDHNkll5OBwB7etcP4AlkSWWHkhx36V3drIZBJEQcgbT7igDg/GVkVkW8iQqHHJH3XXv8ApXk2rWotb1ggxE/zR/SvoDWbFZtMltyGbYNyfNXi/ie2byg+OYW2/gaAOZNfpT8J/wDklng3/sC2X/ohK/NZutfpT8J/+SWeDf8AsC2X/ohKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/AGGov/RE9fGFvG008cSffdgo+pr7P/bW/wCSWaV/2Gov/RE9fIXheLfq0cu0MsKmQg+w/wAaAO90KAXOtKkcamGMrGMH+FRz+ua9CskhutatEl/dkKzKMdOwrivA0D/alkz87gsxA7nvXW6fdtB4yspDtCqnCnnOKAO8R5FtLiBlODGyhh2rl7ZF/tKKMAMIY+fr61r6lrAluWSJGjJzn2FczoN4t7q+ourqViIjBHegDpwAwXGVJPGTwaXEvlnDIQeM55FQFhgYxx0Gf50B8SDkDjkHtQBYJZTzwB6r1pHKNkYAJ5HGMU1GG0HePm6UNGG243qx79sUAOCq21tyhvbk1FG7TMQ25W+8WzwuOwqX5Cj8NxjORwaaxCqUVQULAntQArDjdwONwIX7vtVKWCOTUvtAK+Yy4DLzx6YqyzbFLgEBeW5B/Go7fbM4fKjA428ZHt70AWEhZ4yoTcv8QTt+dULpbpJIjZ7vtfmoLfy/veduHl49923HvW07pBCu4vk/dK8sB6GuY11b0on9n3s9vdxHzUmt2CnIBA+bHHXORgggYNAHuvxKHgU2duPHosDfbB5Xl7vtXv5Xl/vcZz049a8IigaPxCi6QlymiCRCjap5YulOeoMfy7enX5vWjTbeC2iDKEkupwGmlclnkOOrMeWPuSatXmwWM7Bnyq43f3fagDvpFmM0l1OT/pT5D5ySBx1702QKoPIZAcbR1NXbrxDDqXgnQbh4UBA8h5YjlIJF42ke/BFZ9zL5KNIfLVxyWPQ0AQyTtC0myA3AuY/s7J2l54/H3riNImGnate6Tdw+U6yFdr8bOclfc10Oo3DMrXUWfstoVZ3BwCe22uB1ud9Uv7q8SR47jcXTnO7uCfwoA6PWbdoiyFMjHA28AVy72cWhyrOhMi3JykoH8X92txdWTUtAEikJeFNmM4+cdcVgWl7NcRQW92u8BsAjru9cUAeq+CIJtscu6MtL1yP4vb2rqdYliXTHaVkYYxjoGPsK5LwvPc2luqqMj/aPOP6VW8aa2INMubk5IQkKDx9OKAOI8W6rJcXYsoHOB/rAvIwexq5o+ipJGk18quSMqCOoqj4ZihniW6umxJI27ntXVtdFX42kDG1iOB70AXFgjjjjVYtoAznHAArP16/t7DTjfzSDyYlLs57Y7VJfazaRRbp7mEBSd25wo47/AEry7x/rtx4mhbS/DMf2m2kP76Zfu8fwD396AMbXvE9j4kuS1pG8IRcsJQMk57YrIyrShGyeM8cA1T0vS5tMup/7QTypdu0RnqK0nUMqNwSOAC2KAOt8Hq6zxtgCN+MZ6V2tuPJ1RQSpjkU9c9a5PwZE8Ur21yn79BvwCOldbehQ0EjlgysO/wCdAE94GWVDwA3y8V5J4q0/yNUuLa4yY5sjdjoe36169cliuXIAXmuD8d2/nP50T5JHAPtQB4rMrJIyNwVOK/Sb4T/8ks8G/wDYFsv/AEQlfnR4hVBqTNGciRQ5+pHNfov8J/8Aklng3/sC2X/ohKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/Yai/8ARE9fJnhJf+P+TcABDs59yP8ACvrP9tb/AJJZpX/Yai/9ET18neGVLaZqBC7jvjGM49aAPR/Bcc3nTLGV+WLitawb7R4qlbvDEB64NZPgcPH9oPlsrGMAEnIra0Yode1Bl42hMlaALmoXaWqX1wMnZFx/vGovBtiLXTDIyjzZW3n35qO/Zri0mifAMk+Dx94DpW5aW+yJFII2qPunOKAJrm5ihYbnCk/eQdfxp0ReRVkzuB6Y549KptYNLK8k7GQdVCnB/GqTXskMjQ7DlGwDntQB0C4BKhmA9CKlDuHCHBUDvxisqyuGlnCnODyw9TWsmVH73cF6464oAcZGIwPlUA8jmiV0CFpGGwc5zjd+FNmYAclguON3INY+t2/2+ApG7xxkcstAHLeLvFERMlrZMPNx0zgH1zVjwf4rt5Yo4bvEE44O/ow9M1zcXhaa61O7S5IFvbktvx1Hse9aVtJ4c0+yMVyjTXBUgqnO09sUAdlea/ZRoJDcJgZJVWzXnWreKrufUy1hI8EK5Qf7Q9a29M8F211bre6j5kTyjKw7iNlYHiDwpc2F4Wt45ZrXG8SkjC/7JoA6Dw94jmhsoI72FJ3JwjBvmC/41avdUuL8/Zra2kQknazDj6tV/wCFXhW41sR2dosWxm8yWVx/qlHdj9ele/aRp2heFrV0trdL29VMyTyIMP6hewoA8j8B3GreGIZfK8q5tbhQZ7WWAtGSOh571r/2v4RsLZ7zWtO1D7XksIYpP3f/AAEV6xb6+jxHfDBGvLbAgOF7Cm6loOheJbWOPVLCJbiRQd0ZAOeooA+cvE2vjWoy7TeTYrzFGPlwOy4Hf1rh5dVuZLySKNQPMONkfJx9K9P+J3wtXw2kl7bedNpjuCJB/CSckEdq5PQvD0cqDUYZQp8wmMKOgxjp1oAxdYtp1v1t9NeSUyRCQpgqQ2Ov5VN4FEjXjRMzBwchXPI9TXZnTts5nibbdqm0Oec/hXnN7Z3uk6yJJHKThy4kPAcHsKAPZ9OuPLQqrbwRkkn+dcV8RdUTUWSyjm2IQA0q/dZh2rJn8TXTR+XKBDgAtjqFqkbg6hfg7GS3VsozLwfegC3Y38mn2eZ4yVUEDuKuWN/NrsW1ybe0Vcu4PIHeluLdEs5G2lkxyG7n2qrpC2iM+mXp2G6/eRvnBA9D+FAFPWfDel+INTtpYLydbSABGWT/AJa+4rqrqztLPRPL09IoVjGFRFwOnesSVbeCeMXcX2WVZ/s0MTMfnVfun6Gup06ylEiJMIhbSKd/IyvoKAPLdWsbppDJIWAzwx57VnJDhNrvmT72fWvWNU02AxsnkEf3VJzzXnGsWctrcBDH2+XFADbHWJY9agu3Y4UbHIPUe9elQXceo2DsjFmVdwxXkRO0FVUA4wTjv610/hDUZF1GGB+EkBQjNAHpW1ZrQOfvMgJ7c1yvipC+kI/AMZIyO1dRbspsyWxwpG1uvFc/reJNDm8vb5ZAZh/d5oA8K8Qf8hOQZzgAV+jHwn/5JZ4N/wCwLZf+iEr85Nbffqlwe27Ar9G/hP8A8ks8G/8AYFsv/RCUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B+2t/ySzSv+w1F/6Inr5Q8Mf8gjUscHfFjjPrX1f+2t/wAks0r/ALDUX/oievlHw0D/AGLfkEAmWP8ArQB6N4CRStwvzh9g5DYz+Fa1jttfEUgUfLLH8+fUVgeBpWGomN9h3xkLz1NdUYNt8Hlj+ViB15x3oAm1FY44CcZAywP9an0+4+0xoFXkcrt7/WtHxzpX9n7rWJt0M0Akjkbrhh04rjPhy0tzLeROA622PlJxzQB18iNtCfwE9CcY+hqC6sY2IkG5Ohy1aUkZHADKQeQf/r00AgBGVCuOm7NAFewhKD5V8wk5ParwiPO6Q5PRQcgVCm0uFAI7Y6U3ULmPT9OubkqqJGOeckn2oAbczfvCiuPl5J6/hVG6nMRV8kMegA/WodIJNms/8UpLsCPU9Kh1qb7Oh+UBB80jg9BjoKAOQ8T39zGPssUru85y5U4C/wCyPrVfwDpiXXiEls+XZKWK4++3vWdd3DXE0+oy7kiD4iDfxHpkV3fgKIDQPOBXzZXJYk8nHSgDpVIPyuyqCMAbs5rE8WrnS5rYyttmcJtbue+Me1bcLu0qg4LgfOmaxnj+1eMtLtpDm3muY08vqRk9M+9AHr+gacvhn4eWdraqkF/qQDOCBnYen+feq2k20spuA9wYJIQAqM33VP3sZ6jvVvxFcy3ni67gjCoISI2hdfl2qMDn/CqmtQXdtpwmW22vuUD5TgR57H9KANQvaW7SbCkgiC7GB2hj/WpZ7ueKNJY5IySQhXoyr1wB3NVbXT0W2sYpLWVTOC6kKWKk/wCFWdF0x5lnEsbO0OSXY847Z/woA2NGaDXLO607U332l2phMLnLA/XtXz7rFtP4P1m/0qQZtbSTaGAO5lJ4Ne62dw+ma3DFHsNnwS7DAZ/XPWuL/aCs0j8R6BqC/KlyhjkYdHYcgn8KAOQifz4w4wSeuR2rP8SaNFqulSRtHG8sfMbgYK/41okt82wZfjdjn8qXdIQFXaFbO6MjBFAHlyWbT2Cu2VngYxsvUOPeun0vS5LxUOwGNVzhvl/l1qD7MttqdzbsQC7qVB967zTLIwfZ1WMAsdpOcg0AZKaWZY/KnXLOuUOeF+mK5nWNBmju4xdufvBopW48pu31FenS25hkxN8jrh0LDGRVjV7W3uVWdyP3i5BZc5x2FAHm9ih1CdW1ONHngbaGB+8v94e/FXJr3URLFPDFb3MO8oylsEejfhUVwr2l+AwIZiWibGB9DXT6BpI1NMwxRxwlgCAec9TQBmXP2hooXmhcSPydoyBWV4g0V73TWljj5UE56Hivdrzw3bT2vlqyoFAwAMZH1rmbzwxLGjhCfLAOR1zQB8vSgRzOpALg4Oe1WtFO3WLY+aCRKoG05qXxRbG016+jIVAG6AZNUdKY/wBqWm2T5DMu0bcE80AexafIRBIjuTiRgcisWQCLw1fODv3An6c4rYT5BIYsYLFjn0rA8RuLfwdqGxgoKlwScZ5oA8Jv5fOvJpMY3MeK/SL4T/8AJLPBv/YFsv8A0Qlfmu3Jyep5r9KPhP8A8ks8G/8AYFsv/RCUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B+2t/ySzSv+w1F/6Inr5T8OKf8AhHr88DMyYP4V9Wftrf8AJLNK/wCw1F/6Inr5a0MbfCpcbsG6wxHThRQB0XhuVobu1lIOFcBjnoK9KuU3xgFcuTwQeleRWcw8skNJnOeOBXpGmzSXOjxSqfMkbHlg8cigDUutV/tDR1812Z4F2KW64FcpYXx0PWhIuGtbrG/2Oa6OMCSN4lIUk5ZFHINYt5bG70i53LiWAlh68UAdyFZ+SWZTyM8UoQY27AO+axPCGprqmh202W8xBtfnjNbpIIwWXAHzEGgBQ7qoJKFOxrkPG9yLg2unpMEeWQEgHlvautdzG5JHyKAxI5A4ry+0ujqvxBjlf50iZioboMUAdrNM9pbxJCrsAuDgdgK4rWbhtUuY9NkumigwZJ8dVHpXX6/ey21lK8C73lPlrsHA/wDrVxENhJcyyWyrslkI82Rhz9AfSgDH1WaG6uUhthss4B+6Djrjqa9J8E7X8OWmGX5mbt2rm9Y0NdN0wS3BDPGhD7entXTeD4zD4YtIREGDjII6jNAG4pH2na5jKqMjOR+VYmm3zp4thun3BIdQhKDg7u3WruoJczwBImWKMoUbPJ29z9a0/AnhufxDqVhI8LJZWGTLOUwjsDwvuaAPom40eE3t1diJJBOgEkZHLY9DTbywSTSYraKFjCqljGeSRgnaD9atape/2boc95FCZPIh3iIHrgdK+d/FPxC8SeIVKR3Mem6eWOEtWIdh7tQB6BZa3cJdxSXbPa+ajBIskbO3I/Kuv8OwxagoupUXzNuNoPD/AO1Xjtt8QLyDwxa2OxJtXhOwX0yBsx+hHf61s6F8XH0uzii1jRVZl+Xz7Rgq491/rQB6vdaDDLJCYlVVVdpB5OOvFeE/HfXrbWfFltodqTJHpKB3kVuPNJxj6gV7Pq/iB7rwFc6vpqOkkkB8oHqpNfJeiTTPrshvGG6YlxI/Jdu4PvQB2VvdrNHthlXP3dvQqamcN5eExkD5lcbj+dY9vbhpxMqvBzu2Hqx9fpVm8u4bLTpLq8c7UBBVTyWPQUAcp4svZLLxEjpuOEQEYxzn869S8P38PlRmRUcMAw28YryfTtIvPEE51O7JijkOF9WHauis4LvS7sLBzGByhO5aAPW9RiWaPz0bG9eAvH86rXcSjTla/wABVwIyv9a8/v8Ax5LCFiltpZZDgKGAGCO2PSq+vah4m1m2VwIobcjcUzyKAKHiS8jvtf0+3jk3MrnOPTtXqvgZIo5sJNGF/u+hr58giudF8QWk95uBVgWdugzXselXKTtHcwyKQTkMBjmgD2HYAqmVRISemcCqXiNlh0xpYZido+76Vz+j+KIo4nSZn3jrkZArz/4gfEMxWksUUitclSqoo7e/pQB5B49njk8Vag3JAblk7GszRE8zWbTlseYCOOtVZpWlnaVmcyOTuyeprofBFr52rmVg2IV3bsZ69KAPSCMWsgK4Q5+Y9a4j4oyrZeFFgiyWuZlTDdQBzXZXiM8XlEkjqM8V5N8XLwy6xaWRG37NDlsNkFm7Y9qAOAbrX6U/Cf8A5JZ4N/7Atl/6ISvzXYYOO9fpR8J/+SWeDf8AsC2X/ohKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/AGGov/RE9fLXh58eF7hSM4uARzjtX1L+2t/ySzSv+w1F/wCiJ6+V9AzJ4anVCA0VwCfoR/8AWoAuWzM0TbowTnnPpXZ+EdXUoNPmkUKT+7bk8+lcXA7mF1SReDnpyRTrWYqcpuUqMq2cHNAHsMFooumuQ+ZTw3pVe7gSC4mYZ8qZDvPZayfDOvw3UaQ3TLFdAbQxHyt9a6SKKVPMWV43Vzj5RwPpQB5x4L1ldF1e4gnVvscrHgHhTmvVLW4huoRJAYmjPT1NeQeL9Fl0rUXkxutrgllI/kaqaPrV7paA21y4jJJCNzigD1Lxrqqabo87K5WV/lUZ6V5t4T1JbTWop7sbixxnpyao6jq0+pyeZeSNJ3Vc4GaqxM7H5EYufmCqOpoA9rjAdRIQrEfcwait7WIzl1jVCTnOM81weitr6sjWdtN5ZHIk5H610hg1u/Gy9litIW4byuCR9e1AGH461ZZpF06FlMaH526s5q34T0DxbrcsVppqzRQYzGoHI9/b8ame30bSLlmWD7VdgcMx3DPrmum0H4uTaRoQ07TbC3jleQtNOT8xGaAO/wBC+GdvplvE+u3V1qNwDn7DaEsrMf7z9q6iKxuTMiXCNp0KLujtYBtEadPm9T714R4k+Imu31lsfVLlBI3yLG2zj3xTtK8cz23hO+tJLu7uLz/VqzOWIRu3rQB9OeDvEdl4jtLyKDbus5DbyoTkEDofxrh/iF8NbVLK41Lw/AUdSZZbYNxjuU9PpXjHw08VT+DtQh1aOaWe0f8Ad3cJ4Drnr/vCvprwX450TxgJ00mcmeEAywSD5gD0NAHzasTtNGlsryzStsSJBlj7Y/rXsvhr4S2Mlra3HiQPNMMP9lVsIvfDetehW3h7SLS/N/b6fbR3nP74LyM9fpVlNTsGkdFvrVpF+8olGR9aAOY+JN9pGjeDZ7e+uI7OF12Qooxux2Ar5hvrLyI31K32S27NjzByE/DtXo3xW1aPxPq15btPG1jbOFhJ9uuPqa8suNUm0a6ntkYPZlstHn7woA6q3nRrOOaR41ix/rM9vxrz3x5qwvdSS1iKi3hxuMTcMfX8q0NQsH1a2CWTlVZvMjgL4Ark9UsLyynVr+Eoz9eMj0FAHt2kCI6LamBo2iZV3Ko4IA7UpjMrqjZ2n5hhemK8z8M+L5NN05LOeHesZ+TBzXaeFdYj1ppWClJ42A2kkZHegDZm0y3kdZpEjMg5GQeK2rNra8jWNjFDKCF2qMUu35WQlSE5BPUCrWl21vHm5dgVB5Pc0Acp4+0IXemzL5Ia5jcEMB1FYukteaYkSjeRjcD2GK7vxPqIvceUgjkkJjAPfA4rnLi4SzgikuY5G3P5JWMbsN6+woAw9bvLqa2MkLvGSpJcjBGPxrzG6lYsXBkfcdrljyTXq/iGykudJuF2FFRvmZhuz3ryW4lZtrlXiBzlJMBlx7UAQTFXGCp3ZGwKec16d4T07+ytI8y6YI7/ALyRs/d9K5fwVob3N0L+8VtiH5EI/wBZ7mu9nia7lW2jBMandL/dPtQBHZyu1tPfXW1IsGT5v4VHPQ18/wCuahLq2r3d9OxZppC2T2Hbj6V6x8V9cWw0QaXbtie5wGwfuoK8XPWgAbr7V+lHwn/5JZ4N/wCwLZf+iEr81jX6U/Cf/klng3/sC2X/AKISgDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v8Aklmlf9hqL/0RPXyZ4TuYhPLYXDER3S4U9MSDpn2r6z/bW/5JZpX/AGGov/RE9fFqk5GCQfUUAdlsNvcYbcjxkrsPUH6UOiSYljycdV7iodM1WLVFSC+dIr5QFjuG4Eg7BvQ+9TXMUtnOySgxPnjcOvuPUUAOjmdCrKfLfPXriu58H63dB2t5ZPtKORt3thga4YoJF3IBvPUY4p0bywyfu9wc/mMehoA9ev1g1G2azvYswHrkfMD7V5l4h8M3Glu0sReS0JyrgZK+xrVsPGVwkey7j89F4Jxhq1I/FdiygR7oweqSjIPtQB5ygxHkqzKoJ3qePyrvPhxYwXFm1wI90wbBzzt96dDNo0tzJIipbM4xIg5RqyzNcaFqrXOhxCWCTBcKcqRQB6UkTqjAMzknsentUdy8VpDJJcMEiVcnJ/Ss3w7rlzqClZrbyHDZBHQimeJrOO9sXj88+akgfPY+ooAyJ7x7y7jQR/ZbYsBGpX7+e9ag0SydFYW4ZiDkr1Bq2qQ3EUazKv2mJBtVQcfUVpWrIY/ukgHGemT6UAcMvhx3CAuQOW2A7u9bPhHT4otLFy8aylmIyxzitu5TDTyZ25QgLxiq/hSJo9HWMjGXbA7YzQBm3GmW008lvbptWf5gM5yfXFX/AITH+wfiPpg3SpumEb4P+szx+VV3VrHUHlBBUS7Q3cA9q3/BOmx33xI0V5Jv+XgOqjsACaAPZvjj4on8M+CpJrJwl1PJ5S+uO+K+VojfyQyXX2qVA7Es24hiSehr3j9o7FwdIsA2dsctwR/KvI9Otop9Lt3YFpY2xjPBPbigCq1jfXFhgzEXC4KknPGf61XPlag8pJV5I38pweoI711awPt3PncQOnauR8L2Qubm83EbY5SMjv8AWgDXmsClsv2dyo52nNJczRXentDqK7wMEZHPFXBZyW0syRSnYy7gCOB64qjqttcLp0b2e1lxjB60AYF94UFxH52nusqgcIeCPxqtogvND1ANeW88K7CEfb8oPv7V1FncXGkW1vJcwjY5AdOu33FdFDLDc7iNsny8h/egDF07x4oixdQyFkB5XkH3qW5+IMDw7Ird0U45xgZq5No9hMzBogrNwQvpUC+GdKjDFo5W443PxQBm6T4vS/nZLpzHLv8AkLDjituS+aGGQxR75W+ceh9z7Vi6x4cszayTQoLd0UncGJrjY5bxgYY5pSB8oOe3+FAG7rGvXER+xWE0k875Lu3IBJ6Cqul+F7i8u/tGpoVd2DbCM7vr6Vo+GNIaIF2VGkb70j/0rpJ7i106Ld5wiJHLO2SaALUMEVtCI4VAwMFt3SsbXtct9JR44B5lyVyWBGF9z/hWDrPjEtvhscHsWPevPNavisDESFpJuDn9aAMvX9Rk1PVJriRiWJIz61mk5NFFACGv0p+E/wDySzwb/wBgWy/9EJX5rGv0p+E//JLPBv8A2BbL/wBEJQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/ACSzSv8AsNRf+iJ6+LK+0/21v+SWaV/2Gov/AERPXxXQA4HnoK3NL8Q3FvCtteRre2gOfLl5ZP8AdbqKwqM/n60Ad5ax22oW5m0eVnYDL2p/1i/T+8PcVGweQbWLLIBghjhkrjIZ5LeVZYHaORDlXU4Irq7HXLXVCkWtEQ3R4F2Bw3+8P60ASSIoIBY46bh0NMcvHuxgqPbqK0LiGawIMyq9u3SYco/0xURQOjNEygk/db0oAz25XK7selSw3UkDho5GAHO3dgVNIoBYNtJHAwagXBOOBQB6N4KvWvEuZWOZAoVVwOPXFdJHCphAkB5yGz3zXkel30ul3sdxASu3hhn7w716lpupQ6ha+fCd24ZaPPK0ATWsa+QjJlDESDj61LJhHCJtKM+7PSmW3luGC8ofm69eKrRTebcBW6HgA9RigC1cEESxsMu3BGOKj08ra6S5+8EJwBxjnpUsz7lwhKknBNR21qkJli3Z80FsjnB6UAV75hMYgiMIuHdl5xXV/ClVm8baKwZGmWR2OP7u01gG2ML26mQYjBXj+IehruvgtFbW3i9xeQrFIYcWzMMZPfH4UAL8dDcf8JhaBUTyRbDe57DnNedaK8TrJAhy8bFumBzXsvxvuLLztOjSAT6ihO8A/djI6GvHbS3ubE3TMY5HYlwQuAfT8qALsDDyWMoyVzurM0mKMW8rAbY2csMcHr3q3bwyQ6YDIzGZgSx7HNR2yJbRiMthgMg/3h349qANCQkxRJIoYEEBqZIq5AIURqvIFREcbmdtnUVMYpFRgxB47UAZWp2/2sw5J2wv36IDRqxmgKT6en744AUn5Wx1q4qeah3AkKecd/rSRAW4MDsTtOUJ5wKAKUviWOEqmoQGJyRu28gUyXxdo8CH/SQ5/uha8/8AFl61xqMyRvxuILA9Oaxckv8AMPYkUAeg6p4ys72NosSRxMMEqOoqjb6/YW4/0eJm2Dh2Ga5GJck+UR15yaR1Ybicg9eDxQB1kvi6Riywx4JH3gORXPXN1cXMjPI0k2epbpUEYViPnKD1AyalOEbEjOY+yrwWoAjZAVaSbEcUYy2a5K/uftNy8g4Too9q0/EGpmUtaxn90Ovv7VhUAFFFFACGv0p+E/8AySzwb/2BbL/0Qlfmsa/Sn4T/APJLPBv/AGBbL/0QlAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8ks0r/sNRf+iJ6+K6+1P21v8Aklmlf9hqL/0RPXxXQAtFFFABTtwx0ptFAGnpWuX+mArbTZhb70Mg3IfwrorLWdGv9ou0k0y5zkyR/PE31HUVxVKDQB6TJp1xHD9oiihurVs4ktzu+mR1B+tUWEDMFACyYwVbgrXH6dqV3p0olsbmW3k9UPX8OhrpLbxmtwQmt6dDdDoZYx5cmPw4JoAux2Jl5Rw5zgZPIP0q5YLfafcs9uTuPB561Wtm0S+YNYaq1o4yRHdDbj2yODVibS9aii81F8+E/dlhbdx+FAHRWWuqbhmuWe3YrtKjlSatLrUC38Q28DOX9a4hr66hIW4jKheNrryafHqEZ+8pXHpQB6naXlg8irbzwlj1Vm5/WroKYBQ/NnnAzXkRvIS2CV3Dlcrhvzq7beI3tlIiuJjgEfj2oA9QkmiSJ5HdYznqR0/CuS1rWbibVIpLWaWKCIg+YWKsSPSuVuPEV7cR4O5j3qCG11bUWVESWVXOBuGMUAdbFrWo/wBpy3s1xJMsnDBpNxxXXWMokthLFIHTbyvcV5bPoGs2KtiFjgZDLyRS6d4hvNPZBPGcdGzwTQB6q+0opUtnIA+nemuiNHtJztJCsR61yuleLbVoyGViy+h5FFz4oZXBig3pnIVj3oA6aaNxCybj8gw30qW1cvEpXOAuSc1xdz4suJl8s2rRk/e2/wAQqODxNPBEyCLy1HHP1oA7HzFtoJpZG8tPMPLHjB6Vy3irXobW3aG0cNO3BIPSsjWdbuNRiAQMVUbUVeFA9T61z6Wk87b5ojg85zQBW3sXL4/eEnIPPWnrErQOULeapHbtVpLRRIu51Bzj5fmNXGhit1ZrqRYoRyfN4/TqaAM2GLzDlCXxx8o71aSEq+whiT2AyTVG68Q6bb5W2We547fuk/xrHvPEl7OGS3KWkJ4KRDGfqepoA6W4WO2AN08NoO5kbLf98isS98QJHG8WmxsSePOl5P1Udq5x3LvuZiW7knNJn8/WgAZixJY5JOT70lFFABRRRQAhr9KfhP8A8ks8G/8AYFsv/RCV+axr9KfhP/ySzwb/ANgWy/8ARCUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B+2t/wAks0r/ALDUX/oieviwV+kXxQ+H+lfEfQLfSNcuL6C2hulu1azdFcuqOoBLKwxhz29K8w/4ZV8Ef9BXxJ/4EQf/ABmgD4sor7U/4ZV8Ef8AQV8Sf+BEH/xmj/hlXwR/0FfEn/gRB/8AGaAPiuivtT/hlXwR/wBBXxJ/4EQf/GaP+GVfBH/QV8Sf+BEH/wAZoA+K6K+1P+GVfBH/AEFfEn/gRB/8Zo/4ZV8Ef9BXxJ/4EQf/ABmgD4roAr7U/wCGVfBH/QV8Sf8AgRB/8Zo/4ZV8Ef8AQV8Sf+BEH/xmgD4sAz1NW7HUbzT5N9jdTQP0zG5FfZH/AAyr4I/6CviT/wACIP8A4zR/wyr4I/6CviT/AMCIP/jNAHypaeNtVjRUu/IvIx1EyAk/8C61cXxXpNyrjUNDVGP8drJj9DX0/wD8Mq+CP+gr4k/8CIP/AIzR/wAMq+CP+gr4k/8AAiD/AOM0AfMsWp+F5tplkvrfHUbN9TPqnhOCMlJL25bIIUpt/nX0p/wyr4I/6CviT/wIg/8AjNH/AAyr4I/6CviT/wACIP8A4zQB8zy+ObW2G3SdIhj9GnOSPyrDv/F2tX2RJevEuMbYfkGPTivrT/hlXwR/0FfEn/gRB/8AGaP+GVfBH/QV8Sf+BEH/AMZoA+QdO8Q6tpzg2t/OozypbKn8DXQReOTcoIta0+Gde8kI2P8A4V9Pf8Mq+CP+gr4k/wDAiD/4zR/wyr4I/wCgr4k/8CIP/jNAHzZFDp2quH0e82PnPlTHYy/j3pws9WiLD7OzJnqOcn1FfSI/ZV8EDpqviUf9vMH/AMZqeP8AZi8JRrtj17xWo9Bdwj/2lQB82pFqyHK2o6fxMBTpIdTCfvvskCsOTK44r6Nk/Zd8HSHMmt+KWPvdwn/2jUZ/ZX8Enrq3iU/W5g/+M0AfNrXltDHi71q1OP8AngN5qnNr2jQjKm7vH9PuL+INfTv/AAyr4I/6CviT/wACIP8A4zS/8Mq+CP8AoK+JP/AiD/4zQB8n3Xiy7ZWSwhhsoyMHYMsfxNYEs8s7bp5HkY93bNfZ/wDwyr4I/wCgr4k/8CIP/jNH/DKvgj/oK+JP/AiD/wCM0AfFh596SvtT/hlXwR/0FfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/GaAPiuivtT/hlXwR/0FfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/GaAPiuivtT/hlXwR/0FfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/GaAPiuivtT/hlXwR/0FfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/GaAPio1+lPwn/5JZ4N/wCwLZf+iEryr/hlXwR/0FfEn/gRB/8AGa9v8PaVBoOgaZpFo8r22n2sVpE0pBdkjQKCxAAzgDOAKANCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The series of axial CT images shows a distal thoracoabdominal aortic aneurysm. The aneurysmal segment of the suprarenal aorta (arrows) contrasts to the normal-diameter infrarenal aorta (arrowhead, C).",
"    <div class=\"footnotes\">",
"     AAA: abdominal aortic aneurysm; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2839=[""].join("\n");
var outline_f2_49_2839=null;
var title_f2_49_2840="Tetracycline: Drug information";
var content_f2_49_2840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracycline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/16/7429?source=see_link\">",
"    see \"Tetracycline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"    see \"Tetracycline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tetra&reg;;",
"     </li>",
"     <li>",
"      Nu-Tetra",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Tetracycline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F226313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Oral: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Oral: 250-500 twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic bronchitis, acute exacerbation:",
"     </b>",
"     Oral: 500 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erlichiosis:",
"     </b>",
"     Oral: 500 mg 4 times/day for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, severe, treatment (unlabeled use):",
"     </b>",
"     Oral: 250 mg 4 times/day for 7 days with quinidine gluconate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, uncomplicated, treatment (unlabeled use):",
"     </b>",
"     Oral: 250 mg 4 times/day for 7 days with quinine sulfate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinine sulfate duration is region specific; consult CDC for current recommendations (CDC, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     Eradication of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     : Oral: 500 mg 2-4 times/day depending on regimen; requires combination therapy with at least one other antibiotic and an acid-suppressing agent (proton pump inhibitor or H",
"     <sub>",
"      2",
"     </sub>",
"     blocker)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Periodontitis (unlabeled use):",
"     </b>",
"     Oral: 250 mg every 6 hours until improvement (usually 10 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Vibrio cholerae:",
"      </i>",
"     </b>",
"     Oral: 500 mg 4 times/day for 3 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F226328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"      see \"Tetracycline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Children &gt;8 years: Oral: 25-50 mg/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, severe, treatment (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral: 25 mg/kg/day in divided doses every 6 hours (maximum dose: 250 mg every 6 hours) for 7 days with quinidine gluconate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, uncomplicated, treatment (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral: 25 mg/kg/day in divided doses every 6 hours (maximum dose: 250 mg every 6 hours)  for 7 days with quinine sulfate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinine sulfate duration is region specific; consult CDC for current recommendations (CDC, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F226314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F226315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer every 8-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12-24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Slightly dialyzable (5% to 20%) via hemo- and peritoneal dialysis or via continuous arteriovenous or venovenous hemofiltration; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F226316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; no dosing adjustment required",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F226288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered on an empty stomach (ie, 1 hour prior to, or 2 hours after meals) to increase total absorption. Administer at least 1-2 hours prior to, or 4 hours after antacid because aluminum and magnesium cations may chelate with tetracycline and reduce its total absorption.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F226287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections of both gram-positive and gram-negative organisms; also infections due to",
"     <i>",
"      Mycoplasma",
"     </i>",
"     ,",
"     <i>",
"      Chlamydia",
"     </i>",
"     , and",
"     <i>",
"      Rickettsia",
"     </i>",
"     ; indicated for acne, exacerbations of chronic bronchitis, and treatment of gonorrhea and syphilis in patients who are allergic to penicillin; as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12810265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of periodontitis associated with presence of",
"     <i>",
"      Actinobacillus actinomycetemcomitans",
"     </i>",
"     (AA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tetracycline may be confused with tetradecyl sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Achromycin may be confused with actinomycin, Adriamycin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels in infants, increased intracranial pressure, paresthesia, pseudotumor cerebri",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, photosensitivity, pigmentation of nails, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, antibiotic-associated pseudomembranous colitis, diarrhea, discoloration of teeth and enamel hypoplasia (young children), esophagitis, nausea, pancreatitis, staphylococcal enterocolitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, azotemia, renal damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, candidal superinfection, hypersensitivity reactions, superinfection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F226291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracycline or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F226272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephropathy: Outdated drug can cause nephropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Has been (rarely) reported with tetracycline use; usually resolves with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Hepatotoxicity has been reported rarely; risk may be increased in patients with pre-existing hepatic or renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F226334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Tetracycline may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F226303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum concentrations may be decreased if taken with dairy products. Take on an empty stomach 1 hour before or 2 hours after meals to increase total absorption. Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai and St John's wort may also cause photosensitization. Management: Avoid dong quai and St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F226294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. The pharmacokinetics of tetracycline are not altered in pregnant patients with normal renal function. Hepatic toxicity during pregnancy, potentially associated with tetracycline use, has been widely reported in the literature. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas, 2011; Whalley, 1966; Whalley, 1970).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F226320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F226295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracycline is excreted into breast milk (Matsuda, 1984). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Tetracycline binds to calcium. The calcium in the maternal milk will decrease the amount of tetracycline absorbed by the breast-feeding infant (Mitrano, 2009). Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9626655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach (ie, 1 hour prior to, or 2 hours after meals). Take at least 1-2 hours prior to, or 4 hours after antacid.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F226293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tetracycline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $6.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $11.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F226282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal, hepatic, and hematologic function test, temperature, WBC, cultures and sensitivity, appetite, mental status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F226296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Achromycin (AE, AT, BH, CY, EG, IN, IQ, IR, JO, JP, KW, LB, LY, OM, PK, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Achromycin Ear/Eye Oint (NZ);",
"     </li>",
"     <li>",
"      Achromycin V (AE, BH, CY, EG, IQ, IR, JO, JP, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Acromicina (MX);",
"     </li>",
"     <li>",
"      Ambotetra (MX);",
"     </li>",
"     <li>",
"      Ambramicina (CO, IT);",
"     </li>",
"     <li>",
"      Apocyclin (FI);",
"     </li>",
"     <li>",
"      Beatacycline (SG);",
"     </li>",
"     <li>",
"      Biotine (SG);",
"     </li>",
"     <li>",
"      Bocycline (TW);",
"     </li>",
"     <li>",
"      Bristaciclina (ES);",
"     </li>",
"     <li>",
"      Cadicycline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ciclobiotico (PT);",
"     </li>",
"     <li>",
"      Ciclotetryl (AR);",
"     </li>",
"     <li>",
"      Clincor (VE);",
"     </li>",
"     <li>",
"      Conmycin (ID);",
"     </li>",
"     <li>",
"      Cyclabid (ZA);",
"     </li>",
"     <li>",
"      Dhatracin (SG);",
"     </li>",
"     <li>",
"      Dicyclin Forte (IN);",
"     </li>",
"     <li>",
"      Erifor (MX);",
"     </li>",
"     <li>",
"      Florocycline (FR);",
"     </li>",
"     <li>",
"      Hexacycline (FR);",
"     </li>",
"     <li>",
"      Hostacyclin (AT, GR);",
"     </li>",
"     <li>",
"      Hostacycline (IN, PH, ZA);",
"     </li>",
"     <li>",
"      Hostacycline-P (ZA);",
"     </li>",
"     <li>",
"      Hydromycin (TH);",
"     </li>",
"     <li>",
"      Ibicyn (TW);",
"     </li>",
"     <li>",
"      Imex (BG, DE, EE, KP);",
"     </li>",
"     <li>",
"      Infex (BR);",
"     </li>",
"     <li>",
"      Latycin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lenocin (TH);",
"     </li>",
"     <li>",
"      Medocycline (HK);",
"     </li>",
"     <li>",
"      Metrocycline (PH);",
"     </li>",
"     <li>",
"      Monocycline (PH);",
"     </li>",
"     <li>",
"      Optycin (AU);",
"     </li>",
"     <li>",
"      Oricyclin (FI);",
"     </li>",
"     <li>",
"      Panmycin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pantocycline (TH);",
"     </li>",
"     <li>",
"      Quemiciclina-S (PE);",
"     </li>",
"     <li>",
"      Quimocyclar (MX);",
"     </li>",
"     <li>",
"      Recycline (IL);",
"     </li>",
"     <li>",
"      Resteclin (IN);",
"     </li>",
"     <li>",
"      Rimatet (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Servitet (MY);",
"     </li>",
"     <li>",
"      Steclin V (ZA);",
"     </li>",
"     <li>",
"      Subamycin (IN);",
"     </li>",
"     <li>",
"      Tc (PL);",
"     </li>",
"     <li>",
"      Tefilin (DE);",
"     </li>",
"     <li>",
"      Tetrabiotico (EC);",
"     </li>",
"     <li>",
"      Tetracyclinum (PL);",
"     </li>",
"     <li>",
"      Tetramig (FR);",
"     </li>",
"     <li>",
"      Tetrana (TH);",
"     </li>",
"     <li>",
"      Tetrarco (NL);",
"     </li>",
"     <li>",
"      Tetraseptin (CH);",
"     </li>",
"     <li>",
"      Tetrasuiss (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Tetrecu (EC);",
"     </li>",
"     <li>",
"      Tetrex (AE, AU, BH, CY, EG, IQ, IR, JO, JP, KW, LB, LY, MX, OM, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Tevacycline (IL);",
"     </li>",
"     <li>",
"      Topicycline (GB);",
"     </li>",
"     <li>",
"      Trinotrex (BR);",
"     </li>",
"     <li>",
"      Ttmycin (TW);",
"     </li>",
"     <li>",
"      Wintel (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F226271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F226290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Small amount appears in bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Good only with inflammation (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Inflamed meninges: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 8-11 hours; End-stage renal disease: 57-108 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% as unchanged drug); feces (as active form)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Drugs, &ldquo;Requiem for Tetracyclines,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1975, 55(1):142-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/122864/pubmed\" id=\"122864\" target=\"_blank\">",
"        122864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coronado BE, Opal SM, and Yoburn DC, &ldquo;Antibiotic-Induced D-Lactic Acidosis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(11):839-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/7741368/pubmed\" id=\"7741368\" target=\"_blank\">",
"        7741368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuddihy J, &ldquo;Case Report of Benign Intra-cranial Hypertension Secondary to Tetracycline,&rdquo;",
"      <i>",
"       Ir Med J",
"      </i>",
"      , 1994, 87(3):90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/8056550/pubmed\" id=\"8056550\" target=\"_blank\">",
"        8056550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox SA, Berenyi MR, and Straus B, &ldquo;Tetracycline Toxicity Presenting as a Multisystem Disease,&rdquo;",
"      <i>",
"       Mt Sinai J Med",
"      </i>",
"      , 1976, 43(2):129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/130551/pubmed\" id=\"130551\" target=\"_blank\">",
"        130551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner K, Cox T, and Digre KB, &ldquo;Idiopathic Intracranial Hypertension Associated With Tetracycline Use in Fraternal Twins: Case Reports and Review,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1995, 45(1):6-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/7824136/pubmed\" id=\"7824136\" target=\"_blank\">",
"        7824136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon JM and Walker CB, &ldquo;Current Status of Systemic Antibiotic Usage in Destructive Periodontal Disease,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 1993, 64(8 Suppl):760-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/8410616/pubmed\" id=\"8410616\" target=\"_blank\">",
"        8410616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee AG, &ldquo;Pseudotumor Cerebri After Treatment With Tetracycline and Isotretinoin for Acne,&rdquo;",
"      <i>",
"       Cutis",
"      </i>",
"      , 1995, 55(3):165-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/7634848/pubmed\" id=\"7634848\" target=\"_blank\">",
"        7634848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maroon JC and Mealy J Jr, &ldquo;Benign Intracranial Hypertension. Sequel to Tetracycline Therapy in a Child,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1979, 216(9):1479-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/5108523/pubmed\" id=\"5108523\" target=\"_blank\">",
"        5108523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matsuda S, &ldquo;Transfer of Antibiotics Into Maternal Milk,&rdquo;",
"      <i>",
"       Biol Res Pregnancy Perinatol",
"      </i>",
"      , 1984, 5(2):57-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/6743732/pubmed\" id=\"6743732\" target=\"_blank\">",
"        6743732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitrano JA, Spooner LM, and Belliveau P, \"Excretion of Antimicrobials Used to Treat Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections During Lactation: Safety in Breastfeeding Infants,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(9):1103-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/19698015/pubmed\" id=\"19698015\" target=\"_blank\">",
"        19698015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mylonas I, \"Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,\"",
"      <i>",
"       Arch Gynecol Obstet",
"      </i>",
"      , 2011, 283(1):7-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/20814687/pubmed\" id=\"20814687\" target=\"_blank\">",
"        20814687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rams TE and Slots J, &ldquo;Antibiotics in Periodontal Therapy: An Update,&rdquo;",
"      <i>",
"       Compendium",
"      </i>",
"      , 1992, 13(12):1130, 1132, 1134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/1298559/pubmed\" id=\"1298559\" target=\"_blank\">",
"        1298559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sargent E, &ldquo;Tetracycline for Seal Finger,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1980, 244(5):437.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seymour RA and Heasman PA, &ldquo;Pharmacological Control of Periodontal Disease. II. Antimicrobial Agents,&rdquo;",
"      <i>",
"       J Dent",
"      </i>",
"      , 1995, 23(1):5-14",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/7876417/pubmed\" id=\"7876417\" target=\"_blank\">",
"        7876417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seymour RA and Heasman PA, &ldquo;Tetracyclines in the Management of Periodontal Diseases. A Review,&rdquo;",
"      <i>",
"       J Clin Periodontol",
"      </i>",
"      , 1995, 22(1):22-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/7706536/pubmed\" id=\"7706536\" target=\"_blank\">",
"        7706536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/1749296/pubmed\" id=\"1749296\" target=\"_blank\">",
"        1749296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walters BN and Gubbay SS, &ldquo;Tetracycline and Benign Intracranial Hypertension: Report of Five Cases,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1981, 282(6257):19-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandstrat TL and Phillips J, &ldquo;Pseudotumor Cerebri Responsive to Acetazolamide,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):318.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whalley PJ, Adams RH, and Combes B, &ldquo;Tetracycline Toxicity in Pregnancy. Liver and Pancreatic Dysfunction,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1964, 189:357-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/14160508 /pubmed\" id=\"14160508 \" target=\"_blank\">",
"        14160508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whalley PJ, Martin FG, Adams RH, et al, &ldquo;Disposition of  Tetracycline By Pregnant Women With Acute Pyelonephritis,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1970, 36(6):821-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/5487732/pubmed\" id=\"5487732\" target=\"_blank\">",
"        5487732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/49/2840/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9986 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-743D36F484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2840=[""].join("\n");
var outline_f2_49_2840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226309\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226339\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226313\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226328\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226314\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226315\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226316\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226268\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226288\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226287\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12810265\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226337\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226291\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226272\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226334\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226277\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226303\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226280\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226294\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226320\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226295\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626655\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226293\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226282\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226296\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226271\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226290\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/16/7429?source=related_link\">",
"      Tetracycline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=related_link\">",
"      Tetracycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_49_2841="Spontaneous abortion: Management";
var content_f2_49_2841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous abortion: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Haya M Al-Fozan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2841/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/49/2841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous abortion, also known as miscarriage, refers to a pregnancy that ends spontaneously before the fetus has reached a viable gestational age. The management of different types of spontaneous abortion will be discussed here. Other aspects of spontaneous abortion, including the clinical manifestations and diagnosis of the different types of abortion, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THREATENED ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with threatened abortion have traditionally been managed expectantly until their symptoms resolve, a definitive diagnosis of nonviable pregnancy can be made, or there is progression to an inevitable, incomplete, or complete abortion.",
"   </p>",
"   <p>",
"    The use of progestins to reduce the risk of miscarriage among women with threatened abortion is controversial. A meta-analysis that included four randomized trials with a total of 421 women found that the rate of spontaneous abortion was statistically significantly lower with progestin treatment compared with placebo or no treatment (14 versus 26 percent; relative risk 0.53; 95% CI 0.35 to 0.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/1\">",
"     1",
"    </a>",
"    ]. Progestins were administered either orally or vaginally, and subgroup analysis found a significant decrease in the rate of abortion only for oral progestins; the analysis of vaginal progestins lacked sufficient statistical power to detect a difference. There was no significant increase in congenital anomalies or pregnancy-induced hypertension in the progestin group. However, the meta-analysis was limited by the small number of participants and events and poor methodological quality of studies. Many miscarriages are caused by genetic abnormalities in the conceptus. It is unlikely that progestins could prevent a miscarriage of this etiology. The data are insufficient to make a recommendation for or against progestins for women with threatened abortion.",
"   </p>",
"   <p>",
"    Bed rest is commonly recommended, but randomized trials have not found that bed rest at home or in the hospital is beneficial in preventing fetal loss in women with threatened spontaneous abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/2\">",
"     2",
"    </a>",
"    ]. Abstinence from sexual intercourse is also typically advised, although there are no data to support this.",
"   </p>",
"   <p>",
"    There are no high quality data that support use of human chorionic gonadotropin, uterine muscle relaxants (eg, tocolytics, beta-agonists), or vitamin supplementation for preventing pregnancy loss in women with threatened abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEPTIC ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected septic abortion with retained products of conception should be managed by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stabilizing the patient",
"     </li>",
"     <li>",
"      Obtaining blood and endometrial cultures",
"     </li>",
"     <li>",
"      Promptly administering parenteral broad spectrum antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      900 mg every eight hours and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      2 g every four hours; or ampicillin and gentamicin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      500 mg every eight hours; or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 mg daily and metronidazole; or single agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      3.1 g every four hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      4.5 g every six hours, or imipenem 500 mg every six hours).",
"      <br/>",
"      <br/>",
"      Intravenous antibiotics are administered until the patient has improved and been afebrile for 48 hours, then are typically followed by oral antibiotics to complete a 10- to 14-day course. The need to complete a full course with oral antibiotics after clinical improvement has been questioned, based upon data from a randomized trial that found no difference in women who received only a short course of intravenous therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/6\">",
"       6",
"      </a>",
"      ]. This approach requires further evaluation.",
"     </li>",
"     <li>",
"      Surgically evacuating the uterine contents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evacuation of the uterus should begin",
"    <strong>",
"     promptly",
"    </strong>",
"    after initiating antibiotics and stabilizing the patient in cases of suspected septic abortion or retained products of conception as delay in evacuation may be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Suction curettage is less traumatic than sharp curettage. Indications for surgery and possible hysterectomy include failure to respond to uterine evacuation and antibiotics, pelvic abscess, and clostridial necrotizing myonecrosis (gas gangrene). A discolored, woody appearance of the uterus and adnexa, suspected clostridial sepsis, crepitation of the pelvic tissue, and radiographic evidence of air within the uterine wall are indications for total hysterectomy and adnexectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/7\">",
"     7",
"    </a>",
"    ]. Surgery, if indicated, may be performed by laparoscopy.",
"   </p>",
"   <p>",
"    On the other hand, mild endometritis (low grade fever, mild uterine tenderness, empty uterus on ultrasound examination) after a complete spontaneous abortion can be managed with oral broad spectrum antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLETE ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue that is passed should be examined to confirm that it is (or is not) the product of conception. Fetal membranes are readily identifiable and confirm passage of at least part of an intrauterine pregnancy. An embryo may or may not be identified. Passage of an intact gestational sac or contraction of the uterus with scant uterine bleeding and diminishing uterine cramps suggests that a complete abortion has occurred.",
"   </p>",
"   <p>",
"    Placental villi can be difficult to distinguish from organized clot. One method is to rinse with water and then float the tissue in a dish of water, preferably with a good light source underneath. Villi have a frond-like appearance, which has been described as similar to seaweed floating in the ocean (",
"    <a class=\"graphic graphic_picture graphicRef78715 graphicRef61424 \" href=\"UTD.htm?39/8/40068\">",
"     picture 1A-B",
"    </a>",
"    ). Ultrasound examination may be useful for confirming the absence of significant amounts of retained intrauterine tissue, but there are no universally defined criteria for an empty uterus.",
"   </p>",
"   <p>",
"    A complete abortion theoretically should not require therapy, but complete abortions generally cannot be reliably distinguished from incomplete abortions either clinically or ultrasonographically. As a result, some providers perform suction curettage in all of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/9\">",
"     9",
"    </a>",
"    ]. Due to a possible risk of intrauterine adhesions, we do not advocate this approach. In addition, treatment of intrauterine adhesions is not always followed by a pregnancy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical management of complete abortion is not based upon data from comparative trials. It seems clear that surgery is necessary for women with excessive bleeding, unstable vital signs, or obvious signs of infection. Whether the uterus should be evacuated in uncomplicated cases needs to be determined by studies that compare various treatment approaches and consider the type of miscarriage (incomplete or complete), the gestational age, and the clinical status and preferences of the mother. In our experience, if the ultrasound shows an empty uterus and the bleeding is minimal, no further action is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INCOMPLETE, INEVITABLE, AND MISSED ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an incomplete, inevitable, or missed abortion documented by ultrasound examination can be managed surgically, medically, or expectantly. Systematic reviews of randomized clinical trials of surgical, medical, and expectant management of women with first trimester missed or incomplete abortion generally concluded that all of the therapies were effective, but complete evacuation within 48 hours was more likely with surgical than medical management and more likely with medical than expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These analyses were limited by missing data, different approaches to medical and expectant management, and nonstandardized outcomes. Major complications were infrequent for all of the methods, and patient satisfaction could not be assessed.",
"   </p>",
"   <p>",
"    Subsequent to these systematic reviews, a randomized trial (MIST) comparing surgical, medical, and expectant management of failed pregnancy in 1200 women reported that the incidence of infection was 2 to 3 percent for all three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/13\">",
"     13",
"    </a>",
"    ]; thus, the risk of infection is not an important variable in choosing the therapeutic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conventional treatment of first or early second trimester failed pregnancy is dilatation and curettage (D&amp;C) or dilatation and evacuation (D&amp;E) to prevent potential hemorrhagic and infectious complications from the retained products of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/14\">",
"     14",
"    </a>",
"    ]. This procedure carries anesthesia risks and complications such as uterine perforation, intrauterine adhesions, cervical trauma, and infection, which might lead to subsequent infertility or ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/15\">",
"     15",
"    </a>",
"    ]. The risks, however, are small and uterine evacuation can be performed safely and effectively as an office procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical management is appropriate for women who do not want to wait for spontaneous or medically induced evacuation of the uterus (see below) and those with heavy bleeding or intrauterine sepsis in whom delaying therapy could be harmful. Suction curettage is preferable to sharp curettage, which is associated with greater morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/9,17,18\">",
"     9,17,18",
"    </a>",
"    ]. A description of technique is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"     \"Surgical termination of pregnancy: First trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally for two doses 12 hours apart on the day of the surgical procedure) to reduce the risk of postabortal sepsis. This recommendation is based on a meta-analysis that found women given periabortal antibiotics had a 42 percent lower risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/19\">",
"     19",
"    </a>",
"    ]. These trials involved women undergoing induced abortion, but it is likely similar benefits would be observed for women undergoing surgical evacuation of a failed pregnancy. However, the only randomized trial that evaluated antibiotic prophylaxis before curettage for incomplete abortion did not observe a significant decrease in febrile morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of effective medical therapies for inducing abortion has created new options for women who want to avoid surgery and in areas where surgical intervention is not practical.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    (a prostaglandin E1 analog) is the most commonly used such agent. Its safety and effectiveness have been established by multiple randomized and controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The advantages of misoprostol over other drugs (including prostaglandin E2) are its low cost [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/23\">",
"     23",
"    </a>",
"    ], low incidence of side effects when given intravaginally, stability at room temperature, and ready availability. The risk of a major complication is rare.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for medical management of pregnancy failure in the first trimester was illustrated in a large, well-designed trial in which 652 women with missed, incomplete, or inevitable abortion were randomly assigned 3:1 to receive 800 mcg misoprostol intravaginally or undergo vacuum aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/24\">",
"     24",
"    </a>",
"    ]. Misoprostol was repeated two days later (day 3) if expulsion was incomplete, as diagnosed by sonographic examination; vacuum aspiration was performed on day 8 if expulsion was still incomplete.",
"   </p>",
"   <p>",
"    In medically managed patients, complete expulsion occurred in 71 percent by day three and 84 percent by day eight. Pregnancy duration did not affect the rate of successful expulsion, but successful expulsion was lower with missed abortion compared with incomplete or inevitable abortion (81 versus 93 percent). Both medical and surgical therapies were safe, effective, and acceptable to patients.",
"   </p>",
"   <p>",
"    The efficacy of medical treatment with prostaglandins depends upon both the dose and route of administration, but there is no consensus on the optimal choice for either. A single oral dose of 400 mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    resulted in a low rate (13 percent) of expulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/25\">",
"     25",
"    </a>",
"    ], whereas the same dose given multiple times resulted in an expulsion rate of 50 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The expulsion rate was even higher with a dose of 600 to 800 mcg given vaginally (70 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/15,21,24,29-34\">",
"     15,21,24,29-34",
"    </a>",
"    ]. This may be due to the local effect of misoprostol on the uterine cervix, the high drug concentration achieved in uterine tissue, and the increased bioavailability with vaginal administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Buccal administration appears to be as effective as vaginal administration, but is associated with more side effects, probably related to differences in pharmacokinetics for the two routes of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/22\">",
"     22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A well-designed randomized trial noted that women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    experienced significantly longer duration of bleeding and greater fall in hemoglobin than those who underwent curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/37\">",
"     37",
"    </a>",
"    ]. Although other randomized trials have reported that medical and surgical curettage result in a similar amount of blood loss, many of these trials did not clearly define bleeding outcome or collect data prospectively.",
"   </p>",
"   <p>",
"    The optimum dose and route and frequency of administration have not been established. In a consensus paper by an expert group convened by the World Health Organization in 2007, two different regimens of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    were proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For missed abortion &ndash; 800 mcg per vaginam OR 600 mcg sublingually (each of these is a single dose)",
"     </li>",
"     <li>",
"      For incomplete abortion &ndash; 600 mcg orally (single dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our preference is to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    400 mcg per vaginam every four hours for four doses to take advantage of the increased effectiveness of the vaginal route while minimizing the risk of side effects, which are dose and route dependent. The expulsion rate is 70 to 90 percent within 24 hours; thus, some women will still require surgical evacuation. However, the immediate, short-term, and medium-term medical complications associated with misoprostol use are significantly lower than with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combination of a progesterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (400 mcg orally) has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/39\">",
"     39",
"    </a>",
"    ]. Due to low serum progesterone levels in women with abnormal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/40\">",
"     40",
"    </a>",
"    ], the value of adding a progesterone antagonist is questionable and expensive. This hypothesis was supported by a prospective cross-over trial and a randomized controlled trial, both of which reported that misoprostol alone or a combination of misoprostol and mifepristone had similar success rates in treatment of early pregnancy failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=see_link\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are treated medically are instructed to go to the emergency department if they develop excessive bleeding. Tissues that are passed vaginally should be placed in a container and brought to the hospital for analysis.",
"   </p>",
"   <p>",
"    The long-term conception rate and pregnancy outcome are similar for women who undergo medical or surgical evacuation for early pregnancy failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is not used in management of spontaneous abortion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second trimester abortion is associated with higher rates of complications than first trimester abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/44\">",
"     44",
"    </a>",
"    ]. For example, up to 10 percent of women undergoing induced medical abortion will require hospitalization for medical, social, or geographical reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/45\">",
"     45",
"    </a>",
"    ]. There has been no clear evidence of superiority of one mid-trimester abortion method over another in terms of safety and acceptability. In most practices, second trimester abortion over 16 weeks is completed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in the hospital setting and surgical evacuation is reserved for retained products of conception. However, clinicians proficient in mid-trimester surgical pregnancy termination may offer patients surgical evacuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management (EM) is an alternative for women with early pregnancy failure at less than 13 weeks of gestation who have stable vital signs and no evidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/11,46-51\">",
"     11,46-51",
"    </a>",
"    ]. A systematic review including five randomized trials concluded that compared to surgical evacuation, EM was associated with a higher risk of incomplete miscarriage, need for unplanned surgical emptying of the uterus, and bleeding, but was not an unreasonable approach if the woman preferred nonintervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/11\">",
"     11",
"    </a>",
"    ]. Randomized trials comparing medical management to EM have reported similar rates of successful evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Discrepancies in success rates relate to the duration of EM, the medical treatment regimen, the negative value placed on various maternal morbidities, and whether the subjects had asymptomatic early pregnancy failure or incomplete miscarriage.",
"   </p>",
"   <p>",
"    The majority of expulsions occur in the first two weeks after diagnosis; however, some women may require prolonged follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Incomplete miscarriage is more likely to proceed to expulsion within two weeks than a missed abortion. An interval of three to four weeks between diagnosis of nonviable pregnancy and expulsion is not unusual. Most women are willing to wait when appropriately counseled [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/55\">",
"     55",
"    </a>",
"    ] and prepared for what to expect [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If spontaneous expulsion does not occur, medical or surgical treatment can be administered. Following spontaneous or medically induced expulsion, some providers perform an ultrasound examination routinely to evaluate the uterine cavity, others perform this examination selectively in patients whose clinical examination is suggestive of retained products of conception.",
"   </p>",
"   <p>",
"    There are no universally defined criteria for an empty uterus. One option is to proceed with surgical evacuation if retained tissue with a diameter of more than 15 mm is found [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/46\">",
"     46",
"    </a>",
"    ]. Others use a homogeneous intrauterine dimension less than 11 cm2 in combined transverse and sagittal planes to define an empty uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Using the latter criteria, 5 percent of women had complications and 40 percent required another intervention (medical or surgical). However, there is also evidence that increased endometrial thickness is not predictive of morbidity in asymptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. If the ultrasound reveals retained tissue and the patient is asymptomatic or having only minimal bleeding, we offer the patient surgical evacuation of the uterus or expectant management for another two weeks.",
"   </p>",
"   <p>",
"    The largest series evaluating the outcome of EM followed 1096 consecutive patients with suspected first trimester miscarriage for up to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/61\">",
"     61",
"    </a>",
"    ]. Each pregnancy was diagnosed by transvaginal ultrasound as a complete (n = 408), incomplete, missed, or anembryonic miscarriage. Women who did not have a complete miscarriage (n = 686) were offered EM or surgical evacuation. Successful spontaneous abortion occurred in 81 percent of all expectantly managed patients, 91 percent of those with incomplete miscarriages, 76 percent of those with missed abortions, and 66 percent of those with anembryonic pregnancies. Complications, such as infection and excessive pain or bleeding, occurred in 1 percent of expectantly and 2 percent of surgically managed patients.",
"   </p>",
"   <p>",
"    Thus, EM for one month appears to be a safe and effective alternative to immediate surgical evacuation. In addition, sonographic classification of the miscarriage at presentation appears predictive of successful outcome without surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cost analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the MIST trial, 1200 women with a diagnosis of incomplete or missed miscarriage at less than 13 weeks of gestation were randomly assigned to expectant, medical, or surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/62\">",
"     62",
"    </a>",
"    ]. The net societal cost per woman was estimated at 1086, 1410, and 1585 pounds, respectively. However, cost analyses depend on several factors, including the scope of costs considered in the analysis and the community in which the costs are incurred [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTABORTION CARE AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are advised to maintain pelvic rest (ie, nothing per vagina) until two weeks after evacuation or passage of the products of conception, at which time coitus and use of tampons may be resumed. It is customary to advise that pregnancy be deferred for two to three months, although several studies have shown no greater risk of adverse outcome with a shorter interpregnancy interval [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. Any type of contraception, including placement of intrauterine contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/71\">",
"     71",
"    </a>",
"    ], may be started immediately after the abortion has been completed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Light vaginal bleeding can persist for a couple of weeks after the abortion. Patients should call their provider if heavy bleeding, fever, or abdominal pain develops. Menses typically resume within six weeks; if normal menses do not resume, then the presence of a new pregnancy or, rarely, gestational trophoblastic disease should be considered. Although rare, intrauterine adhesions (also known as Asherman's syndrome) could occur after surgical evacuation of the uterus. In the severe form, menses do not resume or are scanty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4112254\">",
"    <span class=\"h2\">",
"     Alloimmunization prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are Rh(D)-negative and unsensitized should receive Rh(D)-immune globulin following surgical evacuation or upon diagnosis if medical management or EM is planned. A dose of 50 mcg is effective through the 12th week of gestation due to the small volume of red cells in the fetoplacental circulation (mean red cell volume at 8 and 12 weeks is 0.33 mL and 1.5 mL, respectively), although there is no harm in giving the standard 300 microgram dose, which is more readily available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4112405\">",
"    <span class=\"h2\">",
"     Resolution of positive hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum hCG values typically return to normal within two to four weeks after a completed abortion (",
"    <a class=\"graphic graphic_table graphicRef53542 \" href=\"UTD.htm?24/55/25468\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. Follow-up hCG testing is unnecessary if normal menstrual cycles resume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4112397\">",
"    <span class=\"h2\">",
"     Grief counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grief counseling is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. It is important to acknowledge the patient's (and partner's) grief and provide empathy and support. Risk factors for abnormal grief following a miscarriage include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of or current depression, anxiety, or other psychiatric disorder",
"     </li>",
"     <li>",
"      Neurotic personality traits",
"     </li>",
"     <li>",
"      Lack of social support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the etiology of the loss is known or suspected, the couple should be informed and counseled about recurrence risks. If reversible risk factors for spontaneous abortion are present, these can be addressed, as appropriate, in a nonjudgmental way. When an etiology cannot be determined, it is important to reassure the woman that there is no evidence that something she might have done (eg, sexual intercourse, heavy lifting, bumping her abdomen, stress) caused the miscarriage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FUTURE REPRODUCTIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of miscarriage in future pregnancy is approximately 20 percent after one miscarriage, 28 percent after two miscarriages, and 43 percent after three or more miscarriages [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There also appears to be an increased risk of preterm delivery in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The risk increases with increasing number of miscarriages (OR 1.05-1.66 after one miscarriage, OR 1.95-2.88 after more than one miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/82\">",
"     82",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Second trimester pregnancy loss is significantly associated with recurrent second-trimester loss and future spontaneous preterm birth. After a second trimester pregnancy loss, one study reported 39 percent of women had a preterm delivery in their next pregnancy, 5 percent had a stillbirth, and 6 percent had a neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/83\">",
"     83",
"    </a>",
"    ]. In another study of 30 women with second trimester loss, the frequency of recurrent second trimester loss was 27 percent and the frequency of subsequent preterm birth was 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2841/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       \"Patient information: Miscarriage (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=see_link\">",
"       \"Patient information: Threatened miscarriage (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       \"Patient information: Miscarriage (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with threatened spontaneous abortion, some data support use of progestins to prevent miscarriage. The data are insufficient to make a recommendation. Other interventions, including bed rest, abstaining from sexual intercourse, treatment with human chorionic gonadotropin, muscle relaxants or vitamin supplementation have not been found to be beneficial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Threatened abortion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend patients with septic abortion be stabilized, administered broad spectrum antibiotics, and undergo surgical evacuation of uterine contents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Septic abortion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High quality evidence from randomized trials has shown that surgical, medical, and expectant management of incomplete, inevitable, or missed abortion all result in evacuation of products of conception in most patients. Surgical evacuation is a more successful primary therapy than medical or expectant management; the effectiveness of the latter two approaches depends upon the duration of time allowed before secondary surgical intervention and upon the type of nonviable pregnancy. Postabortal infection rates are similar for all three approaches, and the frequency of other complications is low. For these reasons, the choice of treatment should be based upon patient preferences. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Incomplete, inevitable, and missed abortion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgical therapy for women who are unstable because of bleeding or infection and for women who want immediate, definitive treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      for women who want to avoid a surgical procedure, but do not want to wait for spontaneous passage of products of conception to occur (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Seventy to 90 percent will have a successful outcome with medical management alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend expectant management for stable women who do not want any medical or surgical intervention, and are willing to wait days to weeks for expulsion to occur (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Bleeding and cramping may be prolonged and surgical evacuation may still be required, but as many as 80 percent of women will have a successful outcome with expectant management alone. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Expectant management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/1\">",
"      Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011; :CD005943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/2\">",
"      Aleman A, Althabe F, Beliz&aacute;n J, Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev 2005; :CD003576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/3\">",
"      Devaseelan P, Fogarty PP, Regan L. Human chorionic gonadotrophin for threatened miscarriage. Cochrane Database Syst Rev 2010; :CD007422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/4\">",
"      Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database Syst Rev 2005; :CD002857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/5\">",
"      Rumbold A, Middleton P, Pan N, Crowther CA. Vitamin supplementation for preventing miscarriage. Cochrane Database Syst Rev 2011; :CD004073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/6\">",
"      Savaris RF, de Moraes GS, Cristovam RA, Braun RD. Are antibiotics necessary after 48 hours of improvement in infected/septic abortions? A randomized controlled trial followed by a cohort study. Am J Obstet Gynecol 2011; 204:301.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/7\">",
"      Stubblefield PG, Grimes DA. Septic abortion. N Engl J Med 1994; 331:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/8\">",
"      Finkielman JD, De Feo FD, Heller PG, Afessa B. The clinical course of patients with septic abortion admitted to an intensive care unit. Intensive Care Med 2004; 30:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/9\">",
"      Forna F, G&uuml;lmezoglu AM. Surgical procedures to evacuate incomplete abortion. Cochrane Database Syst Rev 2001; :CD001993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/10\">",
"      Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP. Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol 2005; 105:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/11\">",
"      Nanda K, Peloggia A, Grimes D, et al. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst Rev 2006; :CD003518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/12\">",
"      Neilson JP, Gyte GM, Hickey M, et al. Medical treatments for incomplete miscarriage (less than 24 weeks). Cochrane Database Syst Rev 2010; :CD007223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/13\">",
"      Trinder J, Brocklehurst P, Porter R, et al. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 2006; 332:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/14\">",
"      Hemminki E. Treatment of miscarriage: current practice and rationale. Obstet Gynecol 1998; 91:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/15\">",
"      Demetroulis C, Saridogan E, Kunde D, Naftalin AA. A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. Hum Reprod 2001; 16:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/16\">",
"      Harris LH, Dalton VK, Johnson TR. Surgical management of early pregnancy failure: history, politics, and safe, cost-effective care. Am J Obstet Gynecol 2007; 196:445.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/17\">",
"      Grimes DA. Unsafe abortion: the silent scourge. Br Med Bull 2003; 67:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/18\">",
"      Tun&ccedil;alp O, G&uuml;lmezoglu AM, Souza JP. Surgical procedures for evacuating incomplete miscarriage. Cochrane Database Syst Rev 2010; :CD001993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/19\">",
"      Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996; 87:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/20\">",
"      Prieto JA, Eriksen NL, Blanco JD. A randomized trial of prophylactic doxycycline for curettage in incomplete abortion. Obstet Gynecol 1995; 85:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/21\">",
"      Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev 2006; :CD002253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/22\">",
"      Blum J, Winikoff B, Gemzell-Danielsson K, et al. Treatment of incomplete abortion and miscarriage with misoprostol. Int J Gynaecol Obstet 2007; 99 Suppl 2:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/23\">",
"      Graziosi GC, van der Steeg JW, Reuwer PH, et al. Economic evaluation of misoprostol in the treatment of early pregnancy failure compared to curettage after an expectant management. Hum Reprod 2005; 20:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/24\">",
"      Zhang J, Gilles JM, Barnhart K, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 2005; 353:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/25\">",
"      de Jonge ET, Makin JD, Manefeldt E, et al. Randomised clinical trial of medical evacuation and surgical curettage for incomplete miscarriage. BMJ 1995; 311:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/26\">",
"      Chung T, Leung P, Cheung LP, et al. A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion. Acta Obstet Gynecol Scand 1997; 76:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/27\">",
"      Chung TK, Cheung LP, Lau WC, et al. Spontaneous abortion: a medical approach to management. Aust N Z J Obstet Gynaecol 1994; 34:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/28\">",
"      Chung TK, Lee DT, Cheung LP, et al. Spontaneous abortion: a randomized, controlled trial comparing surgical evacuation with conservative management using misoprostol. Fertil Steril 1999; 71:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/29\">",
"      Muffley PE, Stitely ML, Gherman RB. Early intrauterine pregnancy failure: a randomized trial of medical versus surgical treatment. Am J Obstet Gynecol 2002; 187:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/30\">",
"      el-Refaey H, Rajasekar D, Abdalla M, et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995; 332:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/31\">",
"      Creinin MD, Moyer R, Guido R. Misoprostol for medical evacuation of early pregnancy failure. Obstet Gynecol 1997; 89:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/32\">",
"      Zal&aacute;nyi S. Vaginal misoprostol alone is effective in the treatment of missed abortion. Br J Obstet Gynaecol 1998; 105:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/33\">",
"      Autry A, Jacobson G, Sandhu R, Isbill K. Medical management of non-viable early first trimester pregnancy. Int J Gynaecol Obstet 1999; 67:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/34\">",
"      Bagratee JS, Khullar V, Regan L, et al. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod 2004; 19:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/35\">",
"      Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/36\">",
"      Khan RU, El-Refaey H, Sharma S, et al. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol 2004; 103:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/37\">",
"      Davis AR, Hendlish SK, Westhoff C, et al. Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynecol 2007; 196:31.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/38\">",
"      Weeks A, Fa&uacute;ndes A. Misoprostol in obstetrics and gynecology. Int J Gynaecol Obstet 2007; 99 Suppl 2:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/39\">",
"      Kollitz KM, Meyn LA, Lohr PA, Creinin MD. Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol 2011; 204:386.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/40\">",
"      Ledger WL, Sweeting VM, Chatterjee S. Rapid diagnosis of early ectopic pregnancy in an emergency gynaecology service--are measurements of progesterone, intact and free beta human chorionic gonadotrophin helpful? Hum Reprod 1994; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/41\">",
"      Gr&oslash;nlund A, Gr&oslash;nlund L, Clevin L, et al. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002; 81:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/42\">",
"      Stockheim D, Machtinger R, Wiser A, et al. A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril 2006; 86:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/43\">",
"      Tam WH, Tsui MH, Lok IH, et al. Long-term reproductive outcome subsequent to medical versus surgical treatment for miscarriage. Hum Reprod 2005; 20:3355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/44\">",
"      Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters 2008; 16:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/45\">",
"      Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 2007; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/46\">",
"      Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet 1995; 345:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/47\">",
"      Chipchase J, James D. Randomised trial of expectant versus surgical management of spontaneous miscarriage. Br J Obstet Gynaecol 1997; 104:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/48\">",
"      Ankum WM, Wieringa-De Waard M, Bindels PJ. Management of spontaneous miscarriage in the first trimester: an example of putting informed shared decision making into practice. BMJ 2001; 322:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/49\">",
"      Wieringa-de Waard M, Vos J, Bonsel GJ, et al. Management of miscarriage: a randomized controlled trial of expectant management versus surgical evacuation. Hum Reprod 2002; 17:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/50\">",
"      Nielsen S, Hahlin M, Platz-Christensen J. Randomised trial comparing expectant with medical management for first trimester miscarriages. Br J Obstet Gynaecol 1999; 106:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/51\">",
"      Shelley JM, Healy D, Grover S. A randomised trial of surgical, medical and expectant management of first trimester spontaneous miscarriage. Aust N Z J Obstet Gynaecol 2005; 45:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/52\">",
"      Banerjee S, Aslam N, Woelfer B, et al. Expectant management of early pregnancies of unknown location: a prospective evaluation of methods to predict spontaneous resolution of pregnancy. BJOG 2001; 108:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/53\">",
"      Cone C, Greenawald MH, Schaffer R Jr. Management of first-trimester spontaneous abortion. J Fam Pract 1999; 48:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/54\">",
"      Casikar I, Bignardi T, Riemke J, et al. Expectant management of spontaneous first-trimester miscarriage: prospective validation of the '2-week rule'. Ultrasound Obstet Gynecol 2010; 35:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/55\">",
"      Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early pregnancy failure--current management concepts. Obstet Gynecol Surv 2001; 56:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/56\">",
"      Ogden J, Maker C. Expectant or surgical management of miscarriage: a qualitative study. BJOG 2004; 111:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/57\">",
"      Chung TK, Cheung LP, Sahota DS, et al. Evaluation of the accuracy of transvaginal sonography for the assessment of retained products of conception after spontaneous abortion. Gynecol Obstet Invest 1998; 45:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/58\">",
"      Leung SW, Pang MW, Chung TK. Retained products of gestation in miscarriage: an evaluation of transvaginal ultrasound criteria for diagnosing an \"empty uterus\". Am J Obstet Gynecol 2004; 191:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/59\">",
"      Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/60\">",
"      Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/61\">",
"      Luise C, Jermy K, May C, et al. Outcome of expectant management of spontaneous first trimester miscarriage: observational study. BMJ 2002; 324:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/62\">",
"      Petrou S, Trinder J, Brocklehurst P, Smith L. Economic evaluation of alternative management methods of first-trimester miscarriage based on results from the MIST trial. BJOG 2006; 113:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/63\">",
"      Doyle, NM, Jimenez-Flores, DJ, Ramin, SM. Medical versus surgical management of missed abortions: An economic analysis. Obstet Gynecol 2004; 103:6S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/64\">",
"      You JH, Chung TK. Expectant, medical or surgical treatment for spontaneous abortion in first trimester of pregnancy: a cost analysis. Hum Reprod 2005; 20:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/65\">",
"      Rocconi RP, Chiang S, Richter HE, Straughn JM Jr. Management strategies for abnormal early pregnancy: a cost-effectiveness analysis. J Reprod Med 2005; 50:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/66\">",
"      Niinim&auml;ki M, Karinen P, Hartikainen AL, Pouta A. Treating miscarriages: a randomised study of cost-effectiveness in medical or surgical choice. BJOG 2009; 116:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/67\">",
"      Vlaanderen W, Fabriek LM, van Tuyll van Serooskerken C. Abortion risk and pregnancy interval. Acta Obstet Gynecol Scand 1988; 67:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/68\">",
"      Goldstein RR, Croughan MS, Robertson PA. Neonatal outcomes in immediate versus delayed conceptions after spontaneous abortion: a retrospective case series. Am J Obstet Gynecol 2002; 186:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/69\">",
"      Wyss P, Biedermann K, Huch A. Relevance of the miscarriage-new pregnancy interval. J Perinat Med 1994; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/70\">",
"      Rud B, Kl&uuml;nder K. The course of pregnancy following spontaneous abortion. Acta Obstet Gynecol Scand 1985; 64:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/71\">",
"      Grimes D, Schulz K, Stanwood N. Immediate post-abortal insertion of intrauterine devices. Cochrane Database Syst Rev 2000; :CD001777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/72\">",
"      Aral K, G&uuml;rkan Zorlu C, G&ouml;kmen O. Plasma human chorionic gonadotropin levels after induced abortion. Adv Contracept 1996; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/73\">",
"      Steier JA, Bergsj&oslash; P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984; 64:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/74\">",
"      Korhonen J, Alfthan H, Yl&ouml;stalo P, et al. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem 1997; 43:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/75\">",
"      Marrs RP, Kletzky OA, Howard WF, Mishell DR Jr. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol 1979; 135:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/76\">",
"      Barnhart KT, Sammel MD, Rinaudo PF, et al. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined. Obstet Gynecol 2004; 104:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/77\">",
"      Frost M, Condon JT. The psychological sequelae of miscarriage: a critical review of the literature. Aust N Z J Psychiatry 1996; 30:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/78\">",
"      Lee C, Slade P. Miscarriage as a traumatic event: a review of the literature and new implications for intervention. J Psychosom Res 1996; 40:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/79\">",
"      Stratton K, Lloyd L. Hospital-based interventions at and following miscarriage: literature to inform a research-practice initiative. Aust N Z J Obstet Gynaecol 2008; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/80\">",
"      Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/81\">",
"      Buchmayer SM, Spar&eacute;n P, Cnattingius S. Previous pregnancy loss: risks related to severity of preterm delivery. Am J Obstet Gynecol 2004; 191:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/82\">",
"      Swingle HM, Colaizy TT, Zimmerman MB, Morriss FH Jr. Abortion and the risk of subsequent preterm birth: a systematic review with meta-analyses. J Reprod Med 2009; 54:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/83\">",
"      Goldenberg RL, Mayberry SK, Copper RL, et al. Pregnancy outcome following a second-trimester loss. Obstet Gynecol 1993; 81:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2841/abstract/84\">",
"      Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: What is the real risk? Am J Obstet Gynecol 2007; 197:581.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5442 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.22.229.50-9649136F8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2841=[""].join("\n");
var outline_f2_49_2841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THREATENED ABORTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEPTIC ABORTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLETE ABORTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INCOMPLETE, INEVITABLE, AND MISSED ABORTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cost analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTABORTION CARE AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4112254\">",
"      Alloimmunization prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4112405\">",
"      Resolution of positive hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4112397\">",
"      Grief counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FUTURE REPRODUCTIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5442|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2783\" title=\"picture 1A\">",
"      Chorionic villi1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31617\" title=\"picture 1B\">",
"      Chorionic villi2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/55/25468\" title=\"table 1\">",
"      HCG postmiscarriage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=related_link\">",
"      Patient information: Threatened miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_49_2842="Hepatic manifestations of sickle cell disease";
var content_f2_49_2842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic manifestations of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Subhas Banerjee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Michael R DeBaun, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/49/2842/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/49/2842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease (SCD) encompasses a group of hemoglobinopathies characterized by a single amino acid substitution in the &szlig;-globin chain. The most frequently occurring form of SCD is sickle cell anemia (HbSS), followed by HbSC and HbS&szlig;-thalassemia. In the United States, 6 to 10 percent of African-American newborns have sickle cell trait (HbSA), and approximately 0.2 percent have sickle cell anemia (HbSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link\">",
"     \"Introduction to hemoglobin mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The liver can be affected by a number of complications due to the disease itself and its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition to the vascular complications from the sickling process, patients with sickle cell disease have often received multiple transfusions, placing them at risk for viral hepatitis, iron overload, and (combined with the effects of chronic hemolysis) the development of pigment gallstones, all of which may contribute to the development of liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\", section on 'Blood transfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Transfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"sickle cell hepatopathy\" has sometimes been used to reflect the overlapping causes of liver dysfunction in these patients. Sickle cell hepatopathy occurs predominantly in patients with homozygous sickle cell anemia, and to a lesser extent in patients with HbSC disease or HbS&szlig;-thalassemia.",
"   </p>",
"   <p>",
"    This topic will review the hepatic manifestation of SCD. Other issues related to SCD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of liver disease in patients with sickle cell disease has not been well established. The major risk factor for liver disease in patients with sickle cell disease is receiving multiple blood transfusions, which is associated with infection (hepatitis B and C) and excessive iron stores.",
"   </p>",
"   <p>",
"    In one report, 32 of 100 patients had abnormal liver biochemical tests during a five-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"     5",
"    </a>",
"    ]. In an autopsy series, hepatomegaly was noted in 91 percent of 70 patients with sickle cell anemia, sickle cell disease, or HbS&szlig;-thalassemia, suggesting that some form of liver involvement is common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/6\">",
"     6",
"    </a>",
"    ]. In other autopsy series, 16 to 29 percent of patients had cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. However, it is unclear whether cirrhosis was due to the sickle cell anemia itself or to concurrent liver disease acquired as a consequence of multiple transfusions, leading to iron overload and chronic hepatitis B or C infection.",
"   </p>",
"   <p>",
"    Although predominantly affecting blacks, sickle cell disease (SCD) is also present in the white population (particularly in Mediterranean countries), in whom the liver disease appears to be milder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. As an example, one study evaluated the presence of liver biochemical abnormalities in white patients with either homozygous sickle cell anemia (40 patients) or compound heterozygotes with HbSC or HbS&szlig;-thalassemia (102 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/12\">",
"     12",
"    </a>",
"    ]. Only 2 of 142 patients had significant liver biochemical abnormalities, both of whom were positive for HBsAg and HCV antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY AND RADIOLOGIC LIVER TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical and radiologic hepatic abnormalities are common in patients with sickle cell disease (SCD). As noted above, a major risk factor for liver biochemical abnormalities in patients with SCD is infection (hepatis B or C) or excessive iron stores related to multiple blood transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Biochemical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated bilirubin levels, predominantly unconjugated, are universal in patients with SCD due to chronic hemolysis. Total bilirubin concentrations are usually &lt;6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (102.6",
"    <span class=\"nowrap\">",
"     micromoles/L),",
"    </span>",
"    but may double during sickle hepatic crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ]. In one series, 72 of 100 patients with sickle cell anemia had an isolated elevation of bilirubin, with no other clinical or laboratory evidence of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"     5",
"    </a>",
"    ]. Bilirubin levels correlated with lactic dehydrogenase levels, suggesting that variable levels found in patients are related to the degree of hemolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ineffective erythropoiesis rather than to disorders of bilirubin transport or processing. The serum aspartate aminotransferase level (AST) is also raised by hemolysis. Thus, AST levels correlate with lactic dehydrogenase levels and serum alanine aminotransferase (ALT) levels may more accurately reflect hepatocyte injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevation of the serum alkaline phosphatase is common, particularly during pain crises. However, bone alkaline phosphatase is the major enzyme fraction contributing to this rise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/14\">",
"     14",
"    </a>",
"    ]. This is supported by the observation that the serum-5' nucleotidase concentration correlates with the ALT and gamma glutamyl transferase levels, but not with alkaline phosphatase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute elevations of the serum ALT and AST are seen in the setting of vasoocclusive crises leading to hepatic ischemia, whereas chronic liver function test abnormalities are usually due to coexisting hepatic pathology. In a study of 130 patients with sickle cell anemia or sickle cell disease, chronic abnormalities in liver function tests were found in 32 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"     5",
"    </a>",
"    ]. In 30 of these patients, the abnormalities could be explained by coexisting liver pathology, including chronic hepatitis B, common bile duct obstruction, and alcohol use. Only two patients had unexplained abnormalities, neither of whom had been tested for antibodies against hepatitis C. In another series of 121 consecutive patients with sickle cell anemia, 11 (9 percent) had chronically raised ALT levels. Of these, nine patients were positive for HCV antibodies and one for HBsAg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated low protein C and protein S levels in patients with sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. It is unclear whether decreased levels of protein C and S were primarily due to decreased hepatic production, or were a consequence of increased consumption. Low levels of protein C and S may increase the risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hyperammonemia due to zinc deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sickle cell anemia excrete excessive amounts of zinc due to impaired renal tubular handling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], which may lead to zinc deficiency.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    therapy may also increase urinary and fecal losses of zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/22\">",
"     22",
"    </a>",
"    ]. A study of 104 patients with sickle cell disease indicated that 44 percent had low plasma levels of zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/23\">",
"     23",
"    </a>",
"    ]. Zinc is a cofactor for ornithine transcarbamylase, a urea cycle enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, zinc deficiency may be associated with inhibition of the urea cycle and hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/25\">",
"     25",
"    </a>",
"    ]. The hyperammonemia may theoretically contribute to encephalopathy in cirrhotic patients with sickle cell anemia, and can be corrected by administration of zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/26\">",
"     26",
"    </a>",
"    ]. Zinc supplementation may also significantly decrease the number of",
"    <span class=\"nowrap\">",
"     sickle/pain",
"    </span>",
"    crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Thus zinc deficiency should be looked for and corrected.",
"   </p>",
"   <p>",
"    Zinc may also regulate copper absorption from the gastrointestinal tract. Enhanced copper absorption and increased ceruloplasmin levels may be seen with zinc deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/25,29\">",
"     25,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous liver biopsy has been associated with serious complications when performed in individuals with sickle cell disease with acute hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, the risk-benefit ratio of obtaining the liver histology must be strongly considered, particularly in light of how the results will alter management. When it has been obtained, liver histology may reflect changes of concurrent chronic viral hepatitis, cholestasis due to common bile duct stones, and features primarily due to the sickle cell anemia itself. Histologic features due to sickle cell anemia include intrasinusoidal sickling with proximal sinusoidal dilatation, Kupffer cell hyperplasia with erythrophagocytosis, and hemosiderosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/6,8,31-33\">",
"     6,8,31-33",
"    </a>",
"    ]. The following findings were observed in a postmortem series of 70 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/6\">",
"     6",
"    </a>",
"    ]: sinusoidal red blood cell distension (71 percent), Kupffer cell erythrophagocytosis (91 percent), iron deposition (47 percent), focal necrosis (35 percent), portal fibrosis (20 percent), regenerative nodules (20 percent), and cirrhosis (16 percent).",
"   </p>",
"   <p>",
"    Other histologic features may reflect the clinical setting. Mild centrilobular necrosis has been described in patients with sickle hepatic crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ]. Widespread anoxic necrosis was seen in two post mortem biopsies in patients with sickle cell intrahepatic cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13,34\">",
"     13,34",
"    </a>",
"    ]. Other findings that may be seen on liver biopsy include perisinusoidal fibrosis, peliosis hepatis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/35\">",
"     35",
"    </a>",
"    ], and extramedullary erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of intrasinusoidal sickling does not correlate with the serum aminotransferase concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5,33,37\">",
"     5,33,37",
"    </a>",
"    ]. It is possible that some of the sickling observed in liver biopsy specimens results from fixation with formaldehyde, which in one study increased the sickle cell count from a mean of 12 to 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging tests are frequently abnormal in patients with SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Computerized tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized tomography (CT) scanning in patients with homozygous disease usually reveals diffuse hepatomegaly, possibly a reflection of expansion of the hepatic reticuloendothelial system. The spleen is usually small and atrophic and may have dense calcifications, often due to repeated splenic infarction. Double heterozygotes (ie, HbSC and HbS&szlig;-thalassemia) usually have splenomegaly and may have infarcts, splenic rupture from extensive infarction and necrosis, hemorrhage, abscess, and acute splenomegaly due to sequestration. A CT scan of the abdomen may also incidentally reveal basal pulmonary pathology, especially in patients presenting with abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging (MRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the advancement in the use of MRI methods to evaluate liver iron, MRI's reliability, and its non-invasive nature, MRI imaging has become the standard approach for assessing liver iron stores in individuals with SCD who are chronically transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/38\">",
"     38",
"    </a>",
"    ]. Many centers use commercial software to quantify liver iron stores, particularly in such patients. MRI in transfusion dependent patients usually shows decreased signal intensity in the liver and pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/39\">",
"     39",
"    </a>",
"    ] due to iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal ultrasound in individuals with SCD is likely to reveal gallstones and increased echogenicity of the liver and pancreas due to iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH THE SICKLING PROCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As suggested above, liver disease in individuals with SCD can be conceptually divided into disorders caused by the sickling process, and those resulting from complications of the disease or its treatment. However, the distinction between these two categories is not always clear since they often exist concurrently. Furthermore, studies describing liver disease in these patients did not always evaluate for secondary causes of liver disease such as hepatitis C. Thus, the relative contribution of these coexisting conditions to the clinical presentation has not always been clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute pain and jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute presentation with pain and jaundice may be due to a several different causes, which may coexist. These include acute sickle hepatic crisis, sickle cell intrahepatic cholestasis, acute viral hepatitis, cholecystitis, and choledocholithiasis with common bile duct obstruction. The diagnosis can usually be established by the medical history and specific laboratory and radiologic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acute sickle hepatic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatic crisis has been observed in approximately 10 percent of patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13,43,44\">",
"     13,43,44",
"    </a>",
"    ]. Patients usually present with acute right upper quadrant pain, nausea, low grade fever, tender hepatomegaly, and jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13,43,44\">",
"     13,43,44",
"    </a>",
"    ]. The serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations are seldom &gt;300",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (5.001",
"    <span class=\"nowrap\">",
"     microkatal/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13,44\">",
"     13,44",
"    </a>",
"    ], although levels &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (16.67",
"    <span class=\"nowrap\">",
"     microkatal/L)",
"    </span>",
"    have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/31\">",
"     31",
"    </a>",
"    ]. The serum total bilirubin concentration is usually &lt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (256.5",
"    <span class=\"nowrap\">",
"     micromoles/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ]. Liver histology may reveal sickle cell thrombi in the sinusoidal space with engorgement by red blood cells. Other features that have been described include Kupffer cell hypertrophy, mild centrilobular necrosis, and occasional bile stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis is probably related to ischemia caused by sinusoidal obstruction. This hypothesis is supported by the observation that cocaine use by patients with sickle cell anemia can precipitate severe and life-threatening crisis due to synergistic hypoxic injury from cocaine induced vasospasm and from sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive treatment with intravenous hydration and analgesia is usually sufficient. Symptoms and laboratory abnormalities usually resolve within 3 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hepatic sequestration crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SCD may acutely sequester large numbers of red blood cells in the spleen, the pulmonary vasculature, and less commonly the liver, often leading to acute anemia, shock, and death. Patients with hepatic sequestration usually present with right upper quadrant pain, rapidly increasing hepatomegaly, and a falling hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. One report described two patients with hepatic sequestration who initially presented with bone pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/46\">",
"     46",
"    </a>",
"    ]. A rapid fall in the hematocrit paralleled a dramatic increase in the liver size, which returned to baseline after three to four days. Liver biochemical tests did not substantially change. Regression of hepatic size was associated with a rapid increase in hemoglobin from 4.2 to 7.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in one patient, indicating that not all sequestered cells were destroyed, and that some may return to the circulation upon resolution of the crisis and relief of sinusoidal obstruction.",
"   </p>",
"   <p>",
"    Treatment of hepatic sequestration crisis, as with splenic sequestration crisis, involves prompt, aggressive restoration of blood volume and red cell mass, along with attempts at reversing the sickling process, using such methodologies as improved oxygenation (including hyperbaric O2), and transfusion with packed red cells. Exchange transfusion may be necessary, especially if respiratory distress is present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Reverse sequestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case of fatal auto transfusion has been described in which resolution of hepatic and pulmonary sequestration was accompanied by a spontaneous and rapid rise in the hemoglobin, from 5.1 to 12.3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    over 24 hours, presumably from release of viable sequestered cells back into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/49\">",
"     49",
"    </a>",
"    ]. Death occurred from the resultant hypervolemia, hypertension, heart failure, and intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/49\">",
"     49",
"    </a>",
"    ]. For this reason, individuals with SCD and hepatic sequestration should typically be given approximately one-half of the typical transfusion volume and monitored closely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion volume'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrahepatic cholestasis may represent a severe variant of sickle cell hepatic crisis. It is due to widespread sickling within the hepatic sinusoids leading to ischemia. Hypoxic damage leads to ballooning of hepatocytes and intracanalicular cholestasis.",
"   </p>",
"   <p>",
"    The presentation is initially similar to that seen with acute sickle hepatic crises, with right upper quadrant pain, nausea and vomiting, fever, tender hepatomegaly, and leukocytosis. However, striking jaundice then develops, accompanied frequently by renal impairment, a bleeding diathesis, and increasing encephalopathy.",
"   </p>",
"   <p>",
"    In various reports, serum ALT levels have ranged from 34 to 3137",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (0.56678 to 53.329",
"    <span class=\"nowrap\">",
"     microkatal/L),",
"    </span>",
"    serum AST levels from 100 to 9881",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (1.667 to 167.977",
"    <span class=\"nowrap\">",
"     microkatal/L),",
"    </span>",
"    and alkaline phosphatase levels have ranged from normal to 860",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (14.3362",
"    <span class=\"nowrap\">",
"     microkatal/L).",
"    </span>",
"    Total serum bilirubin levels may be strikingly high; levels of up to 273",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4668.3",
"    <span class=\"nowrap\">",
"     micromoles/L)",
"    </span>",
"    have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/50\">",
"     50",
"    </a>",
"    ]. In most cases the conjugated fraction exceeds 50 percent of the total bilirubin. The extremely high bilirubin levels are due to a combination of ongoing hemolysis, intrahepatic cholestasis, and renal impairment. LDH levels are usually elevated in the range of 660 to 7760",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (11.02 to 129.59",
"    <span class=\"nowrap\">",
"     microkatal/L).",
"    </span>",
"    Prolongation of the prothrombin and partial thromboplastin time is common. Elevations in blood urea, creatinine, and ammonia are also seen. Hypofibrinogenemia, thrombocytopenia, and lactic acidosis may accompany the liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post mortem liver biopsies in four patients with sickle intrahepatic cholestasis showed dilated canaliculi with bile plugs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/7,13,34,51\">",
"     7,13,34,51",
"    </a>",
"    ]. Scattered bile stained microinfarcts were seen in one of these biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/51\">",
"     51",
"    </a>",
"    ], while widespread anoxic necrosis with areas of acute and chronic inflammation, in addition to the usual findings noted in sickle cell patients (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Liver histology'",
"    </a>",
"    above), were seen in the other three biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/7,13,34\">",
"     7,13,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least 17 probable cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/7,13,34,48,50-56\">",
"     7,13,34,48,50-56",
"    </a>",
"    ]. The syndrome was fatal in nine early cases; more recent reports have described reversal of this process within 48 hours in eight patients, with vigorous exchange transfusions and correction of coagulopathy with fresh frozen plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/34,48,50,53-56\">",
"     34,48,50,53-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion techniques'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The renal impairment in sickle intrahepatic cholestasis has not been well studied, but appears to be reversible and improves concurrently with hepatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/34,54,56\">",
"     34,54,56",
"    </a>",
"    ]. Urine electrolytes were measured in a single case and suggested acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/54\">",
"     54",
"    </a>",
"    ], but the authors attributed this to the patient's aminoglycoside therapy. Renal ultrasound done in a single case demonstrated mildly altered corticomedullary differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/50\">",
"     50",
"    </a>",
"    ]. Multiple focal acute renal infarcts were described on gross examination in a single case at post mortem [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ]. Renal histology was done in a single patient post mortem, and showed numerous hemoglobin casts in the distal convoluted tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/52\">",
"     52",
"    </a>",
"    ]. Hemodialysis was instituted in two patients for anuria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/34,56\">",
"     34,56",
"    </a>",
"    ], and peritoneal dialysis was carried out in a further patient for refractory hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"     13",
"    </a>",
"    ]. Two of these patients succumbed to their illness, but one of the patients treated with hemodialysis survived. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Benign hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the severe cholestasis described above, marked \"benign\" predominantly conjugated hyperbilirubinemia of up to 57",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (974.7",
"    <span class=\"nowrap\">",
"     micromoles/L)",
"    </span>",
"    with only a mild elevation in serum ALT has been described in children and adults who had minimal or no symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/5,57\">",
"     5,57",
"    </a>",
"    ]. The hyperbilirubinemia resolved spontaneously within two to eight weeks with no subsequent recurrences. It is possible that these cases represent a benign variant of intrahepatic cholestasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Chronic intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single case report described a patient with sickle cell anemia and very high bilirubin levels of &gt;88",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1504.8",
"    <span class=\"nowrap\">",
"     micromoles/L)",
"    </span>",
"    due to chronic intrahepatic cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/58\">",
"     58",
"    </a>",
"    ]. He had no abdominal pain and no hematological evidence of increased hemolysis. He responded dramatically to an exchange transfusion, with his bilirubin falling to 10",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    He developed repeated episodes of hyperbilirubinemia during a three-year follow-up, requiring regular exchange transfusions to keep his hemoglobin S levels &lt;20 percent to prevent recurrent intrahepatic cholestasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DISORDERS RELATED TO COEXISTING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal liver disorders seen in patients with SCD that are not a direct consequence of the sickling process include cholelithiasis, iron overload, and chronic viral hepatitis. Some specific medical treatments may also be associated with liver toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cholelithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of pigmented gallstones in SCD is directly related to the rate of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Gallstones occur in children as young as three to four years of age and are eventually found in approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. The prevalence of gallstones is lower in patients with HbSC disease and HbS&szlig;-thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Most patients are asymptomatic. However, in a study of 509 adult patients with SCD, 48 percent of those 18 to 47 years of age and 69 percent of those &ge;47 had undergone cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of acute cholecystitis and sickle hepatic crisis can be similar. Biliary scintigraphy may be useful in ruling out acute cholecystitis although it is not always diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/66\">",
"     66",
"    </a>",
"    ]. Elective cholecystectomy should be considered in patients with symptomatic gallstones, and in patients in whom gallstone related symptomatology cannot be differentiated from sickle cell hepatic crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in making a decision regarding cholecystectomy, the increased morbidity observed in sickle cell disease patients undergoing elective surgery should also be considered. Acute chest syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    ) develops in 10 percent of patients, and pain crises develop in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the risk can be substantially decreased with the use of preoperative simple blood transfusion therapy for individuals with hemoglobin SS, with a goal to raise the hemoglobin to approximately 10.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    prior to surgery. For individuals with hemoglobin SS or other types of SCD where the baseline hemoglobin is greater than 10.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    partial exchange transfusion should be considered so that the hyperviscous syndrome does not occur.",
"   </p>",
"   <p>",
"    Red blood cell pheresis designed to decrease the hemoglobin S level to &lt;30 percent does not confer any advantage over simple blood transfusion therapy and should be avoided, except under special circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic cholecystectomy is recommended because it is associated with a shorter hospital length of stay and has been associated with lower rates of postoperative complications, although it does not reduce the risk of sickle cell-related complications compared with open cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/67,68,70\">",
"     67,68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Excessive iron stores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing excessive iron stores is a direct function of the number of blood transfusions received. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .) In patients with sickle cell anemia, serum ferritin levels correlate with the number of units of blood transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/71\">",
"     71",
"    </a>",
"    ]. Rises in serum ferritin occur during painful vasoocclusive sickle crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/72\">",
"     72",
"    </a>",
"    ], and hence steady state ferritin levels provide a better estimate of the degree of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have received multiple transfusions, increased deposition of iron occurs within reticuloendothelial cells, including Kupffer cells. The correlation of plasma steady state ferritin levels with hepatic iron stores is not known precisely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. However, at least two studies found a poor correlation of plasma ferritin with hepatic iron stores as determined by liver biopsy in patients who were receiving chronic transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chelation therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    or intravenous or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    results in increased urinary and biliary excretion of iron [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/74\">",
"     74",
"    </a>",
"    ] and is associated with significant falls in serum ferritin and plasma ALT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/22\">",
"     22",
"    </a>",
"    ]. Oral chelation has proven to be safe and effective in individuals with SCD and excessive iron stores and has become the preferred method of chelation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/77\">",
"     77",
"    </a>",
"    ]. An oral chelator drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    (Ferriprox), has received FDA approval; however, extensive experience in the treatment of excessive iron stores in SCD has been limited in the US.",
"   </p>",
"   <p>",
"    Histological progression to fibrosis in sickle cell patients with iron overload has been poorly studied. In an autopsy series of 70 patients with sickle cell anemia and sickle &beta;-thalassemia, 33 patients were found to have variable degrees of parenchymal iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/6\">",
"     6",
"    </a>",
"    ]. Cirrhosis was seen in three of these patients, and parenchymal iron accumulation was considered to be severe enough to make a diagnosis of hemochromatosis as the etiology for the cirrhosis. However, hepatic iron content was not determined on biopsy, and other etiologies contributing to the cirrhosis were not excluded.",
"   </p>",
"   <p>",
"    Another series focused on 11 homozygous patients who were followed over 5 to 10 years during which they received a mean of 180 units of packed red blood cells together with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (2 g) with each transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/78\">",
"     78",
"    </a>",
"    ]. Despite the deferoxamine, two patients went on to develop significant hepatic iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exchange transfusions or red blood cell pheresis results in a lower delivered iron load and in slower rises in the serum ferritin compared with conventional blood transfusions, and may be the best way to prevent significant iron overload from developing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/71\">",
"     71",
"    </a>",
"    ]. Erythrocytapheresis, which preferentially removes sickled cells and older erythrocytes, may also retard iron accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of chronic viral hepatitis is increased in patients with SCD compared with the general population. In addition, patients with SCD may be more susceptible to developing severe disease when acutely infected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/80\">",
"     80",
"    </a>",
"    ]. Thus, all patients with SCD and chronic liver disease should be vaccinated against hepatitis A and B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of chronic hepatitis B infection in sickle cell anemia patients is low in large scale studies from the United States (0 to 3.3 percent seropositivity for HBsAg), reflecting the low prevalence of infection in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/16,81\">",
"     16,81",
"    </a>",
"    ]. In parts of the world with a high prevalence of hepatitis B, higher rates of chronic hepatitis B exist in sickle cell patients compared with the general population. Low-dose intradermal vaccination against hepatitis B is effective and immunogenic in sickle cell patients and may provide a more economical alternative for communities where the cost of vaccination is limiting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against hepatitis C virus have been detected in 10 to 20 percent of patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/16,83,84\">",
"     16,83,84",
"    </a>",
"    ]. The risk of infection is increased in patients who have received multiple transfusions. In one study, antibody to HCV was detected more often in patients who had received &gt;10 units of packed red blood cells (23 versus 8 and 0 percent in those who received &lt;10 units or no transfusions, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/81\">",
"     81",
"    </a>",
"    ]. The natural history of chronic hepatitis C and the rate of progression to cirrhosis in sickle cell anemia patients are unknown.",
"   </p>",
"   <p>",
"    With improved screening techniques, the likelihood of acquiring new HCV infection with blood transfusion in the United States is now extremely small (approximately 1:1,900,000 units when nucleic acid testing is employed) (",
"    <a class=\"graphic graphic_figure graphicRef53650 \" href=\"UTD.htm?1/3/1086\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Miscellaneous liver disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of liver abnormalities have been described in association with SCD including hepatic infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/85\">",
"     85",
"    </a>",
"    ], pyogenic liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/86-89\">",
"     86-89",
"    </a>",
"    ], Budd Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/92,93\">",
"     92,93",
"    </a>",
"    ], focal nodular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], malignant histiocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/96\">",
"     96",
"    </a>",
"    ], primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/93\">",
"     93",
"    </a>",
"    ], and mesenteric thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/97\">",
"     97",
"    </a>",
"    ]. The etiologic role of the SCD in some of these settings is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Complications from medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications used to treat patients with SCD may also affect hepatic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Androgenic steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic steroids have been used in the past as therapy for sickle cell disease with severe anemia. Reversible hepatic toxicity, with hyperbilirubinemia has been described following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"     oxymetholone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    increases HbF levels, decreases the frequency of pain crises and the acute chest syndrome and transfusion requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. It does not appear to influence the frequency of hepatic sequestration crises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/99,103\">",
"     99,103",
"    </a>",
"    ]. Hydroxyurea treatment may result in a return of splenic function, with revisualization of the spleen on 99m Tc-sulfur colloid liver-spleen scans [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/104\">",
"     104",
"    </a>",
"    ]. Abnormal liver biochemical tests occur in less than 10 percent of patients treated with hydroxyurea, and reverse upon cessation of the medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop end-stage liver disease may require liver transplantation, which has only been infrequently described in patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/105-109\">",
"     105-109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, liver transplantation was successful in a 12-year-old child who received regular blood transfusions to maintain HbS levels at &lt;20 percent for the first six months to minimize damage to the graft from SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 46-year-old women with SCD and liver failure due to hepatitis C underwent transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/105\">",
"       105",
"      </a>",
"      ] with perioperative transfusions to decrease HbS levels to &lt;25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/107\">",
"       107",
"      </a>",
"      ]. Mild elevations in plasma ALT levels and liver biopsy changes of sinusoidal congestion with sludging by sickled cells, and focal hepatocyte necrosis were noted postoperatively on day 39. Although her postoperative recovery was complicated by the development of an intracerebral hemorrhage, transplantation was otherwise successful.",
"     </li>",
"     <li>",
"      A patient with HbS&szlig;-thalassemia and cryptogenic cirrhosis undergoing transplantation has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/107\">",
"       107",
"      </a>",
"      ]. Perioperative transfusions were used to keep hemoglobin S levels low. Despite this, early graft function was poor with very low levels of factor V at days one and five. Severe cholestasis developed, with the bilirubin peaking at 44",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      at day seven.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      was subsequently used to decrease the incidence of sickle crises posttransplant. At six months posttransplant, transient allograft dysfunction was noted due to a sickle crisis leading to multiple hepatic infarcts, but subsequent graft function was satisfactory.",
"     </li>",
"     <li>",
"      A living related liver transplantation has been carried out in a child with acute liver failure due to sickle cell intrahepatic cholestasis syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/49/2842/abstract/108\">",
"       108",
"      </a>",
"      ]. However, outflow obstruction prompted retransplantation three months later. The child eventually succumbed to vascular complications related to sickle cell disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"       \"Living donor liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The liver can be affected by a number of complications due to sickle cell disease itself and to treatment. The term \"sickle cell hepatopathy\" has sometimes been used to reflect the overlapping causes of liver dysfunction in these patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factor for liver disease in patients with sickle cell disease is receiving multiple blood transfusions, which is associated with infection (hepatitis B and C) and excessive iron stores.",
"     </li>",
"     <li>",
"      Biochemical and radiologic hepatic abnormalities are common in patients with sickle cell disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory and radiologic liver tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several clinical features can be attributed to the sickling process, while others may be due to coexisting conditions. The distinction between the two is not always clear. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Disorders associated with the sickling process'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Disorders related to coexisting conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/1\">",
"      Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sickle-cell trait in a large ambulatory population. Genet Epidemiol 1987; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/2\">",
"      Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology 2001; 33:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/3\">",
"      Berry PA, Cross TJ, Thein SL, et al. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. Clin Gastroenterol Hepatol 2007; 5:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/4\">",
"      Ebert EC, Nagar M, Hagspiel KD. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 2010; 8:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/5\">",
"      Johnson CS, Omata M, Tong MJ, et al. Liver involvement in sickle cell disease. Medicine (Baltimore) 1985; 64:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/6\">",
"      Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 1980; 69:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/7\">",
"      SONG YS. Hepatic lesions in sickle cell anemia. Am J Pathol 1957; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/8\">",
"      GREEN TW, CONLEY CL, BERTHRONG M. [The liver in sickle cell anemia]. Bull Johns Hopkins Hosp 1953; 92:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/9\">",
"      Mills LR, Mwakyusa D, Milner PF. Histopathologic features of liver biopsy specimens in sickle cell disease. Arch Pathol Lab Med 1988; 112:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/10\">",
"      McGrew CJ Jr. Letter: sickle cell trait in the nonblack population. JAMA 1975; 232:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/11\">",
"      Schilir&ograve; G, Samperi P, Consalvo C, et al. Clinical, hematological, and molecular features in Sicilians with sickle cell disease. Hemoglobin 1992; 16:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/12\">",
"      Samperi P, Consalvo C, Romano V, et al. Liver involvement in white patients with sickle-cell disease. Arch Pediatr Adolesc Med 1996; 150:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/13\">",
"      Sheehy TW. Sickle cell hepatopathy. South Med J 1977; 70:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/14\">",
"      Brody JI, Ryan WN, Haidar MA. Serum alkaline phosphatase isoenzymes in sickle cell anemia. JAMA 1975; 232:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/15\">",
"      Mohamed AO, Jansson A, Ronquist G. Increased activity of 5' nucleotidase in serum of patients with sickle cell anaemia. Scand J Clin Lab Invest 1993; 53:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/16\">",
"      DeVault KR, Friedman LS, Westerberg S, et al. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994; 18:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/17\">",
"      Karayalcin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol Oncol 1989; 11:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/18\">",
"      Tam DA. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 1997; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/19\">",
"      Wright JG, Malia R, Cooper P, et al. Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels? Br J Haematol 1997; 98:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/20\">",
"      Karayalcin G, Lanzkowsky P, Kazi AB. Zinc deficiency in children with sickle cell disease. Am J Pediatr Hematol Oncol 1979; 1:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/21\">",
"      Yuzbasiyan-Gurkan VA, Brewer GJ, Vander AJ, et al. Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. Am J Hematol 1989; 31:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/22\">",
"      Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med 1993; 122:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/23\">",
"      Leonard MB, Zemel BS, Kawchak DA, et al. Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr 1998; 132:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/24\">",
"      Rabbani P, Prasad AS. Plasma ammonia and liver ornithine transcarbamoylase activity in zinc-deficient rats. Am J Physiol 1978; 235:E203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/25\">",
"      Brewer GJ, Hill GM, Dick RD, et al. Interactions of trace elements: clinical significance. J Am Coll Nutr 1985; 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/26\">",
"      Prasad AS, Rabbani P, Warth JA. Effect of zinc on hyperammonemia in sickle cell anemia subjects. Am J Hematol 1979; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/27\">",
"      Prasad AS, Beck FW, Kaplan J, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol 1999; 61:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/28\">",
"      Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. J Assoc Physicians India 1995; 43:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/29\">",
"      Brewer GJ, Hill GM, Prasad AS, Cossack ZT. Biological roles of ionic zinc. Prog Clin Biol Res 1983; 129:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/30\">",
"      Zakaria N, Knisely A, Portmann B, et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood 2003; 101:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/31\">",
"      Rosenblate HJ, Eisenstein R, Holmes AW. The liver in sickle cell anemia. A clinical-pathologic study. Arch Pathol 1970; 90:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/32\">",
"      Diggs LW, Ching RE. Pathology of sickle cell anemia. South Med J 1934; 27:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/33\">",
"      Omata M, Johnson CS, Tong M, Tatter D. Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci 1986; 31:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/34\">",
"      Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterol 1995; 90:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/35\">",
"      Charlotte F, Bachir D, N&eacute;nert M, et al. Vascular lesions of the liver in sickle cell disease. A clinicopathological study in 26 living patients. Arch Pathol Lab Med 1995; 119:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/36\">",
"      Aken'ova YA, Olasode BJ, Ogunbiyi JO, Thomas JO. Hepatobiliary changes in Nigerians with sickle cell anaemia. Ann Trop Med Parasitol 1993; 87:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/37\">",
"      Barrett-Connor E. Sickle cell disease and viral hepatitis. Ann Intern Med 1968; 69:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/38\">",
"      Hankins JS, Smeltzer MP, McCarville MB, et al. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. Eur J Haematol 2010; 85:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/39\">",
"      Ghugre NR, Wood JC. Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med 2011; 65:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/40\">",
"      Flyer MA, Haller JO, Sundaram R. Transfusional hemosiderosis in sickle cell anemia: another cause of an echogenic pancreas. Pediatr Radiol 1993; 23:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/41\">",
"      Siegelman ES, Outwater E, Hanau CA, et al. Abdominal iron distribution in sickle cell disease: MR findings in transfusion and nontransfusion dependent patients. J Comput Assist Tomogr 1994; 18:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/42\">",
"      Adler DD, Glazer GM, Aisen AM. MRI of the spleen: normal appearance and findings in sickle-cell anemia. AJR Am J Roentgenol 1986; 147:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/43\">",
"      Diggs LW. Sickle cell crises. Am J Clin Pathol 1965; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/44\">",
"      Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology 1986; 90:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/45\">",
"      Saltzman JR, Johnston DE. Sickle cell crisis and cocaine hepatotoxicity. Am J Gastroenterol 1992; 87:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/46\">",
"      Hatton CS, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. Br Med J (Clin Res Ed) 1985; 290:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/47\">",
"      Hern&aacute;ndez P, Dortic&oacute;s E, Espinosa E, et al. Clinical features of hepatic sequestration in sickle cell anaemia. Haematologia (Budap) 1989; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/48\">",
"      Sheehy TW, Law DE, Wade BH. Exchange transfusion for sickle cell intrahepatic cholestasis. Arch Intern Med 1980; 140:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/49\">",
"      Lee ES, Chu PC. Reverse sequestration in a case of sickle crisis. Postgrad Med J 1996; 72:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/50\">",
"      St&eacute;phan JL, Merpit-Gonon E, Richard O, et al. Fulminant liver failure in a 12-year-old girl with sickle cell anaemia: favourable outcome after exchange transfusions. Eur J Pediatr 1995; 154:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/51\">",
"      KLION FM, WEINER MJ, SCHAFFNER F. CHOLESTASIS IN SICKLE CELL ANEMIA. Am J Med 1964; 37:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/52\">",
"      OWEN DM, ALDRIDGE JE, THOMPSON RB. AN UNUSUAL HEPATIC SEQUELA OF SICKLE CELL ANEMIA: A REPORT OF FIVE CASES. Am J Med Sci 1965; 249:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/53\">",
"      Svarch E, Gonz&aacute;lez A, Villaescusa R, Basanta P. Plasma exchange for acute cholestasis in homozygous sickle cell disease. Haematologia (Budap) 1986; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/54\">",
"      Morrow JD, McKenzie SW. Survival after intrahepatic cholestasis associated with sickle cell disease. J Tenn Med Assoc 1986; 79:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/55\">",
"      Betrosian A, Balla M, Kafiri G, et al. Reversal of liver failure in sickle cell vaso-occlusive crisis. Am J Med Sci 1996; 311:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/56\">",
"      Khan MA, Kerner JA. Reversal of hepatic and renal failure from sickle cell intrahepatic cholestasis. Dig Dis Sci 2011; 56:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/57\">",
"      Buchanan GR, Glader BE. Benign course of extreme hyperbilirubinemia in sickle cell anemia: analysis of six cases. J Pediatr 1977; 91:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/58\">",
"      O'Callaghan A, O'Brien SG, Ninkovic M, et al. Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Gut 1995; 37:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/59\">",
"      Rennels MB, Dunne MG, Grossman NJ, Schwartz AD. Cholelithiasis in patients with major sickle hemoglobinopathies. Am J Dis Child 1984; 138:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/60\">",
"      Adam S, Jonassaint J, Kruger H, et al. Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 2008; 121:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/61\">",
"      Webb DK, Darby JS, Dunn DT, et al. Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Child 1989; 64:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/62\">",
"      Sarnaik S, Slovis TL, Corbett DP, et al. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. J Pediatr 1980; 96:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/63\">",
"      Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from The Jamaican Cohort study. J Pediatr 2000; 136:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/64\">",
"      Bond LR, Hatty SR, Horn ME, et al. Gall stones in sickle cell disease in the United Kingdom. Br Med J (Clin Res Ed) 1987; 295:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/65\">",
"      Irizarry K, Rossbach HC, Ignacio JR, et al. Sickle cell intrahepatic cholestasis with cholelithiasis. Pediatr Hematol Oncol 2006; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/66\">",
"      D'Alonzo WA Jr, Heyman S. Biliary scintigraphy in children with sickle cell anemia and acute abdominal pain. Pediatr Radiol 1985; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/67\">",
"      Malone BS, Werlin SL. Cholecystectomy and cholelithiasis in sickle cell anemia. Am J Dis Child 1988; 142:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/68\">",
"      Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/69\">",
"      Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood 1997; 89:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/70\">",
"      Goers T, Panepinto J, Debaun M, et al. Laparoscopic versus open abdominal surgery in children with sickle cell disease is associated with a shorter hospital stay. Pediatr Blood Cancer 2008; 50:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/71\">",
"      Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol 1987; 78:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/72\">",
"      Brownell A, Lowson S, Brozovi�� M. Serum ferritin concentration in sickle cell crisis. J Clin Pathol 1986; 39:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/73\">",
"      Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/74\">",
"      Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/75\">",
"      Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer 2008; 50:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/76\">",
"      Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/77\">",
"      Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/78\">",
"      Laulan S, Bernard JF, Boivin P. [Systematic blood transfusions in adult homozygote sickle-cell anemia. Study of 11 cases followed for 5 to 10 years]. Presse Med 1990; 19:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/79\">",
"      Adams DM, Schultz WH, Ware RE, Kinney TR. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/80\">",
"      Yohannan MD, Arif M, Ramia S. Aetiology of icteric hepatitis and fulminant hepatic failure in children and the possible predisposition to hepatic failure by sickle cell disease. Acta Paediatr Scand 1990; 79:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/81\">",
"      Hasan MF, Marsh F, Posner G, et al. Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol 1996; 91:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/82\">",
"      Mok Q, Underhill G, Wonke B, et al. Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease. Arch Dis Child 1989; 64:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/83\">",
"      Jeannel D, Fretz C, Traore Y, et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 1998; 55:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/84\">",
"      al-Fawaz I, Ramia S. Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major. Arch Dis Child 1993; 69:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/85\">",
"      Gauthier N, Cornud F, Vissuzaine C. Liver infarction in sickle cell disease. AJR Am J Roentgenol 1985; 144:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/86\">",
"      Chong SK, Dick MC, Howard ER, Mowat AP. Liver abscess as an unusual complication in sickle cell anemia. J Pediatr Gastroenterol Nutr 1993; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/87\">",
"      Brittain HP, De la Torre A, Willey EN. A case of sickle cell disease with an abscess arising in an infarct of the liver. Ann Intern Med 1966; 65:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/88\">",
"      Lama M. Hepatic abscess in sickle cell anaemia: a rare manifestation. Arch Dis Child 1993; 69:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/89\">",
"      Shulman ST, Beem MO. An unique presentation of sickle cell disease: pyogenic hepatic abscess. Pediatrics 1971; 47:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/90\">",
"      Sty JR. Ultrasonography: hepatic vein thrombosis in sickle cell anemia. Am J Pediatr Hematol Oncol 1982; 4:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/91\">",
"      Attal HC, Gupta VL, Salkar HR. Budd-Chiari syndrome due to inferior vena cava obstruction in sickle cell trait. J Assoc Physicians India 1984; 32:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/92\">",
"      el Younis CM, Min AD, Fiel MI, et al. Autoimmune hepatitis in a patient with sickle cell disease. Am J Gastroenterol 1996; 91:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/93\">",
"      Chuang E, Ruchelli E, Mulberg AE. Autoimmune liver disease and sickle cell anemia in children: a report of three cases. J Pediatr Hematol Oncol 1997; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/94\">",
"      Markowitz RI, Harcke HT, Ritchie WG, Huff DS. Focal nodular hyperplasia of the liver in a child with sickle cell anemia. AJR Am J Roentgenol 1980; 134:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/95\">",
"      Heaton ND, Pain J, Cowan NC, et al. Focal nodular hyperplasia of the liver: a link with sickle cell disease? Arch Dis Child 1991; 66:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/96\">",
"      Wong WS, Sherman NE, Moss AA. Malignant histiocytosis in a patient with sickle cell anemia: CT findings. J Comput Assist Tomogr 1983; 7:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/97\">",
"      Arnold KE, Char G, Serjeant GR. Portal vein thrombosis in a child with homozygous sickle-cell disease. West Indian Med J 1993; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/98\">",
"      Alexanian R, Nadell J. Oxymetholone treatment for sickle cell anemia. Blood 1975; 45:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/99\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/100\">",
"      Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/101\">",
"      Koren A, Segal-Kupershmit D, Zalman L, et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr Hematol Oncol 1999; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/102\">",
"      de Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 1997; 19:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/103\">",
"      Saleh AW Jr, Velvis HJ, Gu LH, et al. Hydroxyurea therapy in sickle cell anemia patients in Cura&ccedil;ao, The Netherlands Antilles. Acta Haematol 1997; 98:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/104\">",
"      Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996; 88:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/105\">",
"      Kindscher JD, Laurin J, Delcore R, Forster J. Liver transplantation in a patient with sickle cell anemia. Transplantation 1995; 60:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/106\">",
"      Lang T, Berquist WE, So SK, et al. Liver transplantation in a child with sickle cell anemia. Transplantation 1995; 59:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/107\">",
"      Lerut JP, Claeys N, Laterre PF, et al. Hepatic sickling: an unusual cause of liver allograft dysfunction. Transplantation 1999; 67:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/108\">",
"      Emre S, Schwartz ME, Shneider B, et al. Living related liver transplantation for acute liver failure in children. Liver Transpl Surg 1999; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/49/2842/abstract/109\">",
"      Mekeel KL, Langham MR Jr, Gonzalez-Peralta R, et al. Liver transplantation in children with sickle-cell disease. Liver Transpl 2007; 13:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3589 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-87592D432B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2842=[""].join("\n");
var outline_f2_49_2842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY AND RADIOLOGIC LIVER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Biochemical tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hyperammonemia due to zinc deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Computerized tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Magnetic resonance imaging (MRI)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISORDERS ASSOCIATED WITH THE SICKLING PROCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute pain and jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acute sickle hepatic crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hepatic sequestration crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reverse sequestration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Benign hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chronic intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DISORDERS RELATED TO COEXISTING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cholelithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Excessive iron stores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Miscellaneous liver disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Complications from medical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Androgenic steroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3589|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/3/1086\" title=\"figure 1\">",
"      Decline post transfusion HCV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_49_2843="SMART mnemonic for difficult cricothyrotomy";
var content_f2_49_2843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The SMART&copy; mnemonic for difficult cricothyrotomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         S",
"        </strong>",
"        urgery (recent or remote)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         M",
"        </strong>",
"        ass (hematoma, abscess, or other mass)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A",
"        </strong>",
"        ccess or",
"        <strong>",
"         A",
"        </strong>",
"        natomy&nbsp;(obesity, poor landmarks, or otherwise poor access)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         R",
"        </strong>",
"        adiation (or other tissue deformity or scarring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T",
"        </strong>",
"        umor (including intrinsic airway tumor)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; The Difficult Airway Course&reg;: Emergency.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2843=[""].join("\n");
var outline_f2_49_2843=null;
var title_f2_49_2844="ACCP Rx bioprosthetic valve";
var content_f2_49_2844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ninth ed: ACCP evidence-based clinical practice guidelines: Antithrombotic therapy in patients with bioprosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          For the first three months after bioprosthetic mitral valve replacement (MVR),&nbsp;vitamin K antagonist (VKA) therapy (target INR, 2.5;range, 2.0-3.0)&nbsp;is suggested over no VKA therapy&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          For the first three months after surgical bioprosthetic aortic valve replacement (AVR) in patients who are in sinus rhythm and have no other indication for VKA therapy, aspirin (50 to 100 mg/day) is suggested over VKA therapy.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          For the first three months after transcatheter aortic&nbsp;bioprosthetic valve implantation, aspirin (50 to 100 mg/d) plus clopidogrel (75 mg/d) is suggested over VKA therapy and over no antiplatelet therapy.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          &nbsp;For the first three months after mitral valve repair with an annular ring in patients who are in sinus rhythm, antiplatelet therapy is suggested over VKA therapy.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          After the first three months&nbsp;following bioprosthetic&nbsp;valve replacement in patients&nbsp;in normal sinus rhythm,&nbsp;aspirin&nbsp;therapy is suggested&nbsp;over no&nbsp;aspirin therapy.&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          In patients undergoing aortic valve repair, aspirin (50 to 100 mg/d) is suggested over VKA therapy.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.&nbsp;Chest. 2012;141:e576S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2844=[""].join("\n");
var outline_f2_49_2844=null;
var title_f2_49_2845="Antimicrobial sulf";
var content_f2_49_2845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sulfonamide antimicrobials (sulfonylarylamines)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       G6PD risk*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Systemic agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfadiazine",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       As single agent or in combination with pyrimethamine.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfadoxine",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       As single agent&bull; or in combination with pyrimethamine. Long acting&Delta;.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfaguanidine&bull;",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Gastrointestinal antimicrobial.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfamerazine&bull;",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       In combination with other sulfonamides or trimethoprim.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfamethizole&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Urinary tract antimicrobial.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfamethazine (sulfadimidine)&bull;",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       As single agent or in combination with other sulfonamides.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfamethoxazole",
"      </td>",
"      <td>",
"       Variable",
"      </td>",
"      <td>",
"       In combination with trimethoprim or as single agent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfametopyrazine&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       In combination with pyrimethamine. Long acting&Delta;.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfamoxole&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       In combination with trimethoprim.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfapyridine&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Rarely used due to crystalluria risk.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfasalazine (salazosulfapyridine, salazopyrin)",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       Rheumatologic/GI agent (NON antimicrobial) releases sulfapyridine in contact with gut flora.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfisoxazole (sulfafurazole)",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       As single agent or in combination with erythromycin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Topical and ophthalmic agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mafenide",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Topical solution or cream.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Silver sulfadiazine",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Topical cream or ointment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfacetamide",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       As single agent ophthalmic solution, ointment, various topicals, vaginal or in combination with sulfabenzamide, sulfathiazole or prednisolone.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulfanilamide",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       As single agent vaginal or in combination with other antimicrobials.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk in G6PD deficiency may vary by type. See: file://www.g6pd.org/favism/english/index.mvc?pgid=avoid.",
"     <br>",
"      &bull; Not available commercially in United States.",
"      <br>",
"       &Delta; Long acting sulfonamides may be more frequently implicated in allergic reactions and are cleared slowly upon discontinuation.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2845=[""].join("\n");
var outline_f2_49_2845=null;
var title_f2_49_2846="Carboplatin and paclitaxel with RT for EGJ cancer";
var content_f2_49_2846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weekly carboplatin and paclitaxel chemotherapy with concurrent radiotherapy for esophageal and esophagogastric junction (EGJ) cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Carboplatin and paclitaxel are each given weekly for five weeks with concurrent radiotherapy (RT) followed by surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS)* and administer over one hour; special tubing needed.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, 22, and 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC",
"        <sup>",
"         &Delta;",
"        </sup>",
"        = 2 mg/mL x min IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS",
"        <sup>",
"         &loz;",
"        </sup>",
"        and administer over 30 minutes after paclitaxel.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, 22, and 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). We recommend prophylaxis with a combination of a 5-HT3 receptor antagonist plus dexamethasone on days 1, 8, 15, 22, and 29, and with a 5-HT3 antagonist on days when radiation alone is given. Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\" and \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Carboplatin is an irritant. Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not justified (incidence of neutropenic fever &lt;1 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of paclitaxel may be needed for liver impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . Carboplatin dose is calculated based upon renal function by use of the Calvert formula",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes, renal, and liver function weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity/neurologic toxicity:",
"        </strong>",
"        Weekly doses of paclitaxel and carboplatin should not be repeated unless the ANC is at least 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is at least 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Reduce paclitaxel dose by 20 percent for ANC &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        for a week or longer, or severe peripheral neuropathy",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal toxicity:",
"        </strong>",
"        Alterations in renal function during therapy require a recalculation of the carboplatin dose. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony stimulating factor: CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.",
"     <br/>",
"     * For paclitaxel administration, use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through a polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"     <br/>",
"     &Delta; AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula: total dose (mg) = (target AUC) x (GFR + 25). If using measured creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Gaast AV, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric cancer: Results from a multinational randomized phase III study (abstract 4004). J Clin Oncol 2010; 28:302s.",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 5, 2011).",
"      </li>",
"      <li>",
"       Paraplatin (carboplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 5, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2846=[""].join("\n");
var outline_f2_49_2846=null;
var title_f2_49_2847="Schatzki ring following balloon dilation";
var content_f2_49_2847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schatzki ring following balloon dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wider distal esophageal lumen without the ring and a small amount of bleeding is seen following balloon dilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_49_2847=[""].join("\n");
var outline_f2_49_2847=null;
